This is where the end of cancer begins.
When together,
We become a force unmistakable.
A movement undeniable.
A light that cannot dim.
When we take
Our wild impossible dreams
And make them possible
Make them true
We rise up as one
When we stand up
When we Stand Up To Cancer.

Dear Members of the Stand Up To Cancer Community:

On behalf of our dedicated scientists, partners, staff, and patient advocates that make up the Stand Up To Cancer community, I am pleased to be able to share with you our June 2022 SU2C Science Portfolio.

This document presents the extraordinary work of Stand Up To Cancer, advancing translational research and health equity to speed the development of new treatments for cancer while ensuring these advances are available to everyone who needs them. Since 2009, this network has been supported by generous pledges of more than $746 million, funding the work of more than 2,000 scientists and contributing to the US Food and Drug Administration approval of nine new cancer therapies.

In this booklet, you will find information on more than 125 team science grants and awards, more than 50 grants to individuals, and information about the 260-plus clinical trials conducted by our vast network of researchers. Their work has provided countless insights into potential new treatments for cancer. We are so grateful to all the donors that have made this research possible. SU2C continues, with help from our media and entertainment allies, to bring messages about the importance of cancer prevention and participation in cancer clinical trials to communities across the nation. These awareness campaigns are a crucial part of our work to ensure that everyone has access to the most effective cancer treatments.

All of this has been accomplished as the result of the dedication of the scientists and advocates participating in SU2C research projects and the staff both at SU2C and the American Association for Cancer Research.

Thank you all for your commitment and dedication to this work.

With warm regards,

Russell Chew
President and CEO
Stand Up To Cancer
TABLE OF CONTENTS
<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
<th>Title</th>
<th>Description</th>
</tr>
</thead>
</table>
| 20   | DREAM TEAMS | SU2C Colorectal Cancer Health Equity Dream Team | Community Collaboration to Advance Racial/Ethnic Equity in CRC Screening  
**Team Leader:** Jennifer Haas, MD, MSc, Massachusetts General Hospital |
| 22   | DREAM TEAMS | SU2C Health Equity Breakthrough Team | DISRUPT: Diversity and InclusiSon in Research Underpinning Prevention and Therapy Trials  
**Team Leader:** Nina A. Bickell, MD, MPH, Icahn School of Medicine at Mount Sinai |
| 23   | DREAM TEAMS | SU2C Canada–Lustgarten Foundation–Pancreatic Cancer Canada PASS Convergence Dream Team | PASS-01- Pancreatic Adenocarcinoma Signature Stratification for Treatment-01  
**Team Co-leader:** Jennifer Knox, MD, University Health Network  
**Team Co-leader:** Elizabeth Jaffee, MD, John Hopkins University |
| 24   | DREAM TEAMS | SU2C Canada Metastatic Breast Cancer Dream Team | Targeting mRNA Translation to Effectively Treat Metastatic Breast Cancer  
**Team Leader:** Nahum Sonenberg, PhD, McGill University |
| 25   | DREAM TEAMS | SU2C Meg Vosburg T-Cell Lymphoma Dream Team | Tailoring CAR-based Immunotherapy Strategies to T-Cell Lymphoma  
**Team Leader:** Helen E. Heslop, MD, Baylor College of Medicine |
| 26   | DREAM TEAMS | SU2C Multiple Myeloma Dream Team | Screening and Interception of Precursor Myeloma  
**Team Leader:** Irene M. Ghobrial, MD, Dana-Farber Cancer Institute |
| 27   | DREAM TEAMS | SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team | Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTiME)  
**Team Leader:** Avrum E. Spira, MD, Boston University |
| 29   | DREAM TEAMS | SU2C–Lustgarten Foundation Pancreatic Cancer Interception Dream Team | Interception Pancreatic Cancer in High-Risk Cohorts  
**Team Leader:** Anirban Maitra, MBBS, The University of Texas MD Anderson Cancer Center |
| 30   | DREAM TEAMS | St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team | Immunogenomics to Create New Therapies for High-Risk Childhood Cancers  
**Team Leader:** John M. Maris, MD, Children’s Hospital of Philadelphia |
| 32   | DREAM TEAMS | SU2C Colorectal Cancer Dream Team | Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer  
**Team Leader:** Luis A. Diaz Jr., MD, Memorial Sloan Kettering Cancer Center |
| 34   | DREAM TEAMS | SU2C Canada–Canadian Cancer Society Breast Cancer Dream Team | Translational Development of Novel Drugs Targeting Tumor Vulnerabilities  
**Team Leader:** Tak W. Mak, PhD, Campbell Family Institute for Breast Cancer Research at Princess Margaret Cancer Centre |
| 36   | DREAM TEAMS | SU2C–Cancer Research UK–Lustgarten Foundation Pancreatic Cancer Dream Team | Reprogramming of Transcriptional Circuity to Control Pancreatic Cancer  
**Team Leader:** Daniel D. Von Hoff, MD, Translational Genomics Research Institute (TGEN) |
<table>
<thead>
<tr>
<th>Page</th>
<th>Team</th>
<th>Description</th>
<th>Leader(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>38</td>
<td>SU2C Canada Cancer Stem Cell Dream Team</td>
<td>Targeting Brain Tumor Stem Cell Epigenetic and Molecular Networks</td>
<td>Peter B. Dirks, MD, PhD, The Hospital for Sick Children</td>
</tr>
<tr>
<td>39</td>
<td>SU2C-American Cancer Society Lung Cancer Dream Team</td>
<td>Targeting KRAS-Mutant Lung Cancers</td>
<td>Jedd D. Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center, Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Justin F. Gainor, MD, Massachusetts General Hospital Cancer Center</td>
</tr>
<tr>
<td>41</td>
<td>SU2C-Ovarian Cancer Research Alliance-National Ovarian Cancer Coalition Ovarian Cancer Dream Team</td>
<td>DNA Repair Therapies for Ovarian Cancer</td>
<td>Alan D. D’Andrea, MD, Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>43</td>
<td>SU2C-Dutch Cancer Society Colorectal Cancer Early Detection Dream Team</td>
<td>Molecular Early Detection of Colorectal Cancer (MEOCC)</td>
<td>Gerrit A. Meijer, MD, PhD, Netherlands Cancer Institute</td>
</tr>
<tr>
<td>44</td>
<td>Van Andel Institute-SU2C Cancer Epigenetics Dream Team</td>
<td>Bringing Epigenetic Therapy to the Forefront of Cancer Management, II</td>
<td>Peter A. Jones, PhD, DSc (h), Van Andel Institute</td>
</tr>
<tr>
<td>46</td>
<td>SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team</td>
<td>Transforming Pancreatic Cancer to Treatable Disease</td>
<td>Elizabeth M. Jaffee, MD, Johns Hopkins University</td>
</tr>
<tr>
<td>48</td>
<td>SU2C-Dutch Cancer Society Tumor Organoids Dream Team</td>
<td>A New Preclinical Model for Drug Sensitivity Analysis</td>
<td>Hans C. Clevers, MD, PhD, Hubrecht Institute</td>
</tr>
<tr>
<td>49</td>
<td>SU2C-St. Baldrick’s Foundation Pediatric Cancer Dream Team</td>
<td>Immunogenomics to Create New Therapies for High-Risk Childhood Cancers</td>
<td>John M. Maris, MD, Children’s Hospital of Philadelphia</td>
</tr>
<tr>
<td>52</td>
<td>SU2C-Cancer Research Institute Cancer Immunology Dream Team</td>
<td>Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy</td>
<td>James P. Allison, PhD, The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>54</td>
<td>SU2C-Prostate Cancer Foundation Prostate Cancer Dream Team</td>
<td>Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer</td>
<td>Eric J. Small, MD, University of California, San Francisco</td>
</tr>
<tr>
<td>57</td>
<td>SU2C-Prostate Cancer Foundation Prostate Cancer Dream Team</td>
<td>Precision Therapy of Advanced Prostate Cancer</td>
<td>Arul M. Chinnaiyan, MD, PhD, University of Michigan</td>
</tr>
<tr>
<td>59</td>
<td>SU2C-Melanoma Research Alliance Melanoma Dream Team</td>
<td>Personalized Medicine for Patients With BRAF Wild-Type (BRAFwt) Cancer</td>
<td>Jeffrey M. Trent, PhD, Translational Genomics Research Institute</td>
</tr>
<tr>
<td>60</td>
<td>SU2C Pancreatic Dream Team</td>
<td>Cutting Off the Fuel Supply: A New Approach to the Treatment of Pancreatic Cancer</td>
<td>Craig B. Thompson, MD, (2009–2011), University of Pennsylvania</td>
</tr>
<tr>
<td>Page</td>
<td>SU2C Program</td>
<td>Title</td>
<td>Team Leader(s)</td>
</tr>
<tr>
<td>------</td>
<td>--------------</td>
<td>-------</td>
<td>----------------</td>
</tr>
<tr>
<td>61</td>
<td>SU2C Epigenetics Dream Team</td>
<td>Bringing Epigenetic Therapy to the Forefront of Cancer Management</td>
<td>Stephen B. Baylin, MD</td>
</tr>
<tr>
<td>63</td>
<td>SU2C Circulating Tumor Cell (CTC) Dream Team</td>
<td>Bioengineering and Clinical Applications of Circulating Tumor Cell Chip</td>
<td>Daniel A. Haber, MD, PhD</td>
</tr>
<tr>
<td>64</td>
<td>SU2C PI3K Dream Team</td>
<td>Targeting the PI3K Pathway in Women’s Cancers</td>
<td>Lewis C. Cantley, PhD</td>
</tr>
<tr>
<td>66</td>
<td>SU2C Breast Cancer Dream Team</td>
<td>An Integrated Approach to Targeting Breast Cancer Molecular Subtypes and Their Resistance Phenotypes</td>
<td>Dennis J. Slamon, MD, PhD</td>
</tr>
<tr>
<td>68</td>
<td>RESEARCH TEAMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>SU2C Lung Cancer Health Equity Research Team</td>
<td>Southeastern Consortium for Lung Cancer Health Equity</td>
<td>Robert A. Winn, MD</td>
</tr>
<tr>
<td>70</td>
<td>Stand Up To Cancer–Fanconi Anemia Research Fund–Farrah Fawcett Foundation Head and Neck Cancer Research Team</td>
<td>Precision Therapy for Fanconi Anemia and HPV-Related Head and Neck Cancers</td>
<td>Agata Smogorzewska, MD, PhD</td>
</tr>
<tr>
<td>71</td>
<td>SU2C-CRUK Pediatric Cancer New Discoveries Challenge Research Team</td>
<td>Combinatorial Targeting of Oncogene-Driven Childhood Cancer</td>
<td>John Anderson, MBBS, MRCP, PhD</td>
</tr>
<tr>
<td>72</td>
<td>SU2C-CRUK Pediatric Cancer New Discoveries Challenge Research Team</td>
<td>Targeting R-loop Stability in Ewing Sarcoma</td>
<td>Alexander Bishop, DPhil</td>
</tr>
<tr>
<td>73</td>
<td>SU2C-CRUK Pediatric Cancer New Discoveries Challenge Research Team</td>
<td>BRAINatomy: A Validated Anatomical Atlas of Childhood Neuroradiation Damage</td>
<td>Martin G. McCabe, MB/BChir, PhD</td>
</tr>
<tr>
<td>74</td>
<td>SU2C Gastric Cancer Interception Research Team</td>
<td>Early Detection and Interception of Diffuse and Intestinal Gastric Cancer</td>
<td>Andrew T. Chan, MD</td>
</tr>
<tr>
<td>75</td>
<td>Pancreatic Cancer Collective Research Teams—Computational Approaches to Identifying High-Risk Pancreatic Cancer Populations</td>
<td>Identification of Genomic and Immune Factors in High-Risk Populations for Pancreatic Cancer</td>
<td>Raul Rabadan, PhD</td>
</tr>
<tr>
<td>76</td>
<td>Pancreatic Cancer Collective Research Teams—Computational Approaches to Identifying High-Risk Pancreatic Cancer Populations</td>
<td>Identifying Individuals at High Risk of Pancreatic Cancer Through Machine Learning Analysis of Clinical Records and Images</td>
<td>Chris Sander, PhD</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Team Leader</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>77</td>
<td>Pancreatic Cancer Collective Research Team—New Therapies Challenge</td>
<td>Targeting SHP2 in Pancreatic Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Team Leader: René Bernards, PhD, Netherlands Cancer Institute</td>
<td></td>
</tr>
<tr>
<td>78</td>
<td>Pancreatic Cancer Collective Research Team—New Therapies Challenge</td>
<td>Exploiting DNA Repair Gene Mutations in Pancreatic Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Team Leader: Alan D. D’Andrea, MD, Dana-Farber Cancer Institute</td>
<td></td>
</tr>
<tr>
<td>80</td>
<td>Pancreatic Cancer Collective Research Team—New Therapies Challenge</td>
<td>Adoptive Transfer of TGF-β-Resistant TIL to Defeat Immunosuppressive PDAC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Team Leader: Patrick Hwu, MD, The University of Texas MD Anderson Cancer Center</td>
<td></td>
</tr>
<tr>
<td>81</td>
<td>Pancreatic Cancer Collective Research Team—New Therapies Challenge</td>
<td>Combined Targeting of MEK1/2 and Autophagy for Pancreatic Cancer Therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Team Leader: Martin McMahon, PhD, University of Utah</td>
<td></td>
</tr>
<tr>
<td>82</td>
<td>Pancreatic Cancer Collective Research Team—New Therapies Challenge</td>
<td>Targeting Stem Cell Signals in Pancreatic Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Team Leader: Tannishtha Reya, PhD, University of California, San Diego</td>
<td></td>
</tr>
<tr>
<td>83</td>
<td>Pancreatic Cancer Collective Research Team—New Therapies Challenge</td>
<td>Molecularly Targeted Radionuclide Therapy via the Integrin avβ6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Team Leader: Julie L. Sutcliffe, PhD, University of California, Davis</td>
<td></td>
</tr>
<tr>
<td>84</td>
<td>Pancreatic Cancer Collective Research Team—New Therapies Challenge</td>
<td>Immunotherapy Targeting Mutant KRAS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Team Leader: Robert H. Vonderheide, MD, DPhil, University of Pennsylvania</td>
<td></td>
</tr>
<tr>
<td>85</td>
<td>SU2C–Lustgarten Foundation Pancreatic Cancer Interception Research Team</td>
<td>Developing Novel Approaches to Detect and Treat Early Pancreatic Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Team Leader: David P. Ryan, MD, Massachusetts General Hospital</td>
<td></td>
</tr>
<tr>
<td>86</td>
<td>SU2C–LUNGevity Foundation–American Lung Association Lung Cancer</td>
<td>Blood-Based Early Interception of Lung Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interception Research Team</td>
<td>Team Leader: Lecia V. Sequist, MD, Massachusetts General Hospital</td>
<td></td>
</tr>
<tr>
<td>87</td>
<td>SU2C–Lustgarten Foundation Translational Research Team</td>
<td>Chimeric Antigen Receptor T-cell (CAR T) Therapy for Pancreatic Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Team Leader: Carl H. June, MD, University of Pennsylvania</td>
<td></td>
</tr>
<tr>
<td>88</td>
<td>Laura Ziskin Translational Award Research Team</td>
<td>Phosphatidylinositol 3-kinase δ Inhibition to Treat Patients With Relapsed or Refractory Follicular Lymphoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Team Leader: Siddhartha Mukherjee, MD, Columbia University</td>
<td></td>
</tr>
<tr>
<td>89</td>
<td>SU2C–Farrah Fawcett Foundation HPV Research Team</td>
<td>Therapeutic CD8 Vaccines Against Conserved E7 HPV Epitopes Identified by MS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Team Leader: Ellis L. Reinherz, MD, Dana-Farber Cancer Institute</td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>SU2C–Dutch Cancer Society Translational Research Team</td>
<td>Prospective Use of DNA-Guided Personalized Cancer Treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Team Leader: Emile E. Voest, MD, PhD, Netherlands Cancer Institute</td>
<td></td>
</tr>
</tbody>
</table>
## TABLE OF CONTENTS

### SU2C CONVERGENCE RESEARCH TEAMS

<table>
<thead>
<tr>
<th>Page</th>
<th>Team Title</th>
<th>Team Leader</th>
</tr>
</thead>
<tbody>
<tr>
<td>91</td>
<td>SU2C Convergence 3.1416 Research Team</td>
<td>Ileana Cristea, PhD, Princeton University</td>
</tr>
<tr>
<td>92</td>
<td>Molecular and Biophysical Definition of Tumor–Host Interactions and Impact on Tumorigenesis and Therapeutic Response</td>
<td>Ileana Cristea, PhD, Princeton University</td>
</tr>
<tr>
<td>94</td>
<td>SU2C Convergence 3.1416 Research Team</td>
<td>Kenya Honda, MD, PhD, Keio University, Japan</td>
</tr>
<tr>
<td>96</td>
<td>Integrating Gnotobiotic, Organoid, and Metabolomic Pipelines to Probe the Cancer–Microbiome Connection</td>
<td>Calvin Kuo, MD, PhD, Stanford University</td>
</tr>
<tr>
<td>98</td>
<td>SU2C Convergence 3.1416 Research Team</td>
<td>Dan Littman, MD, PhD, New York University Grossman School of Medicine</td>
</tr>
<tr>
<td>100</td>
<td>Integrating Microbiome and Organoid Analyses of Patient Cohorts for Immuno-oncology Therapeutic Development</td>
<td>Calvin Kuo, MD, PhD, Stanford University</td>
</tr>
<tr>
<td>101</td>
<td>Multi-omic Analysis of Immune System and Microbiota Influence on Temporal and Spatial Evolution of Tumor Microenvironments</td>
<td>Calvin Kuo, MD, PhD, Stanford University</td>
</tr>
<tr>
<td>102</td>
<td>SU2C Convergence 3.1416 Research Team</td>
<td>Rong Fan, PhD, Yale University</td>
</tr>
<tr>
<td>103</td>
<td>Intra-team Collaboration: The Multi-organ Organoid Chemostat Group</td>
<td>Mark M. Davis, PhD, Stanford University</td>
</tr>
<tr>
<td>104</td>
<td>Correlating Immunological Health to Cancer Susceptibility</td>
<td>Benjamin Greenbaum, PhD, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>105</td>
<td>SU2C Convergence Research Team</td>
<td>Vinod Balachandran, MD, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>106</td>
<td>Computational Deconstruction of Neoantigen-TCR Degeneracy for Cancer Immunotherapy</td>
<td>Benjamin Greenbaum, PhD, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>107</td>
<td>SU2C Convergence Research Team</td>
<td>Constantine S. Mitsiades, MD, PhD, Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>108</td>
<td>Single-Cell Functional Multi-omics to Characterize and Monitor CAR T Therapy</td>
<td>E. John Wherry, PhD, University of Pennsylvania</td>
</tr>
<tr>
<td>109</td>
<td>Machine Learning for Cancer Immunotherapy</td>
<td>E. John Wherry, PhD, University of Pennsylvania</td>
</tr>
<tr>
<td>110</td>
<td>SU2C–Lustgarten Foundation Convergence Research Team</td>
<td>E. John Wherry, PhD, University of Pennsylvania</td>
</tr>
<tr>
<td>111</td>
<td>Computational Deconstruction of Neoantigen-TCR Degeneracy for Cancer Immunotherapy</td>
<td>E. John Wherry, PhD, University of Pennsylvania</td>
</tr>
<tr>
<td>112</td>
<td>SU2C Convergence Research Team</td>
<td>E. John Wherry, PhD, University of Pennsylvania</td>
</tr>
<tr>
<td>113</td>
<td>Integrating Experimental and Computational Pipelines to Develop Biomarkers of Tumor Cell Resistance to NK Cells</td>
<td>E. John Wherry, PhD, University of Pennsylvania</td>
</tr>
<tr>
<td>114</td>
<td>Responders and Non-responders to Endometrial Cancers With Mismatch Repair</td>
<td>E. John Wherry, PhD, University of Pennsylvania</td>
</tr>
<tr>
<td>115</td>
<td>SU2C Convergence Research Team</td>
<td>E. John Wherry, PhD, University of Pennsylvania</td>
</tr>
<tr>
<td>116</td>
<td>Connecting Immune Health and Tumor Biology in Gynecologic Cancers</td>
<td>E. John Wherry, PhD, University of Pennsylvania</td>
</tr>
</tbody>
</table>

**JUNE 2022 STAND UP TO CANCER SCIENCE PORTFOLIO 2009-2022**
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Team Lead/Co-Leaders</th>
</tr>
</thead>
<tbody>
<tr>
<td>108</td>
<td>SU2C–Breast Cancer Research Foundation Convergence Research Team</td>
<td>Peter P. Lee, MD, City of Hope</td>
</tr>
<tr>
<td></td>
<td>Ecology of the Tumor Microenvironment in Breast Cancer</td>
<td></td>
</tr>
<tr>
<td>109</td>
<td>SU2C–National Science Foundation Convergence Research Team</td>
<td>Anthony G. Letai, MD, PhD, Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td></td>
<td>Rational Design of Anticancer Drug Combinations with Dynamic Multi-Dimensional Input</td>
<td></td>
</tr>
<tr>
<td>110</td>
<td>SU2C–National Science Foundation Convergence Research Team</td>
<td>Ross Levine, MD, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td></td>
<td>Genetic, Epigenetic, and Immunological Underpinnings of Cancer Evolution Through Treatment</td>
<td></td>
</tr>
<tr>
<td>111</td>
<td>SU2C–National Science Foundation-Lustgarten Foundation Convergence Research Team</td>
<td>Peter O’Dwyer, MD, University of Pennsylvania, Jeffrey Dresin, MD, Memorial Sloan Kettering Cancer Center, Jedd Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td></td>
<td>Liberating T-Cell Mediated Immunity to Pancreatic Cancer</td>
<td></td>
</tr>
<tr>
<td>112</td>
<td>SU2C CATALYST® TEAMS</td>
<td></td>
</tr>
<tr>
<td>113</td>
<td>SU2C Catalyst® Research Team With Support From Jazz Pharmaceuticals</td>
<td>Patrick Grohar, MD, PhD, Children’s Hospital of Philadelphia</td>
</tr>
<tr>
<td></td>
<td>The LiFFT Study (Lurbinectedin in FET-Fusion Tumors)</td>
<td></td>
</tr>
<tr>
<td>114</td>
<td>SU2C Catalyst® Research Team With Support From Jazz Pharmaceuticals</td>
<td>Fred R. Hirsch, MD, PhD, Icahn School of Medicine at Mount Sinai</td>
</tr>
<tr>
<td></td>
<td>Identification of Combination Therapeutics Using JZP-815 for the Treatment of NSCLC</td>
<td></td>
</tr>
<tr>
<td>115</td>
<td>Lung Cancer Health Equity SU2C Catalyst® Research Team</td>
<td>Vamsidhar Veicheti, MD, New York University Grossman School of Medicine</td>
</tr>
<tr>
<td></td>
<td>Technology-Enabled Immunotherapy Monitoring in NYC Minority NSCLC Patients</td>
<td></td>
</tr>
<tr>
<td>116</td>
<td>SU2C Catalyst® Research Team Grant Program With Support From Mirati Therapeutics</td>
<td>Ryan B. Corcoran, MD, PhD, Massachusetts General Hospital</td>
</tr>
<tr>
<td></td>
<td>Targeting Adaptive and Acquired Resistance to Direct KRAS Inhibition</td>
<td></td>
</tr>
<tr>
<td>117</td>
<td>SU2C Catalyst® Research Team With Support From Genentech</td>
<td>Sean M. McBride, MD, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td></td>
<td>Atezolizumab, Abiraterone, and SBRT in Hormone Sensitive Prostate Cancer</td>
<td></td>
</tr>
<tr>
<td>118</td>
<td>SU2C Catalyst® Research Team With Support From Genentech</td>
<td>Elizabeth A. Mittendorf, MD, PhD, Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td></td>
<td>Combination Sacituzumab and Atezolizumab to Prevent Recurrence in Triple Negative Breast Cancer (TNBC)</td>
<td></td>
</tr>
<tr>
<td>119</td>
<td>Pediatric SU2C Catalyst® Research Team With Support From Bristol Myers Squibb</td>
<td>Uri Tabori, MD, The Hospital for Sick Children</td>
</tr>
<tr>
<td></td>
<td>Clinical Translation of Novel Immune-Based Combination Therapies for Pediatric Hypermutant Cancers</td>
<td></td>
</tr>
<tr>
<td>120</td>
<td>Pediatric SU2C Catalyst® Research Team With Support From Bristol Myers Squibb</td>
<td>Maryam Fouledi, MD, Nationwide Children’s Hospital</td>
</tr>
<tr>
<td></td>
<td>Immunomodulation to Treat Poor-Prognosis Pediatric Brain Tumors</td>
<td></td>
</tr>
</tbody>
</table>
### TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>SU2C Catalyst® Research Team With Support From</th>
<th>Title of Project</th>
<th>Team Leader(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>121</td>
<td>Bristol Myers Squibb</td>
<td>Targeting Epigenetic Dysregulation in Pediatric Cancer</td>
<td>Kimberly Stegmaier, MD, Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>122</td>
<td>Genentech</td>
<td>Neoadjuvant Therapy for Patients With High-Risk Stage III Melanoma</td>
<td>Matthew S. Block, MD, PhD, Mayo Clinic</td>
</tr>
<tr>
<td>123</td>
<td>Genentech</td>
<td>Immunotherapy Combination Strategies in ER-Positive Metastatic Breast Cancer</td>
<td>Ingrid A. Mayer, MD, Vanderbilt University</td>
</tr>
<tr>
<td>125</td>
<td>Genentech</td>
<td>Overcoming Urothelial Cancer Atezolizumab Resistance by Epigenetic Therapy</td>
<td>Peter A. Jones, PhD, DSc, Van Andel Institute</td>
</tr>
<tr>
<td>126</td>
<td>Bristol Myers Squibb</td>
<td>Tumor Infiltrating Lymphocyte Adoptive T-Cell Therapy for Non-small Cell Lung Cancer (NSCLC)</td>
<td>Eric B. Haura, MD, H. Lee Moffitt Cancer Center &amp; Research Institute; Scott J. Antonia, MD, PhD, Duke University</td>
</tr>
<tr>
<td>127</td>
<td>Bristol Myers Squibb</td>
<td>Immunotherapy to Prevent Progression in Multiple Myeloma</td>
<td>Irene M. Ghobrial, MD, Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>128</td>
<td>Merck</td>
<td>Pembrolizumab and Radiation Therapy to Improve Outcome in High-Risk Sarcoma</td>
<td>David G. Kirsch, MD, PhD, Duke University Medical School</td>
</tr>
<tr>
<td>129</td>
<td>Bristol Myers Squibb</td>
<td>Reversing Primary Anti-PD-1 Resistance with Ipilimumab and Nivolumab</td>
<td>Antoni Ribas, MD, PhD, University of California, Los Angeles</td>
</tr>
<tr>
<td>130</td>
<td>Merck</td>
<td>Targeting VDR to Make Pancreatic Cancer Competent for Immunotherapy</td>
<td>Daniel D. Von Hoff, MD, Translational Genomics Research Institute</td>
</tr>
<tr>
<td>132</td>
<td>Merck</td>
<td>Combined Epigenetic Therapy and Pembrolizumab for Advanced Non-small Cell Lung Cancer (NSCLC)</td>
<td>Stephen B. Baylin, MD, Johns Hopkins University</td>
</tr>
<tr>
<td>134</td>
<td>Bristol Myers Squibb</td>
<td>Combined Approaches by Immune Checkpoint Inhibition for Hypermutant Cancers</td>
<td>Uri Y. Tabori, MD, The Hospital for Sick Children</td>
</tr>
<tr>
<td>135</td>
<td>Merck</td>
<td>DNA Repair Therapies for Ovarian Cancer</td>
<td>Alan D. D’Andrea, MD, Dana-Farber Cancer Institute</td>
</tr>
</tbody>
</table>
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>136</td>
<td>INNOVATIVE RESEARCH GRANTS</td>
</tr>
<tr>
<td>137</td>
<td>CLASS OF 2017</td>
</tr>
<tr>
<td>138</td>
<td>CLASS OF 2016</td>
</tr>
<tr>
<td>139</td>
<td>CLASS OF 2011</td>
</tr>
<tr>
<td>140</td>
<td>CLASS OF 2009</td>
</tr>
<tr>
<td>141</td>
<td>THE PHILLIP A. SHARP INNOVATION IN COLLABORATION AWARDS</td>
</tr>
<tr>
<td>142</td>
<td>CLASS OF 2020</td>
</tr>
<tr>
<td>142</td>
<td>CLASS OF 2019</td>
</tr>
<tr>
<td>142</td>
<td>CLASS OF 2018</td>
</tr>
<tr>
<td>143</td>
<td>CLASS OF 2017</td>
</tr>
<tr>
<td>143</td>
<td>CLASS OF 2016</td>
</tr>
<tr>
<td>143</td>
<td>CLASS OF 2015</td>
</tr>
<tr>
<td>143</td>
<td>CLASS OF 2014</td>
</tr>
<tr>
<td>144</td>
<td>ADDITIONAL AWARDS AND PRIZES</td>
</tr>
<tr>
<td>148</td>
<td>REVIEWERS</td>
</tr>
<tr>
<td>153</td>
<td>INDEX BY TYPES OF CANCER</td>
</tr>
<tr>
<td>155</td>
<td>INDEX BY PERSON</td>
</tr>
<tr>
<td>161</td>
<td>THANK YOU</td>
</tr>
</tbody>
</table>
**ADVISORY COMMITTEES**

**SU2C Scientific Advisory Committee**

**Phillip A. Sharp, PhD**  
Chairperson  
Institute Professor  
Koch Institute for Integrative Cancer Research  
Massachusetts Institute of Technology

**Elizabeth H. Blackburn, PhD**  
Vice Chairperson  
Professor Emerita  
The University of California, San Francisco

**Raymond N. DuBois, MD, PhD**  
Vice Chairperson  
Director, Hollings Cancer Center  
Dean, College of Medicine  
Medical University of South Carolina

**Lee J. Helman, MD**  
Vice Chairperson  
Director, Osteosarcoma Institute  
Adjunct Clinical Professor of Pediatrics  
Cancer and Blood Disease Institute  
CHLA, Keck School of Medicine, University of Southern California

**Arnold J. Levine, PhD**  
Vice Chairperson  
Professor Emeritus  
Institute for Advanced Study and Cancer Institute of New Jersey

**William G. Nelson, MD, PhD**  
Vice Chairperson  
Director, Sidney Kimmel Comprehensive Cancer Center  
Johns Hopkins University

**Edith A. Perez, MD**  
Vice Chairperson  
Chief Medical Officer, Bolt Biotherapeutics  
Professor of Medicine, Mayo Clinic

**Julian Adams, PhD**  
Chief Executive Officer  
Gamida-Cell

**Carlos L. Arteaga, MD**  
Lisa K. Simmons Distinguished Chair in Comprehensive Oncology  
UT Southwestern Harold C. Simmons Cancer Center

**Alan Bernstein, PhD**  
President and CEO  
Canadian Institute for Advanced Research

**John D. Carpten, PhD**  
Director of the Institute for Translational Genomics  
Keck School of Medicine of University of Southern California

**Judy E. Garber, MD, MPH**  
Chief, Division for Cancer Genetics and Prevention  
Dana-Farber Cancer Institute

**Richard B. Gaynor, MD**  
President, Research and Development  
BioNTech US Inc.

**Laurie H. Glimcher, MD**  
President and CEO  
Dana-Farber Cancer Institute

**Nancy F. Goodman**  
Executive Director and Founder  
Kids v Cancer

**James L. Gulley, MD, PhD**  
Center for Cancer Research  
National Cancer Institute

**William N. Hait, MD, PhD**  
Global Head of External Innovation  
Janssen, Pharmaceutical Companies of Johnson & Johnson

**Waun Ki Hong, MD (In Memorium)**  
The University of Texas MD Anderson Cancer Center
William G. Kaelin, Jr., MD  
Sidney Farber Professor of Medicine,  
Harvard Medical School  
Dana-Farber Cancer Institute

Michael B. Kastan, MD, PhD  
Director  
Duke Cancer Institute

Guillermina (Gigi) Lozano, PhD  
Chairman and Professor  
The University of Texas MD Anderson Cancer Center

Tak W. Mak, PhD  
Chief Scientific Officer  
Campbell Family Institute

Andre Nussenzweig, PhD  
Chief, Laboratory of Genome Integrity  
NIH Distinguished Investigator  
Center for Cancer Research National Cancer Institute

Roderic I. Pettigrew, MD, PhD  
Chief Executive Officer,  
Engineering Health (EnHealth)  
Executive Dean  
Texas A&M University

Cecil B. Pickett, PhD  
President, R&D (Retired)  
Biogen Inc.

Arlene H. Sharpe, MD, PhD  
George Fabyan Professor of Comparative Pathology  
Co-Director, Harvard Institute of Translational Immunology  
Co-Director, Evergrande Center for Immunologic Diseases Harvard Medical School

Laura K. Shawver, PhD  
President and CEO  
Silverback Therapeutics

David A. Tuveson, MD, PhD  
Professor and Director  
Cold Spring Harbor Laboratory Cancer Center

Alan Bernstein, PhD  
Co-chairperson  
President and CEO  
Canadian Institute for Advanced Research

Phillip A. Sharp, PhD  
Chairperson  
Institute Professor  
Koch Institute for Integrative Cancer Research  
Massachusetts Institute of Technology

Carlos L. Arteaga, MD  
Lisa K. Simmons Distinguished Chair in Comprehensive Oncology  
UT Southwestern Harold C. Simmons Cancer Center

Jenny C. Chang, MD  
Emily Herrmann Chair in Cancer Research and Director  
Methodist Cancer Center at Houston Methodist Hospital

Carol L. Prives, PhD  
Da Costa Professor  
Columbia University

Patrick J. Sullivan  
Advocate President  
Team Finn Foundation
ADVISORY COMMITTEES

SU2C Catalyst Executive Committee

Phillip A. Sharp, PhD
Chairperson
Institute Professor
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology

Lee J. Helman, MD
Director, Osteosarcoma Institute
Adjunct Clinical Professor of Pediatrics
Cancer and Blood Disease Institute
CHLA, Keck School of Medicine,
University of Southern California

Arnold J. Levine, PhD
Professor Emeritus
Institute for Advanced Study and
Cancer Institute of New Jersey

William G. Nelson, MD, PhD
Vice Chairperson
Director, Sidney Kimmel Comprehensive
Cancer Center
Johns Hopkins University

Cecil B. Pickett, PhD
President, R&D (Retired)
Biogen Inc.

Lillian L. Siu, MD
Professor, Staff Medical Oncologist and
Director of Phase I Program
Princess Margaret Cancer Centre

Pediatric SU2C Catalyst Executive Committee

Phillip A. Sharp, PhD
Chairperson
Institute Professor
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology

Alan D. D’Andrea, MD
Director, Susan F. Smith Center
for Women’s Cancers
Dana-Farber Cancer Institute

Lisa R. Diller, MD
Chief Medical Officer, Dana-Farber/Boston
Children’s Cancer and Blood Disorders Center
Dana-Farber Cancer Institute

Raymond N. DuBois, MD, PhD
Director, Hollings Cancer Center
Dean, College of Medicine
Medical University of South Carolina

Arnold J. Levine, PhD
Professor Emeritus
Institute for Advanced Study and Cancer
Institute of New Jersey
**SU2C Health Equity Committee**

**Edith A. Perez, MD**  
Chairperson  
Chief Medical Officer, Bolt Biotherapeutics  
Professor of Medicine, Mayo Clinic

**Cheryl A. Boyce (In Memoriam)**  
Retired Executive Director  
Ohio Commission on Minority Health

**John D. Carpten, PhD**  
Director of the Institute for Translational Genomics  
Keck School of Medicine of University of Southern California

**Andrew T. Chan, MD, MPH**  
Professor of Medicine  
Harvard Medical School

**Shawna Hudson, PhD**  
Professor and Research Division Chief, Department of Family Medicine and Community Health  
Rutgers Robert Wood Johnson Medical School

**Chanita Hughes-Halbert, PhD**  
Vice Chair for Research and Professor, Department of Population and Public Health Sciences  
Associate Director for Cancer Equity  
Norris Comprehensive Cancer Center  
University of Southern California

**Elizabeth M. Jaffee, MD**  
Deputy Director  
The Sidney Kimmel Comprehensive Cancer Center  
Johns Hopkins University

**Guillermina (Gigi) Lozano, PhD**  
Chairman and Professor  
The University of Texas MD Anderson Cancer Center

**John Whyte, MD, MPH**  
Chief Medical Officer  
WebMD

**Raymond M. Williams, JD**  
Senior Counsel  
DLA Piper

**David R. Wilson, PhD**  
Director of the Tribal Health Research Office  
National Institutes of Health

**Karen M. Winkfield, MD, PhD**  
Executive Director  
Meharry-Vanderbilt Alliance

**Robert A. Winn, MD**  
Director  
Massey Cancer Center  
Virginia Commonwealth University
ABOUT SU2C
Founded in 2008 by women leaders in the entertainment and media industries, Stand Up To Cancer is a groundbreaking movement that accelerates cancer research and gets new therapies to patients quickly to save lives now.

Since our founding, Stand Up To Cancer has supported more than 175 science projects to multi-year, multi-institution collaborations with budgets of up to $22 million. More than $746 million has been pledged for these efforts. We have funded 125 team science projects, as well as 50 individuals through our Innovative Research Grants for early-career researchers and other grants. And more than 260 clinical trials enrolling more than 19,000 patients have been launched. To date, SU2C research has contributed to nine FDA approvals of cancer therapies.

SU2C’s research projects bring together top investigators from different institutions to accelerate the discovery and delivery of new therapies, and they have evolved to include an array of industry collaborations, as well. Focusing on accelerating the development of new therapies, new methods of cancer interception, and new approaches to making these treatments and screening available to all, we have created grant mechanisms that fund meaningful team-based research projects. Collectively, they offer opportunities for cancer science and cancer treatment questions to be answered using a variety of techniques.

- Our flagship Dream Team grants fund multidisciplinary, multi-institutional, collaborative teams to take innovative ideas from concept to patient.

- Research Teams bring together scientists from different institutions answering important questions about cancer research and treatment.

- SU2C Convergence Grants unite physical and computational scientists with oncologists to ask fundamental questions about cancer biology, producing insights that can be rapidly applied for patient benefits.

- SU2C Catalyst® teams use funding, compounds, and other materials from the pharmaceutical and biotechnology industries to rapidly assess new treatment combinations.

- Innovative Research Grants support cutting-edge cancer research that might not receive funding through traditional channels.

- And the Phillip A. Sharp Innovation in Collaboration Award, the Ziskin Prize, the Jim Toth Sr. Breakthrough Lung Cancer Research Award, the Peggy Prescott Early Career Award, and the Golden Arrow Award provide support for smaller projects to rapidly explore the newest and most exciting ideas emerging from the cancer research community.

To further support development of cancer treatments that are effective across all communities, the SU2C Health Equity Committee continues to help us find ways to lower the barriers of access to new treatments for all cancer patients.

With mounting evidence for the need to develop precision medical treatments and interventions to serve diverse patient populations, we are supporting the inclusion of historically under-represented racial and ethnic minority populations in clinical trials that we fund. SU2C staff continue to produce educational materials for the public to drive awareness of clinical trials and participation, as well.
DREAM TEAMS
Community Collaboration to Advance Racial/Ethnic Equity in CRC Screening

**PRINCIPALS:**
- Tinka Duran, MPH, Great Plains Tribal Chairmen’s Health Board
- Sapna Syngal, MD, MPH, Dana-Farber Cancer Institute
- Staci J. Wendt, PhD, Providence System Research Hub
- Bill Wright, PhD, Providence System Research Hub

**PROJECT MANAGERS:**
- Suzanne Brodney, PhD, Massachusetts General Hospital, Sbrodney@mgh.harvard.edu
- Rhea Cabardo, Providence Saint John’s Health

**ADVOCATES:**
- Marsha Baker, Fight CRC; Steve Baker Colorectal Cancer Alliance
- Cathy Jeffries
- Kimberly Schoolcraft, Fight CRC
- Helena L Williams

**SPECIFIC AIMS:**

**AIM 1.** Develop and conduct a two-arm, multilevel, multicomponent, pragmatic trial randomized at the level of the community health center to compare two population outreach approaches, Cologuard or fecal immunochemical test (FIT), to increase CRC screening.

**AIM 2.** Conduct patient follow-up after an abnormal Cologuard or FIT screening test result.

**AIM 3.** Mentor a new generation of underrepresented in medicine and underrepresented in public health researchers focused on CRC prevention and control.

**AIM 4:** Design and deploy a community-based campaign to increase CRC screening rates in a demographically diverse impact zone within Los Angeles County.

**WEBSITE:**
https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-health-equity-dream-team/
Community Engagement Grants:
Local organizations are supporting grassroots engagement to increase colorectal cancer screening in each Stand Up To Cancer Zone.

**Boston**
Greater Boston Nazarene Compassionate Center
Whittier Street Health Center

**Los Angeles**
Black Women for Wellness
Corazon y Caracter
TRAPMedicine

**Great Plains Tribal Communities in South Dakota**
Oyate Health Center
SU2C Health Equity Breakthrough Team BT6209

DISRUPT: Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

**GRANT TERM:** May 2021 – April 2025

**KEY PERSONNEL:**

**Team Leader:**
Nina A. Bickell, MD, MPH,
Icahn School of Medicine at Mount Sinai

**Team Co-leader:**
Karen Hubbard, PhD,
City College of New York

**Principals:**
- Bruce Rapkin, PhD,
  Albert Einstein College of Medicine
- Mary Beth Terry, PhD,
  Columbia University

**Project Managers:**
- Nicholas Bove,
  Albert Einstein College of Medicine,
nicholas.bove@einsteinmed.edu
- Kimberly Burke,
  Columbia University,
  krb2160@cumc.columbia.edu
- Kelly Smith Elgart,
  Albert Einstein College of Medicine,
kellysmith176@gmail.com
- Leo Spychala, MPH,
  City College of New York,
  lspychala@ccny.cuny.edu
- Ariana Tao,
  Albert Einstein College of Medicine
  ariana.tao@einsteinmed.org
- Radhi M. Yagnik, MS,
  Icahn School of Medicine at Mount Sinai,
  Radhi.Yagnik@mountsinai.org

**Advocates:**
- Rev. Zorina Costello,
  DMin, MDiv, MS,
  Center for Spirituality and Health,
  Icahn School of Medicine at Mount Sinai
- Ivis Sampayo, SHARE Cancer Support
- Desiree Walker

**Specific Aims:**

**AIM 1.** Address community norms regarding participation in cancer research.

**AIM 2.** Disrupt current practice by making cancer clinical trials an easy and accessible choice for every patient.

**AIM 3.** Disrupt norms in clinical trial design and methods by supporting basic science discovery that will increase its relevance to questions essential to reducing cancer health inequities.

**Websites:**

https://standuptocancer.org/research/research-portfolio/dream-teams/health-equity-breakthrough-dream-team/

https://www.stopcancernyc.org/
PASS-01- Pancreatic Adenocarcinoma Signature Stratification for Treatment-01

**GRANT TERM:** August 2020 – February 2024

**KEY PERSONNEL:**

**Team Co-leader:**
Jennifer Knox, MD, University Health Network

**Team Co-leader:**
Elizabeth Jaffee, MD, John Hopkins University

**Principals:**
- Andrew Aquirre, MD, PhD, Dana-Farber Cancer Institute
- Steven Gallinger, MD, Ontario Institute for Cancer Research
- Daniel King, MD, Northwell Health Center for Advanced Medicine
- Daniel Laheru, MD, Johns Hopkins University
- Eileen O’Reilly, MD, Memorial Sloan Kettering Cancer Center
- Kenneth Yu, MD, Memorial Sloan Kettering Cancer Center

**Collaborator:**
- David Tuveson, MD, PhD, Cold Spring Harbor Laboratory

**Project Manager:**
- Anna Dodd, University Health Network, Anna.Dodd@uhn.ca

**Specific Aims:**

**AIM 1.** Determine the PFS benefit of modified FOLFIRINOX (mFFX) compared with gemcitabine/nab-paclitaxel (GA) as first-line treatment in metastatic pancreatic ductal adenocarcinoma (PDAC) in a randomized phase II trial.

**AIM 2.** Explore biomarker correlation to treatment response and patient outcomes.

**AIM 3.** Evaluate concordance between patient response and outcomes with model (PDO) profiles, signatures, and pharmacotyping.

**AIM 4.** Compile a detailed genomic annotation of advanced PDAC patients on first-line chemotherapy.

**Clinical Trial:**
A Randomized Multicentre Phase II Trial to Evaluate the Two Standard Chemotherapy Regimens, Modified FOLFIRINOX (mFFX) and Gemcitabine/Nab-Paclitaxel (GA), in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma; NCT04469556; Recruiting

**Website:**
https://standuptocancer.ca/the-science/pass-dream-team/
SU2C Canada Metastatic Breast Cancer Dream Team DT5745

**Targeting mRNA Translation to Effectively Treat Metastatic Breast Cancer**

**GRANT TERM:** July 2019 – September 2022, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Nahum Sonenberg, PhD, McGill University

**Team Co-leader:**
Michael N. Pollak, MD, Lady Davis Institute for Medical Research

**Principals:**
- Lynne-Marie Postovit, PhD, Queens University
- Poul H. B. Sorenson, MD, PhD, BC Cancer Research Institute

**Project Manager:**
Harvey W. Smith, PhD, McGill University, harvey.smith2@mcgill.ca

**Advocates:**
- Candace Cook
- Lynn Gentile, Lynn and Joe Gentile Hope Fund

**Specific Aims:**

**AIM 1.** Run clinical trial of the MNK inhibitor EFT508 in patients with metastatic breast cancer.

**AIM 2.** Conduct pharmacodynamic studies of the MNK inhibitor EFT508 in patients with metastatic breast cancer.

**Clinical Trial:**

Trial to Assess the Safety, Pharmacodynamic Effects, Pharmacokinetics, and Efficacy of the MNK Inhibitor Tomivosertib (eFT508) in Combination With Paclitaxel, Following a Run-In Period of Tomivosertib Monotherapy, in Patients With Advanced Breast Cancer; NCT04261218; Recruiting

**Website:**
http://www.standuptocancer.ca/en/dream_teams/view/metastatic_breast_cancer_dream_team
Tailoring CAR-based Immunotherapy Strategies to T-Cell Lymphoma

**GRANT TERM:** March 2019 – August 2022, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:** Helen E. Heslop, MD, Baylor College of Medicine

**Team Co-leader:** Gianpietro Dotti, MD, University of North Carolina at Chapel Hill

**Principals:**
- Bayard L. Powell, MD, Wake Forest University Health Sciences
- Katy Rezvani, MD, PhD, The University of Texas MD Anderson Cancer Center

**Project Manager:**
- Reynaldo Herrera, Baylor College of Medicine, Reynaldo.Herrera@bcm.edu

**Advocates:**
- Gustavo Ayala, University of Texas Health Science Center at Houston
- Bambi Grilley, Baylor College of Medicine
- Ruth Sorelle, Baylor College of Medicine
- Patty Spears, University of North Carolina at Chapel Hill

**Specific Aims:**

**AIM 1.** Conduct a series of phase I clinical trials of CAR-ACT targeting different T-cell antigens in patients with resistant TCLs.

**AIM 2.** Identify factors that shape responses to CAR-ACT and thus inform the next generation of immune cell engineering.

**AIM 3.** Test additional modifications of CAR-ACT to improve their function against resistant TCLs.

**Clinical Trials:**

Phase I Study of Relapsed CD30 Expressing Lymphoma Treated With CD30 CAR T Cells (RELY-30); NCT02917083; Recruiting

Phase I Study of the Administration of T Lymphocytes Co-expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma; NCT03602157; Recruiting

Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T-Cell Lymphoma; NCT04083495; Recruiting

Phase I Study Evaluating the Safety and Activity of Allogeneic Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas; NCT04288726; Recruiting

**Website:**
https://standuptocancer.org/research/research-portfolio/dream-teams/t-cell-lymphoma-dream-team
SU2C Multiple Myeloma Dream Team DT6046

Screening and Interception of Precursor Myeloma

**GRANT TERM:** September 2018 – August 2022, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Principals:**
- Gad A. Getz, PhD, Broad Institute
- Jeremiah A. Johnson, PhD, Massachusetts Institute of Technology
- Prashant Kapoor, MBBS, Mayo Clinic
- Timothy R. Rebbeck, PhD, Harvard T. H. Chan School of Public Health

**Project Director:**
- Elizabeth Kitzenberg
  Dana-Farber Cancer Institute

**Team Leader:**
Irene M. Ghobrial, MD, Dana-Farber Cancer Institute

**Team Co-leader:**
Ivan M. Borrello, MD, Johns Hopkins University School of Medicine

**Project Manager:**
- Julia Colchie,
  Dana-Farber Cancer Institute,
  julia_colchie@dfci.harvard.edu

**Advocates:**
- Jenny M. Ahlstrom, Crowd Care Foundation
- Cheryl A. Boyce (deceased)
- Marie Cherisol
- Rebecca A. Nutley
- Kelly Smith
- Yaphet Smith

**Specific Aims:**

**AIM 1.** Establish a screen-detected prospective cohort study of monoclonal gammopathy of undetermined significance (MGUS)/smoldering multiple myeloma (SMM) patients at risk for multiple myeloma (MM) (Predicting Progression of Developing Myeloma in a High-Risk Screened Population, PROMISE).

**AIM 2.** Dissect genomic characteristics of clonal evolution from MGUS/SMM to MM and germline variants of high-risk individuals at risk of developing MGUS/SMM.

**AIM 3.** Evaluate the role of race, obesity, and health-related comorbidities on progression from pre-MM states to MM.

**AIM 4.** Define the permissive tumor microenvironment in MGUS/SMM.

**AIM 5.** Develop novel imaging and therapeutic approaches to detect and intercept disease progression at the precursor stages of the disease.

**Clinical Trial:**

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE); NCT03689595; Recruiting

**Websites:**

https://standuptocancer.org/research/research-portfolio/dream-teams/precursor-myeloma-dream-team/

https://www.enroll.promisestudy.org/

---

**THE PROMISE STUDY**

Will you join the mission to help stop myeloma before it starts?!
Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)

**GRANT TERM:** March 2018 – August 2022, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:** Avrum E. Spira, MD, Boston University

**Team Co-leader:** Steven M. Dubinett, MD, University of California, Los Angeles

**Principals:**
- Charles Swanton, MD, PhD, Francis Crick Institute
- Carina Mari Aparici, MD, Stanford University
- Julie R. Brahmer, MD, Johns Hopkins University
- Matthew L. Meyerson, MD, PhD, Dana-Farber Cancer Institute

**Project Manager:**
- Sarah Mazilli, PhD, Boston University, mazzilli@bu.edu

**Advocates:**
- Marcia Horn, JD, International Cancer Advocacy Network
- Kim Norris, Lung Cancer Foundation of America

**Specific Aims:**

**AIM 1.** Establish a Pre-Cancer Genome Atlas (PCGA) to identify genomic, transcriptomic, and immune determinants of lung squamous and adenomatous premalignancy.

**AIM 2.** Identify molecular and imaging markers that distinguish malignant from benign indeterminate pulmonary nodules and circulating DNA markers that predict tumor recurrence.

**AIM 3A.** Develop molecular biomarkers to enable precision interception approaches in ongoing clinical trials of lung cancer interception.

**AIM 3B.** Discover baseline biomarkers predictive of therapeutic response to neoadjuvant therapy with immune checkpoint inhibitors and temporal markers of therapeutic efficacy.

**AIM 3C.** Assess therapeutic efficacy of adjuvant chemotherapy and immunotherapy among patients with subclinical evidence of lung cancer recurrence using ctDNA.

**Website:**
SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team DT6045

Clinical Trials:
Neoadjuvant Nivolumab, or Nivolumab in Combination with Ipilimumab, in Resectable Non-small Cell Lung Cancer; NCT02259621; Recruiting
18F-FSPG PET/CT and Integrated Biomarkers for Early Lung Cancer Detection in Patients With Indeterminate Pulmonary Nodules; NCT03824535; Recruiting
Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-Based Chemotherapy in Completely Resected Stage 2-3 NSCLC (MERMAID-1); NCT04385368; Recruiting
Intercepting Pancreatic Cancer in High-Risk Cohorts

**GRANT TERM:** February 2018 – July 2022, administered by the American Association for Cancer Research

**Project Manager:**
- Pamela Constantinou Papadopoulos, PhD, The University of Texas MD Anderson Cancer Center, pcpapadopoulos@mdanderson.org

**Advocates:**
- Barbara J. Kenner, PhD, Kenner Family Research Fund
- Scott Nelson

**Specific Aims:**

**AIM 1.** Enhance access to germline testing and screening protocols for cancer interception in high-risk cohorts and combine this with novel imaging algorithms to diagnose early PDAC lesions that are currently undetectable.

**AIM 2.** Intercept pancreatic cancer in high-risk cohorts using targeted immune prevention.

**AIM 3.** Develop a blood test for identifying individuals at risk for PDAC who would be candidates for early detection using imaging.

**Clinical Trial:**
- GENetic Education Risk Assessment and TEsting Study (GENERATE); NCT03762590; Active, not recruiting
- Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined with Nivolumab and Ipilimumab for Patients with Resected MMR-p Colorectal and Pancreatic Cancer; NCT04117087; Recruiting
- Mutant KRAS-Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer; NCT05013216; Not yet recruiting

**Website:**
St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team DT6065

Immunogenomics to Create New Therapies for High-Risk Childhood Cancers

**GRANT TERM:** December 2017 – May 2022, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
John M. Maris, MD, Children’s Hospital of Philadelphia

**Team Co-leader:**
Crystal L. Mackall, MD, Stanford University

**Principals:**
- Nabil M. Ahmed, MD, Baylor College of Medicine
- Lia Gore, MD, University of Colorado
- Rimas Orentas, PhD, Seattle Children’s Hospital
- Paul M. Sondel, MD, PhD, University of Wisconsin, Madison
- Poul H. B. Sorensen, MD, PhD, BC Cancer Research Institute
- Michael D. Taylor, MD, PhD, The Hospital for Sick Children

**Investigators:**
- Kenneth B. DeSantes, MD, University of Wisconsin, Madison
- Dimiter Dimitrov, PhD, University of Pittsburgh
- Terry J. Fry, MD, University of Colorado
- Stephan Grupp, MD, PhD, Children’s Hospital of Philadelphia
- Rosandra N. Kaplan, MD, National Cancer Institute
- Michelle Monje, MD, Stanford University
- Daniel Morgenstern, MA, MBChir, PhD, The Hospital for Sick Children
- Julie R. Park, MD, Seattle Children’s Hospital
- D. William Parsons, MD, PhD, Texas Children’s Hospital
- Kirk R. Schultz, MD, BC Cancer Research Institute
- Nirali N. Shah, MD, MHSc, National Cancer Institute

**Project Manager:**
- Jennifer L. Baldi, Children’s Hospital of Philadelphia, baldij@email.chop.edu

**Advocates:**
- Kelly Cotter, University of Wisconsin
- Kelly Forebough, Seattle Children’s Hospital
- Bambi J. Grilley, Baylor College of Medicine
- Gavin Lindberg, Children’s Hospital of Philadelphia
- Melanie Frost Moll, Baylor College of Medicine
- Antonia Palmer, The Hospital for Sick Children
- Kevin Reidy, University of Colorado
- Carlos Sandi, Stanford University and the National Cancer Institute
- Lori Schultz, University of Wisconsin
- Patrick J. Sullivan, BC Cancer Research Institute

**Specific Aims:**

**AIM 1.** Discover and validate cell surface proteins as immunotherapeutic targets for high-risk pediatric cancers.

**AIM 2.** Perform preclinical optimization of candidate immunotherapeutics and IND-enabling studies to support the development of clinical trials for pediatric cancers with few therapeutic options.

**AIM 3.** Conduct pivotal pediatric cancer immunotherapy trials.
Clinical Trials:

Phase I Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for HER2-Positive Recurrent/Refractory Pediatric Central Nervous System Tumors; NCT03500991; Recruiting

Phase I Dose-Escalation Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-Expressing B-Cell Malignancies; NCT03448393; Recruiting

Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-06: Phase I/II Study of CD19-Specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma; NCT03684889; Active, not recruiting

Phase I Study of EGFR806-Specific CAR T Cell Locoregional Immunotherapy for EGFR-Positive Recurrent or Refractory Pediatric Central Nervous System Tumors; NCT03638167; Recruiting

Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults; NCT03618381; Recruiting

Phase II Study of Humanized CD19-Directed Chimeric Antigen Receptor–Modified T Cells (huCART19) for Very High Risk Subsets of B-Cell Acute Lymphoblastic Leukemia (B-ALL); NCT03792633; Recruiting

Treatment of CMV Infections With Viral-Specific T Cells Against CMV in Pediatric and Adult Immunocompromised Patients or Recipients of Allogeneic Stem Cell Transplantation; NCT03798301; Recruiting

Phase I Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Kidney Transplant Recipients; NCT03950414; Recruiting

GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor-Modified T Cells (GD2CART) for Sarcoma and Neuroblastoma to Increase Systemic Tumor Exposure; NCT04539366; Not yet recruiting

Open-Label Dose-Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors; NCT03478462; Recruiting

Phase I Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors; NCT04185038; Recruiting

Phase I/II Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia; NCT03971799; Recruiting

Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults; NCT04483778; Recruiting

Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B-Cell Malignancies; NCT04088864; Recruiting

Phase I Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T Cells (GD2CART) for Diffuse Intrinsic Pontine Gliomas (DiPG) and Spinal Diffuse Midline Gliomas (DMG); NCT04196413; Recruiting

Phase I Trial of Autologous HER2-Specific CAR T Cells in Pediatric Patients With Refractory or Recurrent Ependymoma; NCT04903080; Not yet recruiting

Website:
https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/
SU2C Colorectal Cancer Dream Team DT6044

Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer

**GRANT TERM:** July 2017 – June 2023, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:** Luis A. Diaz Jr., MD, Memorial Sloan Kettering Cancer Center

**Team Co-leader:** Lewis C. Cantley, PhD, Weill Cornell Medical College

**Team Co-leader:** Zhenghe J. Wang, PhD, Case Western Reserve University

**Principals:**

- Nilofer S. Azad, MD, Johns Hopkins University
- Ryan B. Corcoran, MD, PhD, Massachusetts General Hospital

**Project Manager:**

- Michelle F. Lamendola-Essel, DrHSc, Memorial Sloan Kettering Cancer Center lamendom@mskcc.org

**Advocates:**

- Erika Brown, Paltown Development Foundation
- Anjee Q. Davis, Fight Colorectal Cancer
- Joanna R. Fuchs, MD, Dana-Farber/ Harvard SPORE
- Manju George, Paltown Development Foundation
- Ivelisse Page, Believe Big
- Martha Raymond, Michael’s Mission
- Nancy Roach, Fight Colorectal Cancer
- Steven Schwarze, Paltown Development Foundation

**Specific Aims:**

**AIM 1.** Harness the immune system to treat colorectal cancer.

**AIM 2.** High impacted targeted pathway blockade in colorectal cancer.

**AIM 3.** Develop high-dose vitamin C as a therapy for KRAS/BRAF mutant colorectal cancer.

**AIM 4.** Target the glutamine dependence of PIK3CA mutant CRC in combination therapy with novel glutaminase inhibitor CB-839 plus capecitabine.

**AIM 5.** “Precision prevention” for colorectal cancer.

**Website:**

https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/
SU2C Colorectal Cancer Dream Team DT6044

Clinical Trials:

Phase II Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors; NCT01876511; Completed

Phase III Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage 4 Colorectal Carcinoma (KEYNOTE-177); NCT02563002; Active, not recruiting

Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer; NCT02861300; Recruiting

Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer; NCT03104439; Recruiting

Phase II Study of High-Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies; NCT03146962; Recruiting

Phase II Study of Dabrafenib and Trametinib in Combination With PDR001 in Patients With BRAFV600E Metastatic Colorectal Cancer; NCT03668431; Recruiting

Phase Ib/II Open-Label Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer; NCT02437136; Withdrawn

Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch Repair-Proficient (MSS) Colorectal Cancer; NCT03711058; Recruiting

Early Identification and Treatment of Occult Metastatic Disease in Stage 3 Colon Cancer; NCT03803553; Recruiting

Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair-Deficient Solid Tumors; NCT04165772; Recruiting

Phase II Study of Temozolomide, Cisplatin, and Nivolumab in MMR-Proficient Colorectal Cancer; NCT04457284; Recruiting
SU2C Canada–Canadian Cancer Society Breast Cancer Dream Team DT6144

Translational Development of Novel Drugs Targeting Tumor Vulnerabilities

**GRANT TERM:** January 2016 – June 2022, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Tak W. Mak, PhD, Campbell Family Institute for Breast Cancer Research at Princess Margaret Cancer Centre

**Team Co-leader:**
Samuel Aparicio, BM, BCh, PhD, University of British Columbia

**Principals:**
- Karen A. Gelmon, MD, British Columbia Cancer Agency
- Morag Park, PhD, Goodman Cancer Research Centre and McGill University
- Kathleen I. Pritchard, MD, University of Toronto, Sunnybrook Health Sciences Centre of Toronto

**Project Manager:**
Thorsten Berger, PhD, University Health Network
tberger@uhnres.utoronto.ca

**Advocates:**
- Wendie den Brok, MD, BC Cancer Agency Research Centre
- Randy Mellon, Think Pink Direct
- Zuri Scrivens, The Beautiful Gift

**Specific Aims:**

**AIM 1.** Pursue basic and translational development of CFI-400945, CX5461, and CFI-402257.

**AIM 2.** Conduct proof-of-concept clinical trials of CFI-400945, CX5461, and CFI-402257.

**Clinical Trials:**

Phase I Study of CX5461; NCT02719977; Active, not recruiting

Open-Label Dose-Escalation, Safety, and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Advanced Cancer; NCT01954316; Active, not recruiting

Open-Label Dose-Escalation, Safety, and Pharmacokinetic Study of CFI-402257 Administered Orally to Patients With Advanced Solid Tumors; NCT02792465; Recruiting

**Website:**
https://standuptocancer.ca/su2c-canada-canadian-cancer-society-breast-cancer-dream-team/
Clinical Trials (Cont’d):

Phase Ib and Open-Label Phase II Study of CFI-402257 in Combination With Weekly Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer; NCT03568422; Recruiting

Phase II Study of CFI-400945 in Patients With Advanced/Metastatic Breast Cancer; NCT03624543; Recruiting

Phase II Study of CFI-400945 and Durvalumab in Patients With Advanced/Metastatic Triple-Negative Breast Cancer (TNBC); NCT04176848; Recruiting
Reprogramming of Transcriptional Circuitry to Control Pancreatic Cancer

**GRANT TERM:** January 2016 – June 2020, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Daniel D. Von Hoff, MD, Translational Genomics Research Institute (TGEN)

**Team Co-leader:**
Gerard I. Evan, PhD, University of Cambridge

**Team Co-leader:**
Ronald M. Evans, PhD, Salk Research Institute for Biological Studies

**Principals:**
- David J. Propper, MBChB, MD, PhD, Barts Cancer Institute and London NHS Trust
- Joshua D. Rabinowitz, MD, PhD, Princeton University

**Advocates:**
- Suzanne Berenger, Bain & Company, Inc.
- Devah Pager, PhD, Harvard University (deceased)
- Jill E. Pechacek, MD (deceased)
- Howard Young, General Wholesale Beer Company

**Project Managers:**
- Jatan Clark, TGEN
- Stacie Smith, TGEN

**Specific Aims:**

**AIM 1.** Define super-enhancer networks in the cellular milieu of pancreatic cancer.

**AIM 2.** Determine the mechanisms that mediate crosstalk between super-enhancer networks both within cells and between them, including metabolic dependencies.

**AIM 3.** Determine the utility of super-enhancer disruption in treating pancreatic cancer. (Work on this Aim is continuing as an SU2C subproject.)

**Website:**
https://standuptocancer.org/research/research-portfolio/dream-teams/reprogramming-of-pancreatic-cancer-dream-team/
SU2C–Cancer Research UK–Lustgarten Foundation
Pancreatic Cancer Dream Team DT6014

Clinical Trials:

Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma; NCT02754726; Active, not recruiting

Phase II Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer; NCT03336216; Active, not recruiting

Phase Ib/II Trial of High-Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Band + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Received No Prior Therapy for Their Metastatic Pancreatic Cancer; NCT03410030; Active, not recruiting

Phase II Pilot Trial of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD); NCT03415854; Active, not recruiting

Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer; NCT03520790; Active, not recruiting

Phase Ib/II Randomized Clinical Trial of Chemotherapy With Nab-Paclitaxel/Gemcitabine/Cisplatin +/- the AXL Inhibitor Bemcentinib for Patients With Metastatic Pancreatic Cancer; NCT03649321; Recruiting

Phase I Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors; NCT03490669; Terminated (safety and PK/PD data from dose escalation support further development; dose expansion canceled)

MinPAC: Phase II, International, Open-Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer; NCT03117920; Completed
Targeting Brain Tumor Stem Cell Epigenetic and Molecular Networks

**Grant Term:** October 2015 – March 2021, administered by the American Association for Cancer Research

**Key Personnel:**

**Team Leader:**
Peter B. Dirks, MD, PhD, The Hospital for Sick Children

**Team Co-leader:**
Samuel Weiss, PhD, University of Calgary

**Principals:**
- Cheryl H. Arrowsmith, PhD, University of Toronto
- Gary D. Bader, PhD, University of Toronto
- Nada Jabado, MD, PhD, McGill University
- Mathieu Lupien, PhD, University Health Network
- Marco A. Marra, PhD, University of British Columbia
- Michael W. Salter, MD, PhD, The Hospital for Sick Children
- Michael D. Taylor, MD, PhD, The Hospital for Sick Children
- Michael Tyers, PhD, Université de Montreal

**Project Managers:**
- Fiona J. Coutinho, PhD, The Hospital for Sick Children
  Fiona.coutinho@sickkids.ca
- Tracey Richards, The Hospital for Sick Children
  tracey.richards@sickkids.ca

**Advocates:**
- Wendy M. Durigon, Jessica’s Footprint Foundation
- Patrick J. Sullivan, Team Finn Foundation

**Specific Aims:**

**AIM 1.** Conduct a comprehensive investigation of genomic, epigenomic, and metabolomic profiles of BTSCs to define networks of self-renewal, therapeutic resistance, and targetable vulnerabilities.

**AIM 2.** Identify targets whose pharmacological inhibition is efficacious on BTSCs from GBM and PFA ependymoma.

**AIM 3.** Preclinically test five targets to accelerate translation to the clinic.

**Clinical Trial:**

Phase I/IIb Trial of Combined 5-Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain and Solid Tumors; NCT03206021; Recruiting

**Websites:**
- [www.cancerstemcellteam.com](http://www.cancerstemcellteam.com)
- [https://standuptocancer.ca/su2c-canada-cancer-stem-cell-dream-team/](https://standuptocancer.ca/su2c-canada-cancer-stem-cell-dream-team/)
Targeting KRAS-Mutant Lung Cancers

**GRANT TERM:** August 2015 – January 2021, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Co-leader:**
- Jedd D. Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center

**Team Co-leader:**
- Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute

**Team Co-leader:**
- Justin F. Gainor, MD, Massachusetts General Hospital Cancer Center

**Principals:**
- David R. Gandara, MD, University of California, Davis
- Gad A. Getz, PhD, Broad Institute
- Roy S. Herbst, MD, PhD, Yale University
- John V. Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center
- Frank McCormick, PhD, University of California, San Francisco
- Drew M. Pardoll, MD, PhD, Johns Hopkins University
- Charles M. Rudin, MD, PhD, Memorial Sloan Kettering Cancer Center

**Project Managers:**
- Lalitha Ramanathapuram, PhD, Memorial Sloan Kettering Cancer Center
- Cam Anh Tran, Dana-Farber Cancer Institute

**Advocates:**
- Andrea E. Ferris, LUNGevity Foundation
- Jeffrey L. Wigbels, Cypress Group at Morgan Stanley

**Specific Aims:**

**AIM 1.** Target KRAS and downstream pathways.

**AIM 2.** Target the immune system for treatment of KRAS-mutant lung cancers. (Work on this Aim is continuing as an SU2C subproject.)

**AIM 3.** Integrate targeted therapies with immunotherapies for KRAS-mutant lung cancers.

**Clinical Trials:**

Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer Alone and in Combination With Chemotherapy; NCT02710396; Active, not recruiting

Phase Ib Trial of Pembrolizumab (MK-3475) and Trametinib Focused on Advanced KRAS-Mutant Non-small Cell Lung Cancer; NCT03299088; Active, not recruiting

**Websites:**
SU2C–American Cancer Society Lung Cancer Dream Team DT5977

**Clinical Trials (Cont’d):**

BATTLE-2 Program: Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-small Cell Lung Cancer; NCT03225664; Active, not recruiting

Phase I Trial of RO5126766 (CH5126766) in Patients With Advanced KRAS-Mutant Lung Adenocarcinomas; NCT03681483; Active, not recruiting

Phase I Trial of Trametinib and Ponatinib in Patients With KRAS-Mutant Advanced Non-small Cell Lung Cancer; NCT03704688; Active, not recruiting

Open-Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL-2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors; NCT02079740; Recruiting

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-small Cell Lung Cancer. NCT02259621; Recruiting

Phase I/II Trial Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC; NCT03581487; Recruiting

Phase I/II Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100); NCT03600883; Recruiting

Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation; NCT03785249; Recruiting

Phase I Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, and Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours; NCT02586987; Completed
SU2C–Ovarian Cancer Research Alliance–National Ovarian Cancer Coalition
Ovarian Cancer Dream Team DT5978

DNA Repair Therapies for Ovarian Cancer

**GRANT TERM:** July 2015 – June 2019, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:** Alan D. D’Andrea, MD, Dana-Farber Cancer Institute

**Team Co-leader:** Elizabeth M. Swisher, MD, University of Washington

**Principals:**
- Gini F. Fleming, MD, University of Chicago
- Maria Jasin, PhD, Memorial Sloan Kettering Cancer Center
- Scott H. Kaufmann, MD, PhD, Mayo Clinic, Rochester
- Karen H. Lu, MD, The University of Texas MD Anderson Cancer Center

**Project Managers:**
- Alexandra Feinstein, Dana-Farber Cancer Institute
- Donald R. Watson, Dana-Farber Cancer Institute

**Advocates:**
- Jamie Crase, University of Washington
- Sue Friedman, FORCE
- Kathleen A. Gavin, Minnesota Ovarian Cancer Alliance
- Deborah Polinsky, SHARE

**Specific Aims:**

**AIM 1.** Characterize mechanisms of sensitivity and resistance to PARPi that can identify individual ovarian cancers that are hypersensitive to PARPi monotherapy.

**AIM 2.** Evaluate novel drug combinations that extend the use of PARPi to HR-proficient ovarian cancers.

**AIM 3.** Develop ovarian cancer genetic testing and surgical prevention models, which could increase access to ovarian cancer genetic testing and ovarian cancer prevention.

**Websites:**
SU2C–Ovarian Cancer Research Alliance–National Ovarian Cancer Coalition
Ovarian Cancer Dream Team DT5978

Clinical Trials:

Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors; NCT01434316; Recruiting

Stand Up To Cancer: MAGENTA (Making Genetic Testing Accessible); NCT02993068; Recruiting

WISP (Women Choosing Surgical Prevention); NCT02760849; Active, not recruiting

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple-Negative Breast Cancer or High Grade Serous Ovarian Cancer; NCT01623349; Completed

Phase I/II Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer; NCT02657889; Active, not recruiting

A Phase II, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2); NCT01891344; Active, not recruiting
Molecular Early Detection of Colorectal Cancer (MEDOCC)

**Grant Term:** April 2015 – September 2022, administered by the American Association for Cancer Research

**Key Personnel:**

**Team Leader:** Gerrit A. Meijer, MD, PhD, Netherlands Cancer Institute

**Team Co-leader:** Victor E. Velculescu, MD, PhD, Johns Hopkins University

**Principals:**

- Veerle Coupé, PhD, VU University Medical Center
- Evelien Dekker, MD, PhD, University of Amsterdam
- Manon van Engeland, PhD, Maastricht University Medical Center
- James G. Herman, MD, University of Pittsburgh
- Miriam Koopman, MD, PhD, University Medical Center Utrecht
- Ernst J. Kuipers, MD, PhD, Erasmus University Medical Center

**Project Manager:** Meike de Wit, PhD, Netherlands Cancer Institute, m.d.wit@nki.nl

**Advocates:**

- Joop Kroes, Foundation for Patients With Cancer of the Digestive Tract (Stichting Voor Patiënten met Kanker aan het Spijsverteringskanaal, SPKS)
- Marcia Horn, JD, International Cancer Advocacy Network
- Huig Schipper (inactive)

**Specific Aims:**

**AIM 1.** Develop and clinically validate a cost-effective molecular screening test for CRC that outperforms the current state-of-the-art FIT.

**AIM 2.** Develop and clinically validate a better test for residual disease detection and monitoring in comparison with a cancer stem cell-based DNA promoter methylation prognostic biomarker.

**Clinical Trial:**

Prospective Data Collection Initiative on Colorectal Cancer—A Prospective Observational Cohort Study; sub-study of NCT02070146; Recruiting

**Website:**

Bringing Epigenetic Therapy to the Forefront of Cancer Management, II

**GRANT TERM:** October 2014 – December 2022

**KEY PERSONNEL:**

**Team Leader:**

Peter A. Jones, PhD, DSc (h),
Van Andel Institute

**Team Co-leader:**

Stephen B. Baylin, MD,
Johns Hopkins University

**Principals:**

- Anthony B. El-Khoueiry, MD, University of Southern California
- Kirsten Grønbæk, MD, DMSc, Rigshospitalet and Biotech Research and Innovation Centre (BRIC)
- Jean-Pierre J. Issa, MD, Coriell Institute for Medical Research
- Kenneth P. Nephew, PhD, Indiana University School of Medicine
- Feyruz V. Rassool, PhD, University of Maryland School of Medicine
- Charles M. Rudin, MD, PhD, Memorial Sloan Kettering Cancer Center
- Benjamin A. Youngblood, PhD, St. Jude Children’s Research Hospital

**Project Managers:**

- Penny Berger, Van Andel Institute, Penny.Berger@vai.org
- Ryan Burgos, Van Andel Institute, ryan.burgos@vai.org
- Revathi Penumatsa, Van Andel Institute, Revathi.Penumatsa@vai.org

**Advocate:**

- Beth Flory

**Specific Aims:**

**AIM 1.** Conduct a phase I study of guadecitabine combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib or TAS-102 in previously treated metastatic colorectal cancer patients.

**AIM 2.** Conduct a phase I/II study of combination therapy with the DNA methyltransferase inhibitor (DNMTi) SGI110 and the poly ADP ribose polymerase (PARP) inhibitor BMN673 (talazoparib) for acute myeloid leukemia (AML) in adult patients unfit for cytotoxic chemotherapy or with relapsed/refractory disease.

**AIM 3.** Conduct a phase I/II multicenter study combining guadecitabine, a DNA methyltransferase inhibitor, with Atezolizumab, an immune checkpoint inhibitor, in patients with intermediate or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.

**AIM 4.** Conduct a randomized phase II study of epigenetic priming with azacitidine and entinostat or oral azacitidine alone prior to nivolumab in subjects with recurrent metastatic non-small cell lung cancer.

**Websites:**

- [Visit](https://vari.vai.org/vai-su2c-dream-team/)
- [Visit](https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-dream-team-ii/)
Van Andel Institute–SU2C Cancer Epigenetics Dream Team DT5957

Specific Aims (Cont’d):

AIM 5. Conduct a study of epigenetics, vitamin C, and abnormal hematopoiesis—restoring physiological vitamin C levels to the normal range: influence on epigenetic regulation in normal and malignant hematopoiesis.

AIM 6. Conduct a phase Ib clinical trial to assess the safety and tolerability followed by a phase II trial to evaluate efficacy of guadecitabine and durvalumab in patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CLG), and pancreatic cancer.

AIM 7. Conduct a phase I dose-escalation study of E7727, an oral cytidine deaminase inhibitor (CDAi), with oral decitabine in subjects with solid tumors.


Clinical Trials:

Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab Versus Nivolumab Alone in Subjects With Recurrent Metastatic Non-Small Cell Lung Cancer; NCT01928576; Active, not recruiting

Epigenetics, Vitamin C, and Abnormal Hematopoiesis—Role of Vitamin C in Epigenetic Regulation in Hematopoiesis Sub-study on CCUS, Low-Risk MDS, and CMML-0/1; NCT03682029; Recruiting

Multicenter Phase I/II Study of Combination Therapy w/DNA Methyltransferase Inhibitor Decitabine and Poly ADP Ribose Polymerase Inhibitor Talazoparib for Untreated AML in Adults Unfit for Cytotoxic Chemotherapy or R/R AML; NCT02878785; Completed

Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, With Atezolizumab, an Immune Checkpoint Inhibitor, in Patients With Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia; NCT02935361; Active, not recruiting

Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer; NCT03257761; Active, not recruiting

Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi), With Oral Decitabine in Subjects With Solid Tumors; NCT03875287; Recruiting

Phase I/II Study of DS-3201b, an EZH1/2 Inhibitor, in Combination With Irinotecan in Patients With Recurrent Small Cell Lung Cancer; NCT03879798; Recruiting

Phase I Study of SGI-110 Combined With Irinotecan Followed by a Randomized Phase II Study of SGI-110 Combined With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Patients; NCT01896856; Completed

Restoring Physiological Vitamin C Levels to the Normal Range: Influence on Epigenetic Regulation in Normal and Malignant Hematopoiesis; NCT02877277; Completed

Combining Active and Passive DNA Hypomethylation: A Randomized, Placebo-Controlled Phase II Study of the Efficacy and Safety of Oral Vitamin C in Combination With Azacitidine in Patients With Higher-Risk MDS, CMML-2, or Low Blast Count AML; NCT03999723; Recruiting

Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple-Negative or Hormone-Resistant/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer; NCT04134884; Recruiting

A Multicenter, Single-Arm, Pilot Study of The Efficacy and Safety of Metformin in Clonal Cytopenia of Undetermined Significance and Lower-Risk Myelodysplastic Syndrome; NCT04741945; Recruiting
SU2C–Lustgarten Foundation Pancreatic Cancer Dream Team DT5915

Transforming Pancreatic Cancer to Treatable Disease

**GRANT TERM:** July 2014 – June 2023, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Elizabeth M. Jaffee, MD, Johns Hopkins University

**Team Co-leader:**
Robert H. Vonderheide, MD, DPhil, Abramson Cancer Center University of Pennsylvania

**Principals:**
- Philip Greenberg, MD, Fred Hutchinson Cancer Research Center
- Robert D. Schreiber, PhD, Washington University in St. Louis

**Project Manager:**
Stephanie Porter, Johns Hopkins University, sporter@jhmi.edu

**Advocates:**
- Betty Booher, Oregon Health & Science University
- Stuart Rickerson, University of California, San Francisco

**Specific Aims:**

**AIM 1.** Conduct a multicenter phase 2 study designed to test the safety and clinical activity of a PD-1 inhibitor (cemiplimab) with a CXCR4 inhibitor (plerixafor).

**AIM 2.** Conduct a trial to treat patients with their own T cells that have been engineered to recognize mesothelin, a clinical target expressed specifically by pancreatic cancer cells.

**AIM 3.** Conduct a trial to explore whether vaccinating PDA patients with neoantigens derived from their own tumors can reactivate preexisting neoantigen specific T cells, induce T cell responses to additional vaccine induced tumor neoantigens, and induce a measurable clinical response.

**Website:**
SU2C–Lustgarten Foundation Pancreatic Cancer Dream Team DT5915

**Clinical Trials:**

Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy; NCT03956056; Recruiting

Phase II Study of Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer; NCT04177810; Recruiting

Phase I Study of Autologous Transgenic T Cells Expressing High Affinity Mesothelin-Specific T-Cell Receptor (TCR) (FH-TCR T_{MSLN}) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma; NCT04809766; Recruiting

Study to Assess the Safety of Continuous IV Administration of the CXCR4 Antagonist Plerixafor (Mozobil) and Assess Its Impact on the Immune Microenvironment in Patients With Advanced Pancreatic, High-Grade Serous Ovarian, and Colorectal Adenocarcinomas; NCT02179970; Completed

First-in-Human Phase I Dose-Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies; NCT02216409; Completed

Randomized Phase II Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS-207 With or Without Nivolumab in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma; NCT02243371; Completed

Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma; NCT02562898; Completed

Phase I Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma; NCT02588443; Completed
SU2C–Dutch Cancer Society Tumor Organoids Dream Team DT5906

A New Preclinical Model for Drug Sensitivity Analysis

**GRANT TERM:** April 2014 – April 2019, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Hans C. Clevers, MD, PhD, Hubrecht Institute

**Team Co-leader:**
Johannes L. Bos, PhD, University Medical Center Utrecht

**Principals:**
- Sir Michael R. Stratton, PhD, Wellcome Trust Sanger Institute
- Lodewyk Wessels, PhD, Netherlands Cancer Institute

**Advocates:**
- Pauline Evers, Leven Met Kanker
- Jeannette Janzen, Leven Met Kanker
- Margreet Jonker, Leven Met Kanker
- Catherine Transler, Leven Met Kanker

**Project Manager:**
- Johan H. van Es, PhD, Hubrecht Institute

**Specific Aims:**

**AIM 1.** Build and validate a large “living” biobank for colon, pancreatic, and breast cancer using organoid technology, thus capturing the genetic variability of these three tumor types.

**AIM 2.** Correlate drug sensitivity with genotype and gene expression in vitro to identify putative biomarkers of drug sensitivity.

**AIM 3.** Validate the dual “genetic/organoid” approach as a predictor of drug response for individual cancer patients.

**AIM 4.** Identify molecular mechanisms of drug sensitivity and resistance.

**Website:**
https://standuptocancer.org/research/research-portfolio/dream-teams/tumor-organoids-preclinical-models-dream-team/

**Website:**
https://standuptocancer.org/research/research-portfolio/dream-teams/tumor-organoids-preclinical-models-dream-team/
SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team DT5908

**Immunogenomics to Create New Therapies for High-Risk Childhood Cancers**

**Grant Term:** July 2013 – June 2018, administered by the American Association for Cancer Research

**Key Personnel:**

**Team Leader:** John M. Maris, MD, Children’s Hospital of Philadelphia

**Team Co-leader:** Crystal L. Mackall, MD, Stanford University

**Principals:**
- Michael C. Jensen, MD, Seattle Children’s Research Institute
- Donald W. Parsons, MD, Baylor College of Medicine
- Paul M. Sondel, MD, PhD, University of Wisconsin, Madison
- Poul H. B. Sorensen, MD, PhD, BC Cancer Research Institute
- Michael D. Taylor, MD, PhD, The Hospital for Sick Children

**Advocates:**
- Beth Anne Baber, PhD, Nicholas Connor Institute
- Kelly Cotter
- Jay Scott, Alex’s Lemonade Stand Foundation
- Liz Scott, Alex’s Lemonade Stand Foundation
- Patrick J. Sullivan, Team Finn Foundation
- Lisa Tichenor, QuadW Foundation
- Mac Tichenor, QuadW Foundation

**Project Manager:**
- Jennifer L. Baldi, Children’s Hospital of Philadelphia

**Specific Aims:**

**AIM 1.** Discover and validate cell surface targets for immunotherapy of high-risk pediatric cancers.

**AIM 2.** Generate and develop therapeutic proteins targeting prioritized cell surface molecules.

**AIM 3.** Conduct pivotal multi-institution pediatric cancer immunotherapy trials.

**Clinical Trials:**

Administration of HER2 Chimeric Antigen Receptor Expressing T Cells for Subjects With Advanced Sarcoma (HEROS); NCT00902044; Recruiting

Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02: A Phase I/II Feasibility and Safety Study of CD19-CAR T-cell Immunotherapy for CD19+ Leukemia; NCT02028455; Recruiting

**Website:**
https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/
Clinical Trials (Cont’d):

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: A Phase I Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma Using Autologous T Cells Lentivirally Transduced to Express CD171-Specific CARs; NCT02311621; Recruiting

Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B-cell Malignancies; NCT02315612; Recruiting

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy; NCT02374333; Recruiting

Phase I Study of Intracranial Injection of T Cells Expressing HER2-Specific Chimeric Antigen Receptors (CAR) in Subjects With Glioblastoma; NCT02442297; Recruiting

TCR-Alpha/Beta and CD19+ Depleted KIR/KIR Ligand-Mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zolendronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High-Risk Solid Tumors; NCT02508038; Recruiting

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells in Pediatric Patients With Chemotherapy-Resistant or Refractory Acute Lymphoblastic Leukemia; NCT02650414; Recruiting

Phase I Study of 131-I Meta-iodobenzylguanidine (mIBG) Followed by Nivolumab and Chimeric 14.18 Anti-GD2 Monoclonal Antibody Produced in Chinese Hamster Ovary Cells (ch14.18/CHO) in Children With Relapsed/Refractory Neuroblastoma; NCT02914405; Recruiting

Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia; NCT03186118; Recruiting

Treatment of Relapsed or Refractory Neuroblastoma With Ex Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2; NCT03209869; Recruiting

Phase I Dose-Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B-cell Malignancies; NCT03241940; Recruiting

Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: Phase I Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma; NCT03330691; Recruiting

Pediatric Leukemia Adoptive Therapy (PLAT)-01: Phase I Feasibility and Safety Study of Cellular Immunotherapy for Relapsed Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T Cells Lentivirally Transduced to Express a CD19-Specific Chimeric Antigen Receptor; NCT01683279; Active, not recruiting

Phase II, Single-Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia; NCT02435849; Active, not recruiting

Pilot Study of Nonviral, RNA-Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCR and 4-1BB Signaling Domains in Patients With Refractory or Relapsed Hodgkin Lymphoma; NCT02624258; Active, not recruiting
SU2C-St. Baldrick’s Foundation Pediatric Cancer Dream Team DT5908

Clinical Trials (Cont’d):

Two-Cohort Pilot Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome (CRS) Management in Pediatric Patients With CD19 Expressing Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (ALL); NCT02906371; Active, not recruiting

Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-04: Phase I Feasibility and Safety Study of CD22-CAR T Cell Immunotherapy for CD22+ Leukemia and Lymphoma; NCT03244306; Active, not recruiting

Administration of HER2 Chimeric Receptor and TGF Beta Dominant Negative Receptor (DNR) Expressing EBV Specific Lymphocytes for Subjects With Advanced HER2-Positive Malignancy (HERCREEM); NCT00889954; Completed

Administration of HER2 Chimeric Antigen Receptor Expressing CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme (HERT-GBM); NCT01109095; Completed

Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B-cell Malignancies; NCT01593696; Completed

CHP959–Phase I/IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR Zeta and 4-1BB Signaling Domains in Patients With Chemotherapy-Resistant or Refractory CD19+ Leukemia and Lymphoma; NCT01626495; Completed

Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With Non-neuroblastoma, GD2+ Solid Tumors; NCT02107963; Completed

Phase II, Single-Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia; NCT02228096; Completed

Phase I, Open-Label, Dose-Escalation Study of MGA271 in Pediatric Patients With B7-H3-Expressing Relapsed or Refractory Solid Tumors; NCT02982941; Completed
SU2C–Cancer Research Institute Cancer Immunology Dream Team DT5907

Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy

**GRANT TERM:** March 2013 – February 2018, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
James P. Allison, PhD,
The University of Texas MD Anderson Cancer Center

**Team Co-leader:**
Drew M. Pardoll, MD, PhD,
Johns Hopkins University

**Team Co-leader:**
Antoni Ribas, MD, PhD,
University of California, Los Angeles

**Team Co-leader:**
Cassian Yee, MD,
The University of Texas MD Anderson Cancer Center

**Team Leader:**
James P. Allison, PhD,
The University of Texas MD Anderson Cancer Center

**Team Co-leader:**
Drew M. Pardoll, MD, PhD,
Johns Hopkins University

**Project Manager:**
James J. Mancuso,
The University of Texas MD Anderson Cancer Center

**Advocates:**
Robert E. Behrens, REB Investments, Inc.
Debra Black, Melanoma Research Alliance
Roy Doumani, JD, University of California, Los Angeles (deceased)
Valerie Guild, AIM at Melanoma
Jonathan W. Simons, MD,
Prostate Cancer Foundation
Mary Elizabeth Williams, Salon.com

**Specific Aims:**

**AIM 1.** Interrogate immune responses within the tumor microenvironment before and after treatment with immune checkpoint blockade.

**AIM 2.** Interrogate the targets of T and B cell responses after checkpoint blockade.

**AIM 3.** Provide therapeutic benefit to patients with advanced tumors by improving the quality of cancer-specific T lymphocytes generated for adoptive cell transfer (ACT) therapy.

**AIM 4.** Develop novel combinatorial therapies based on immune checkpoint blockade.

**Website:**
https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/
SU2C–Cancer Research Institute Cancer Immunology Dream Team DT5907

Clinical Trials:

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-small Cell Lung Cancer; NCT02259621; Recruiting

Phase I Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin; NCT02414269; Recruiting

Phase Ib Study of Cellular Adoptive Immunotherapy Using Autologous Cd8+ Antigen-Specific T Cells and Anti-CTLA4 For Patients With Metastatic Uveal Melanoma; NCT03068624; Recruiting

Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Malignancies; NCT01697527; Active, not recruiting

Phase I/II, Open-Label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors; NCT01928394; Active, not recruiting

Phase II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Melanoma; NCT02027935; Active, not recruiting

Pilot Randomized Tissue-Based Study Evaluating Anti-PD1 Antibody or Anti-PD1 +Bevacizumab or Anti-PD1 + Anti-CTLA-4 in Patients With Metastatic Renal Cell Carcinoma Who Are Eligible for Cytoreductive Nephrectomy, Metastasectomy, or Post-treatment Biopsy; NCT02210117; Active, not recruiting

Exploratory Study of the Biologic Effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination With Ipilimumab Treatment in Subjects With Advanced Melanoma (Unresectable or Metastatic); NCT01621490; Completed

Feasibility Study to Determine T-Cell Responses to Neoantigens Following Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Carcinoma; NCT02113657; Completed

Neoadjuvant Phase Ila Study of Ipilimumab (Formerly known as MDX-010 (BMS-734016)) Plus Hormone Ablation in Men With Prostate Cancer Followed by Radical Prostatectomy; NCT01194271; Completed

Phase II Study of Ipilimumab Plus Androgen Deprivation Therapy in Castrate-Sensitive Prostate Carcinoma; NCT01377389; Completed

NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With Nivolumab PD-1 Blockade; NCT02775292; Completed
Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer

**GRANT TERM:** January 2013 – December 2016, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Eric J. Small, MD, University of California, San Francisco

**Team Co-leader:**
Owen N. Witte, MD, University of California, Los Angeles

**Principals:**
- Tomasz M. Beer, MD, Oregon Health & Science University
- Christopher P. Evans, MD, University of California, Davis, Comprehensive Cancer Center
- Martin E. Gleave, MD, University of British Columbia
- Joshua M. Stuart, PhD, University of California, Santa Cruz

**Project Manager:**
Kelly McNeill, University of California, San Francisco

**Advocates:**
- Roy Doumani, JD, University of California, Los Angeles (deceased)
- Arthur H. Kern, American Media, Inc.

**Specific Aims:**

**AIM 1.** Identify adaptive pathways to abiraterone and enzalutamide active in resistant mCRPC tumors.

**AIM 2.** Validate that identified adaptive pathways cause resistance.

**AIM 3.** Demonstrate the efficacy of co-targeting adaptive pathways.

**Clinical Trials:**

Radiologically Guided Biopsies of Metastatic Castration-Resistant Prostate Cancer (mCRPC) to Identify Adaptive Mechanisms of Resistance; NCT02432001; Active, not recruiting

Phase Ib/II Study of the Oral CDK4/6 Inhibitor LEE011 in Combination With Docetaxel Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer; NCT02494921; Active, not recruiting

Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer; NCT02522715; Active, not recruiting

Single-Arm, Open-Label, Two-Stage Phase II Study of the MEK 1/2 Inhibitor Trametinib in Men With Progressive Metastatic Castrate-Resistant Prostate Cancer; NCT02881242; Active, not recruiting

**Website:**
https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/
Clinical Trials (Cont’d):

Phase II Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-Naive Patients With Progressive Metastatic Castration-Resistant Prostate Cancer; NCT01688492; Active, not recruiting

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer; NCT019462904; Active, not recruiting

Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment; NCT02099864; Active, not recruiting

Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide, Abiraterone, and Prednisone for Castration-Resistant Metastatic Prostate Cancer; NCT01949337; Active, not recruiting

Phase II Randomized, Multicenter Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognostic-Metastatic Castration-Resistant Prostate Cancer; NCT02254785; Active, not recruiting

Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC; NCT02312557; Active, not recruiting

Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy; NCT01253642; Terminated (low enrollment)

Phase II Single-Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide; NCT02215161; Terminated (risk-to-benefit ratio was not acceptable)

An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors; NCT02709889; Terminated (strategic considerations)

PREVAIL: A Multinational Phase III, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy; NCT01212991; Completed

Phase I Trial of ADIPEG 20 Plus Docetaxel in Advanced Solid Tumors With Emphasis on Castration-Resistant Prostate Cancer (CRPC) and Advanced Non-small Cell Lung Cancer (NSCLC); NCT01497925; Completed

Randomized Phase III Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate-Resistant Prostate Cancer; NCT01578655; Completed

Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer (CRPC); NCT01637402; Completed

Randomized Phase II Trial of Immediate Versus Delayed Anti-CTLA4 Blockade Following Sipuleucel-T Treatment for Prostate Cancer Immunotherapy; NCT01804465; Completed

Randomized, Double-Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/Pca Versus Placebo in Men With Metastatic Castration-Resistant Prostate Cancer Eligible for First-Line Chemotherapy; NCT02111577; Completed
SU2C-Prostate Cancer Foundation Prostate Cancer Dream Team DT5904

Clinical Trials (Cont’d):

Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer; NCT02125357; Completed

Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men With Castration-Resistant Prostate Cancer; NCT02228265; Completed

Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients With Metastatic Castration-Resistant Prostate Cancer and No Prior Chemotherapy; NCT01594918; Completed

STRIVE: A Multicenter Phase II, Randomized, Double-Blind Efficacy and Safety Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Therapy; NCT01664923; Completed

Phase II Study of Recombinant Glycosolated Human IL7 (CYT107) After Completion of Standard FDA-Approved Therapy With Sipuleucel-T (Provenge®) for Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer; NCT01881867; Completed

Three-Arm, Randomized, Open-Label, Phase II Study of Radium-223 Dichloride 50 kBq/kg (55 kBq/kg After Implementation of NIST Update) Versus 80 kBq/kg (88 kBq/kg After Implementation of NIST Update), and Versus 50 kBq/kg (55 kBq/kg After Implementation of NIST Update) in an Extended Dosing Schedule in Subjects With Castration-Resistant Prostate Cancer Metastatic to the Bone; NCT02023697; Completed

Phase I Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer; NCT02705469; Completed
Precision Therapy of Advanced Prostate Cancer

**GRANT TERM:** August 2012 – July 2016, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:** Arul M. Chinnaiyan, MD, PhD, University of Michigan

**Team Co-leader:** Charles L. Sawyers, MD, Memorial Sloan Kettering Cancer Center

**Principals:**

- Johann S. de Bono, MBChB, MD, Institute of Cancer Research, Royal Marsden NHS Foundation Trust
- Levi A. Garraway, MD, PhD, Broad Institute
- Philip W. Kantoff, MD, Dana-Farber Cancer Institute
- Peter S. Nelson, MD, University of Washington, Fred Hutchinson Cancer Research Center
- Mark A. Rubin, MD, Weill Cornell Medical College of Cornell University

**Advocates:**

- Woods Brown, University of Michigan
- Thomas A. Farrington, Prostate Health Education Network
- W. Grant Gregory, Memorial Sloan Kettering Cancer Center
- James Kiefert, EdD, Us TOO International, Inc.
- Stanley Klein, Boston Prostate Cancer Support Group
- Ian S. Liston (deceased)
- Douglas Pergament (deceased)

**Project Manager:**

- Karen Giles, University of Michigan

**Specific Aims:**

**AIM 1.** Establish a multi-institutional infrastructure incorporating five leading prostate cancer clinical sites and two sequencing and computational analysis sites, linked with appropriate sample and data coordination.

**AIM 2.** Establish a prospective cohort of 500 patients (the “CRPC 500”) utilizing the multi-institutional infrastructure to support the clinical use of integrative prostate cancer sequencing, analysis, and clinical trial decision making.

**AIM 3.** Conduct parallel, preclinical in vivo functional studies of resistance biomarkers and of SU2C/PCF-sponsored combination therapies.

**AIM 4.** Identify molecular determinants of abiraterone sensitivity and acquired resistance in patients.

**Website:** [https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/](https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/)
SU2C–Prostate Cancer Foundation Prostate Cancer Dream Team DT5903

Specific Aims (Cont’d):

AIM 5. Conduct clinical trials of novel combinations targeting AR and/or the PTEN pathway based on existing preclinical data and an understanding of resistance mechanisms.

AIM 6. Identify molecular determinants of sensitivity and acquired resistance to PARP inhibitors in patients.

Clinical Trials:

Phase II Trial of Olaparib in Patients With Advanced Castration-Resistant Prostate Cancer (TOPARP); NCT01682772; Not recruiting

Phase II Trial of Enzalutamide for Castrate-Resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-Exome and Transcriptome Sequencing; NCT01942837; Active, not recruiting

Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-Resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates; NCT02025010; Active, not recruiting

Phase I Study of Crizotinib in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Before or After Progression on Docetaxel; NCT02207504; Active, not recruiting

Randomized Phase II Study of Enzalutamide (MDV3100) in Combination With AZD5363 in Patients With Metastatic Castration-Resistant Prostate Cancer (RE-AKT); NCT02525068; Not recruiting

Open-Label Pharmacodynamic Study of Abiraterone Acetate in the Treatment of Metastatic, Castration-Resistant Prostate Cancer; NCT01503229; Completed

Randomized Gene Fusion Stratified Phase II Trial of Abiraterone With or Without ABT-888 for Patients With Metastatic Castration-Resistant Prostate Cancer; NCT01576172; Completed

ARMOR 2: A 2-Part, Phase II Trial of Galeterone in the Treatment of Castration-Resistant Prostate Cancer; NCT01709734; Completed

Phase Ib Study of ARN509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate; NCT02106507; Completed
Personalized Medicine for Patients With BRAF Wild-Type (BRAFwt) Cancer

**Grant Term:** April 2012 – June 2017, administered by the American Association for Cancer Research

**Key Personnel:**

**Team Leader:**
Jeffrey M. Trent, PhD, Translational Genomics Research Institute

**Team Co-leader:**
Patricia M. LoRusso, DO, Yale Cancer Center

**Principals:**
- Joshua LaBaer, MD, PhD, Biodesign Institute at Arizona State University
- Svetomir N. Markovic, MD, PhD, Mayo Clinic
- Brian J. Nickoloff, MD, PhD, Michigan State University
- Emanuel F. Petricoin, PhD, George Mason University
- Neal Rosen, MD, PhD, Memorial Sloan Kettering Cancer Center
- Nicholas J. Schork, PhD, J. Craig Venter Institute
- Aleksandar D. Sekulic, MD, PhD, Mayo Clinic
- Jeffrey A. Sosman, MD, Mayo Clinic
- Kristiina Vuori, MD, PhD, Sanford Burnham Prebys Medical Discovery Institute

**Project Manager:**
Cassandra L. Lucas, PhD, Translational Genomics Research Institute

**Advocates:**
- Tracy L. Bame, Freeport-McMoRan Copper & Gold Foundation
- Mark Gorman, JD, National Coalition for Cancer Survivorship
- Derrick M. Hall, Arizona Diamondbacks
- Cornelius A. McGillicuddy III, Liberty Partners Group
- Jane Perlmutter, PhD, Gemini Group

**Specific Aims:**

**AIM 1.** Conduct a randomized pilot study to assess the feasibility and safety of characterizing BRAFwt MM tumors to identify a molecularly informed therapeutic regimen.

**AIM 2.** Iteratively refine and standardize a set of statistical and informatics methodologies for matching treatments to the patient’s tumor, based on its molecular profile.

**AIM 3.** Evaluate whether molecularly informed personalized therapy selection, based on a tumor’s molecular profile (potentially enhanced by the refined methodology for predicting drug response developed in Aim 2), will improve outcomes relative to SoC therapy in BRAFwt MM.

**Clinical Trial:**
Stand Up To Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma; NCT02094872; Completed

**Website:**
https://standuptocancer.org/research/research-portfolio/dream-teams/melanoma-braf-wildtype-dream-team/
Cutting Off the Fuel Supply: A New Approach to the Treatment of Pancreatic Cancer

**Grant Term:** December 2009 – October 2017, administered by the American Association for Cancer Research

**Key Personnel:**

**Team Leader:**
- Craig B. Thompson, MD, PhD (2009–2011), University of Pennsylvania
- Jeffrey A. Drebin, MD, PhD (2011–2015), University of Pennsylvania
- Daniel D. Von Hoff, MD, Translational Genomics Research Institute

**Principals:**
- Chi Van Dang, MD, PhD, University of Pennsylvania
- Joshua D. Rabinowitz, MD, PhD, Princeton University
- Geoffrey M. Wahl, PhD, Salk Institute for Biological Studies

**Advocates:**
- Julie M. Fleshman, JD, Pancreatic Action Network
- Barton A. Kamen, Leukemia and Lymphoma Society (deceased)
- Kerri Kaplan, Lustgarten Foundation
- Randall M. Katz, Milestone Entertainment
- Howard Young

**Specific Aims:**

**AIM 1.** Imaging glucose and/or glutamine uptake in pancreatic tumors.

**AIM 2.** Investigating clinical therapies to impair tumor metabolism and stromal support.

**Clinical Trials:**

Phase I Study: PET Imaging of Cancer Patients Using (18F) 4-L-Fluoroglutamine (2S,4R); NCT01697930; Recruiting

Phase I/II Pharmacodynamics Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer; NCT01506973; Active, not recruiting

Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas; NCT00844649; Completed

Stand Up To Cancer Consortium: Phase II Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer; NCT01196247; Completed

Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer; NCT02030860; Completed

Exploratory Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Metastatic Pancreatic Adenocarcinoma Cancer; NCT02048384; Completed

**Website:**

SU2C Epigenetics Dream Team DT5917

Bringing Epigenetic Therapy to the Forefront of Cancer Management

**Grant Term:** December 2009 – January 2015, administered by the American Association for Cancer Research

**Key Personnel:**

**Team Leader:**
Stephen B. Baylin, MD, Johns Hopkins University

**Team Co-leader:**
Peter A. Jones, PhD, DSc (hc), Van Andel Institute

**Principals:**
- Steven A. Belinsky, PhD, Lovelace Respiratory Research Institute
- Nancy E. Davidson, MD, Fred Hutchinson Cancer Research Center
- Jean-Pierre J. Issa, MD, Coriell Institute for Medical Research

**Advocates:**
- Diana T. Chingos, National Cancer Institute
- Lillie D. Shockney, Johns Hopkins University

**Specific Aims:**

**AIM 1.** Develop molecular markers that predict and monitor the efficacy of cancer epigenetic therapies.

**AIM 2.** Perform clinical trials to bring epigenetic therapy to the forefront of cancer management.

**AIM 3.** Determine whether a key mechanism for efficacy of epigenetic therapy is targeting and exhaustion of self-renewing cancer cells.

**AIM 4.** Develop a clinical trial with a new drug designed to circumvent the instability of 5-AC and DAC.

**AIM 5.** Determine targets in addition to promoter DNA hypermethylation that may be utilized in new cancer epigenetic therapy approaches.

**Clinical Trials:**

Randomized Phase II Study of Epigenetic Priming With Azacitidine and Entinostat or Oral Azacitidine Alone Prior to Nivolumab in Subjects With Recurrent Metastatic Non-small Cell Lung Cancer; NCT01928576; Recruiting

Phase I/II Study of MS275 in Combination With 5-Azacitidine in Patients With Recurrent Advanced Non-small Cell Lung Cancer; NCT00387465; Completed

Phase II Study of Azacitidine and Entinostat in Patients With Metastatic Colorectal Cancer; NCT01105377; Completed

Website:
https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-therapy-2009-dream-team/
SU2C Epigenetics Dream Team DT5917

**Clinical Trials (Cont’d):**

Phase I Dose-Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML); NCT01261312; Completed

Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer; NCT01349959; Completed

Randomized Phase II Trial of Adjuvant Combined Epigenetic Therapy With 5-Azacitidine and Entinostat in Resected Stage 1 Non-small Cell Lung Cancer Versus Standard Care; NCT01207726; Terminated

Randomized Phase II Trial of Cytotoxic Chemotherapy With or Without Epigenetic Priming in Patients With Advanced Non-small Cell Lung Cancer; NCT01935947; Terminated
Bioengineering and Clinical Applications of Circulating Tumor Cell Chip

**Grant Term:** December 2009 – November 2013, administered by the American Association for Cancer Research

**Key Personnel:**

**Team Leader:** Daniel A. Haber, MD, PhD, Massachusetts General Hospital

**Team Co-leader:** Mehmet Toner, PhD, Massachusetts General Hospital

**Principals:**
- Sangeeta N. Bhatia, MD, PhD, Massachusetts Institute of Technology
- John V. Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center
- Bruce E. Johnson, MD, Dana-Farber Cancer Institute
- Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center

**Advocates:**
- Rebecca Douglass, Douglass Family Foundation
- Jeane Ungerleider, Boston IVF

**Specific Aims:**

**AIM 1A.** Examine bioengineering optimization and nanosensing for increased sensitivity.

**AIM 1B.** Perform molecular characterization of CTCs.

**AIM 2.** Investigate clinical applications of the CTC-chip.

**Clinical Trials:**

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy; NCT01961713; Recruiting

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer; NCT00470704; Active, not recruiting

First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-small Cell Lung Cancer and Known Sensitizing EGFR Mutations; NCT00997334; Completed

Detecting EGFR T790M Mutations From Circulating Tumor Cells; NCT01734915; Completed

Phase II Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With Human Epidermal Growth Factor-2 (HER2) Negative Primary Tumors and HER2-Positive Circulating Tumor Cells; NCT01185509; Terminated

**Website:**
[https://standuptocancer.org/research/research-portfolio/dream-teams/circulating-tumor-cells-dream-team/](https://standuptocancer.org/research/research-portfolio/dream-teams/circulating-tumor-cells-dream-team/)
Targeting the PI3K Pathway in Women’s Cancers

**GRANT TERM:** November 2009 – October 2013, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Lewis C. Cantley, PhD,
Beth Israel Deaconess Medical Center

**Team Co-leader:**
Gordon B. Mills, MD, PhD,
The University of Texas MD Anderson Cancer

**Team Co-leader:**
(2009–2012): Charles L. Sawyers, MD,
Memorial Sloan Kettering Cancer Center

**Principals:**
- Carlos L. Arteaga, MD,
  Vanderbilt-Ingram Cancer Center
- José Baselga, MD, PhD, Vall d’Hebron Institute of Oncology (deceased)
- Ramon E. Parsons, MD, PhD, Herbert Irving Comprehensive Cancer Center
- Thomas M. Roberts, PhD, Dana-Farber Cancer Institute
- David B. Solit, MD, Memorial Sloan Kettering Cancer Center

**Advocates:**
- Piru Cantarell, Vall d’Hebron Institute of Oncology
- Ruth Fax, Dana-Farber Cancer Institute
- Elizabeth Frank, Dana-Farber Cancer Institute
- Judi Hirschfield-Bartek, Beth Israel Deaconess Medical Center
- Patricia Lee, Vanderbilt University
- Don Listwin, Canary Foundation
- Jane Perlmutter, Gemini Group
- Sara Weiss, Dana-Farber Cancer Institute

**Project Manager:**
- Donald R. Watson,
  Dana-Farber Cancer Institute

**Specific Aims:**

**AIM 1.** Develop molecular markers and/or imaging modalities that predict the subset of cancers that are likely to respond to PI3K pathway inhibitors.

**AIM 2.** Design and conduct single-agent, molecular marker–driven adaptive trial(s).

**AIM 3.** Develop rational therapeutic combinations of PI3K pathway–targeted drugs.

**AIM 4.** Design and conduct two multi-arm, molecular marker–driven adaptive trials using a rational combination of a PI3K pathway inhibitor with another targeted therapy.

**Website:**
[https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/](https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/)
**SU2C PI3K Dream Team DT5918**

**Clinical Trials:**

Randomized Phase I Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer; NCT01935973; Completed

Phase Ib Trial of BKM120 (a PI3K Inhibitor) or BEZ235 (a PI3K/mTOR Inhibitor) in Combination With Endocrine Therapy in Post-menopausal Patients With Hormone Receptor–Positive Metastatic Breast Cancer; NCT01248494; Completed

Phase Ib Dose-Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer; NCT01263145; Completed

Phase II Trial of AKT Inhibitor MK2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation, or an AKT Mutation, and/or PTEN Loss/PTEN Mutation; NCT01277757; Completed

Phase Ib Trial of BYL719 (an α-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-menopausal Patients With Hormone Receptor–Positive Metastatic Breast Cancer; NCT01791478; Active, not recruiting

Phase II Study of MK-2206 in the Treatment of Recurrent High-Grade Serous Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; NCT01283035; Completed

Phase II Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple-Negative Metastatic Breast Cancer; NCT01629615; Completed

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple-Negative Breast Cancer or High-Grade Serous Ovarian Cancer; NCT01623349; Completed

Phase II, Two-Stage, Two-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer; NCT01312753; Completed

Phase II Evaluation of AZD6244 (NSC#748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma; NCT01011933; Completed

Phase I/II Study of XL147 (SAR245408) Administered in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen; NCT01042925; Completed

Phase I/II Dose-Escalation Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Hormone Receptor–Positive and HER2-Negative Breast Cancer Refractory to a Nonsteroidal Aromatase Inhibitor; NCT01082068; Completed

Three-Arm, Randomized, Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864), and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage 3 or 4a, Stage 4b, or Recurrent Endometrial Cancer; NCT00977574; Active, not recruiting

Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 for the Treatment of Recurrent or Persistent Endometrial Carcinoma; NCT01455493; Completed

Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Letrozole With or Without BYL719 or Buparlisib for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor–Positive, HER2-Negative Breast Cancer; NCT01923168; Completed
DREAM TEAMS
JUNE 2022 STAND UP TO CANCER SCIENCE PORTFOLIO 2009-2022

SU2C Breast Cancer Dream Team DT5920

An Integrated Approach to Targeting Breast Cancer Molecular Subtypes and Their Resistance Phenotypes

**GRANT TERM:** October 2009 – September 2014, administered by the American Association for Cancer Research

**KEY PERSONNEL:**
- **Team Leader:** Dennis J. Slamon, MD, PhD, University of California, Los Angeles
- **Team Co-leader:** Joe W. Gray, PhD, Oregon Health & Science University

**Principals:**
- Alan Ashworth, PhD, UCSF Helen Diller Family Comprehensive Cancer Center
- Joan S. Brugge, PhD, Harvard Medical School
- Arul M. Chinnaiyan, MD, PhD, University of Michigan
- Gregory J. Hannon, PhD, Cold Spring Harbor Laboratory
- David Haussler, PhD, University of California, Santa Cruz
- Craig V. Jordan, DSc, PhD, Fox Chase Cancer Center
- C. Kent Osborne, PhD, Baylor College of Medicine
- Peter K. Sorger, PhD, Harvard Medical School
- Terence P. Speed, PhD, University of California, Berkeley
- Zena Werb, PhD, University of California, San Francisco (deceased)
- Max S. Wicha, MD, University of Michigan

**Advocates:**
- Janice Barlow, Zero Breast Cancer
- Cindy Geoghegan, Patient & Partners, LLC
- Ellen L. Stoval, National Coalition for Cancer Survivorship (deceased)
- Frances M. Visco, National Breast Cancer Coalition

**Website:**

**Specific Aims:**

**AIM 1.** Expand the understanding of the known “driving” initial molecular mechanisms responsible for the pathogenesis and clinical behavior of the three known therapeutic breast cancer subtypes, i.e., estrogen (E2)/estrogen receptor (ER-positive), HER2-positive, and triple-negative (TN) subtypes of breast cancer.

**AIM 2.** Study the “driving” mechanisms responsible for de novo as well as acquired resistance to appropriately targeted treatments of the three known therapeutic breast cancer subtypes, i.e., estrogen (E2)/estrogen receptor (ER-positive), HER2-positive, and triple-negative (TN) breast cancers.
SU2C Breast Cancer Dream Team DT5920

Specific Aims (Cont’d):

**AIM 3.** Investigate the potential initial “driving” pathogenetic as well as de novo or acquired “resistance” mechanisms mediated by “stem/progenitor” breast cancer cells within each or across all of the three known breast cancer therapeutic subtypes, with the ultimate objective being the design, development, and clinical testing of new and innovative therapies for the “tumorigenic” and “resistance” phenotypes potentially mediated by these stem/progenitor cells.

**AIM 4.** Develop new and/or characterize existing relevant and representative cell line and xenograft models, as well as utilize annotated clinical material to query the contributions of “normal” and “malignancy-derived” matrix/stromal components of each breast cancer subtype, including those that might contribute to or mediate the “resistance” phenotype to targeted therapeutics.

**AIM 5.** Develop an integrated discovery and informatics research unit that cuts across the above aims and is designed to deploy, inform, and facilitate implementation of relevant discovery and informatics platforms needed for these aims.

**Clinical Trial:**

Novel (PD 0332991: CDK4/6 Inhibitor, Pfizer) ER-Positive, HER2-Negative Advanced Breast Cancer in Postmenopausal Women; NCT00721409; Completed
RESEARCH TEAMS
Southeastern Consortium for Lung Cancer Health Equity

**GRANT TERM:** February 2022 - January 2025

**KEY PERSONNEL:**

**Team Leader:**
Robert A. Winn, MD,
Virginia Commonwealth University

**Team Co-leader:**
Marvellia E. Ford, PhD,
Medical University of South Carolina

**Principal:**
- Louise Henderson, PhD,
  University of North Carolina at Chapel Hill

**Project Managers:**
- Rosuany Vélez Acevedo, PhD,
  Virginia Commonwealth University,
  velezrn@vcu.edu
- Kate Shaw, Virginia Commonwealth University,
  shawsk2@vcu.edu

**Advocates:**
- Tomma Hargraves, UNC Lineberger Comprehensive Cancer Center
- Rudene Mercer Haynes, Virginia Commonwealth University
- Deborah Roland-Jaremba, MUSC Hollings Cancer Center

**Specific Aims:**

**AIM 1.** Initiate and evaluate a high-impact, multimodal, and multilevel navigation intervention to promote LCS among Black/African American individuals from both rural and urban medically underserved communities in Virginia, North Carolina, and South Carolina.

**AIM 2.** Develop a robust, shared population-based cohort and biorepository to further support research in understanding biologic determinants or risk factors for poor lung cancer outcomes among Black/African American individuals.

**Clinical Trial:**
Interventional trial will be registered in 2022.

**Website:**
https://standuptocancer.org/southeastern-consortium-for-lung-cancer-health-equity-research-team/
**Precision Therapy for Fanconi Anemia and HPV-Related Head and Neck Cancers**

**Grant Term:** October 2021 – September 2024

**Key Personnel:**

**Team Leader:**
Agata Smogorzewska, MD, PhD, The Rockefeller University

**Team Co-leader:**
Barbara Burtness, MD, Yale School of Medicine

**Principals:**
- Amanda Paulovich, MD, PhD, Fred Hutchinson Cancer Research Center
- Markus Grompe, MD, Oregon Health & Science University
- Jorge Silvio Gutkind, PhD, University of California, San Diego

**Project Manager:**
Edward Kaftan, PhD, Yale School of Medicine, edward.kaftan@yale.edu

**Advocates:**
- Allison Breininger
- Peter Krause, MD, Yale School of Medicine

**Specific Aims:**

**AIM 1.** Perform proteogenomic and digital histologic analysis of FA-related and HPV-related HNSCCs to identify common and cohort-specific therapeutic approaches.

**AIM 2.** Identify and test novel therapeutic approaches in HPV-related HNSCC.

**AIM 3.** Identify effective chemoprevention and treatments in FA-associated HNSCC.

**AIM 4.** Assess the toxicity of potential cancer therapeutics using FA mice bone marrow function assays.

**Clinical Trial:**
In development.

**Website:**
https://standuptocancer.org/research/research-portfolio/research-teams/head-and-neck-cancer-research-team/
Combinatorial Targeting of Oncogene-Driven Childhood Cancer

**GRANT TERM:** March 2021 – September 2023

**Team Leader:**
John Anderson, MBBS, MRCP, PhD, University College London Great Ormond Street Institute of Child Health

**Team Co-leader:**
Louis Chesler, MD, PhD, FRCPCH, Institute of Cancer Research

**Principals:**
- Paul M. Sondel, MD, PhD, University of Wisconsin, Madison
- Darren Hargrave, MD, FRCPCH, MRCP, University College London Great Ormond Street Institute of Child Health
- Laura Donovan, PhD, University College London Great Ormond Street Institute of Child Health

**Project Managers:**
- Martin Anyim, PhD, University College London, m.anyim@ucl.ac.uk
- Alethea Cope, PhD, MSc, BSc, University College London, a.cope@ucl.ac.uk

**Advocates:**
- Parker Moss
- Lori R. Schultz, UW Health American Family Children’s Hospital

**Specific Aims:**

**AIM 1.** Evaluate MYC inhibitor combinations with chemotherapy and anti-GD2 antibody in neuroblastoma model.

**AIM 2.** Evaluate MYC inhibitor agents with local delivery of CAR T cells in medulloblastoma model.

**AIM 3.** Optimize CAR T to incorporate into combination studies.

**AIM 4.** Evaluate MYC inhibitor with in situ vaccine in neuroblastoma.

**AIM 5.** Evaluate addition of in situ vaccine to MYC targeting in medulloblastoma.

**AIM 6.** Evaluate addition of in situ vaccine to MYC targeting and systemic CAR T in neuroblastoma.

**AIM 7.** Evaluate addition of in situ vaccine to MYC targeting and systemic CAR T in medulloblastoma.

**Website:**
https://standuptocancer.org/pediatric-cancer-new-discoveries-challenge/
Targeting R-loop Stability in Ewing Sarcoma

GRANT TERM: January 2021 – September 2023

KEY PERSONNEL:

**Team Leader:**
Alexander Bishop, DPhil,
UT Health San Antonio

**Team Co-leader:**
Kevin Hiom, PhD,
University of Dundee

**Principal:**
- Chun Wei-Chen, PhD,
  Beckman Research Institute of the City of Hope

**Project Manager:**
- Sneha Prabhu, MPH,
  UT Health San Antonio,
  prabhus@uthscsa.edu

**Advocates:**
- Laura Jean Rutledge,
  Rutledge Cancer Foundation
- Gregory Aune, UT Health San Antonio

**Specific Aims:**

**AIM 1.** Target SF3B1/SRSF2 complex in EwS to induce toxic levels of R-loops.

**AIM 2.** Disrupt DHX9:EWSR1-FLI1 interaction to promote pathological R-loops.

Website: [https://standuptocancer.org/pediatric-cancer-new-discoveries-challenge/](https://standuptocancer.org/pediatric-cancer-new-discoveries-challenge/)
**SU2C-CRUK Pediatric Cancer New Discoveries Challenge Research Team RT6186**

**BRAINatomy: A Validated Anatomical Atlas of Childhood Neuroradiation Damage**

**GRANT TERM:** April 2021 – September 2023

**KEY PERSONNEL:**

**Team Leader:**
Martin G. McCabe, MB/BChir, PhD, University of Manchester

**Team Co-leader:**
Thomas E. Merchant, BS, DO, PhD, St. Jude Children’s Research Hospital

**Principal:**
- Lara Barazzuol, PhD, University Medical Center Groningen

**Project Manager:**
- Kate Vaughan, PhD, University of Manchester, kate.vaughan@manchester.ac.uk

**Advocates:**
- James Adams
- Helen Bulbeck, Braintrust
- Joshua Goddard
- Adam Thomson, Braintrust

**Specific Aims:**

**AIM 1.** Analyze brain regions responsible for cognitive and endocrine damage in a large, retrospective cohort of children treated with cranial radiotherapy.

**AIM 2.** Prospectively evaluate the functional and biological effects of brain irradiation in a well-described rat model.

**AIM 3.** Compare the effects on multiple brain compartments of irradiation with X-ray photons and high-energy protons.

**Website:**
https://standuptocancer.org/pediatric-cancer-new-discoveries-challenge/
SU2C Gastric Cancer Interception Research Team RT6072

**Early Detection and Interception of Diffuse and Intestinal Gastric Cancer**

**GRANT TERM:** September 2020 – August 2023, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:** Andrew T. Chan, MD, Massachusetts General Hospital

**Team Co-leader:** Sandra W. Ryeom, PhD, Columbia University Irving Medical Center

**Principals:**
- Jeeyun Lee, MD, Samsung Medical Center
- Blase Polite, MD, University of Chicago
- Yanghee Woo, MD, Beckman Research Institute of City of Hope
- Sam S. Yoon, MD, Columbia University Irving Medical Center

**Project Manager:**
- Marina Magicheva-Gupta, Massachusetts General Hospital, mmagicheva-gupta@mgh.harvard.edu

**Advocates:**
- Jason Diaz, Stomach Cancer Awareness Network
- Aki Agata Smith, Stomach Cancer Awareness Network

**Specific Aims:**

**AIM 1.** Discover and optimize molecularly specific imaging agents and novel circulating biomarkers for early-stage GC using mouse models recapitulating the major TCGA GC subtypes.

**AIM 2.** Translate preclinical findings to humans by assessing the feasibility of molecular endoscopic or capsule-based imaging across the spectrum of gastric premalignancy and refine circulating biomarkers within cohorts of individuals undergoing routine GC screening and surgery for early-stage disease.

**AIM 3.** Assess initial performance of a molecular and/or capsule imaging platform for detection of GC and validate circulating biomarkers in locally advanced GC patients enrolled in a clinical trial.

**Clinical Trials:**

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers; NCT02584244; Recruiting

Phase II Study of Neoadjuvant NALIRIFOX Followed by Chemoradiation With Paclitaxel and Carboplatin in Locally Advanced Esophagogastric Cancer; NCT04656041; Recruiting

**Website:**
https://standuptocancer.org/research/research-portfolio/research-teams/gastric-cancer-interception-research-team/
Identification of Genomic and Immune Factors in High-Risk Populations for Pancreatic Cancer

**GRANT TERM:** May 2019 – February 2022

**KEY PERSONNEL:**

**Team Leader:**
Raul Rabadan, PhD, Columbia University

**Team Co-leader:**
Núria Malats, MD, MPH, PhD, Spanish National Cancer Research Centre (CNIO)

**Principals:**
- Tal Korem, PhD, Columbia University
- Gulam Manji, MD, PhD, Columbia University
- Ken Olive, PhD, Columbia University

**Project Manager:**
Paula Ralph-Birkett, Columbia University, pr2470@cumc.columbia.edu

**Specific Aims:**

**AIM 1A.** Identify de novo and germline alterations.

**AIM 1B.** Annotate the non-coding landscape of alterations in pancreatic tumors.

**AIM 2A.** Characterize pathogenic infections in the tumor microenvironment.

**AIM 2B.** Characterize HLA allele-specific expression.

**AIM 3.** Pursue external validation and integration with other data modalities.

**Website:**
Identifying Individuals at High Risk of Pancreatic Cancer Through Machine Learning Analysis of Clinical Records and Images

**GRANT TERM:** May 2019 – April 2022

**KEY PERSONNEL:**

**Team Leader:**
Chris Sander, PhD, Dana-Farber Cancer Institute

**Team Co-leader:**
Regina Barzilay, PhD, Massachusetts Institute of Technology

**Principals:**
- Peter Kraft, PhD, Harvard T. H. Chan School of Public Health
- Michael Rosenthal, MD, PhD, Dana-Farber Cancer Institute
- Brian Wolpin, MD, Dana-Farber Cancer Institute

**Collaborator:**
- Søren Brunak, PhD, University of Copenhagen

**Project Manager:**
- Elizabeth Andrews, Dana-Farber Cancer Institute, ElizabethA_Andrews@dfci.harvard.edu

**Specific Aims:**

**AIM 1.** Curate and annotate data.
**AIM 2.** Extract features from data.
**AIM 3.** Conduct predictive modeling.

**Website:**
https://standuptocancer.org/research/research-portfolio/research-teams/pcc-ai-identifying-individuals/
Targeting SHP2 in Pancreatic Cancer

**GRANT TERM:** November 2018 – June 2023, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

- **Team Leader:** René Bernards, PhD, Netherlands Cancer Institute
- **Team Co-leader:** Hana Algül, MD, PhD, Technical University of Munich
- **Team Co-leader:** Emile E. Voest, MD, PhD, Netherlands Cancer Institute

**Project Manager:**

- Henri van Luenen, PhD, Netherlands Cancer Institute, h.v.luenen@nki.nl

**Advocates:**

- Ab Doorn, The Netherlands Cancer Institute
- Otto Lutz, Arbeitskreis der Pankreatektomierten e.V.

**Specific Aims:**

**AIM 1.** Evaluate the maximum tolerated dose of the SHP2 inhibitor and MEK inhibitor of choice in non-tumor-bearing mice.

**AIM 2.** Identify qualifying biomarkers for response that will allow us to identify patients most likely to respond to the proposed therapy.

**AIM 3.** Test different treatment schedules in different mouse models of pancreatic cancer, in order to maximize the antitumor effect and to minimize toxicity.

**Clinical Trial:**

Phase I/II Study With the Combination of RMC-4630 (SHP2 Inhibitor) and LY3214996 (ERK Inhibitor) in Metastatic KRAS Mutant CRC, PDAC, and NSCLC; NCT04916236; Recruiting

**Website:** [https://standuptocancer.org/research/research-portfolio/research-teams/targeting-shp2/](https://standuptocancer.org/research/research-portfolio/research-teams/targeting-shp2/)
Exploiting DNA Repair Gene Mutations in Pancreatic Cancer

**Team Leader:**
Alan D. D’Andrea, MD, Dana-Farber Cancer Institute

**Team Co-leader:**
James M. Cleary, MD, PhD, Dana-Farber Cancer Institute

**Principals:**
- Andrew Aguirre, MD, PhD, Dana-Farber Cancer Institute
- Geoffrey I. Shapiro, MD, PhD, Dana-Farber Cancer Institute
- Brian M. Wolpin, MD, Dana-Farber Cancer Institute

**Project Manager:**
Donald R. Watson, Dana-Farber Cancer Institute, Donald_watson@dfci.harvard.edu

**Specific Aims:**

**AIM 1.** Assess DNA damage repair (DDR) deficiency in pancreatic cancer.
- PARP inhibition has shown efficacy in patients with HR deficiency, leading to FDA approval for Olaparib.
- Hypothesis: Addition of ATR inhibition may enhance the efficacy of PARP inhibition in the maintenance setting.

**AIM 2.** Target replicative stress in platinum-resistant pancreatic cancer.
- Pancreatic cancers often harbor KRAS, CDKN2A/B, or TP53 mutations which generate replication stress.
- Gemcitabine exacerbates replication stress and causes stalled forks ATR, CHK1, and WEE1 kinases stabilize stalled forks.
- Hypothesis: Combining gemcitabine with ATR/CHK1/WEE1 inhibitors worsen replication stress by inhibiting pathways designed to compensate for replication stress and cause cell death.

**Clinical Trials:**
Phase Ib/IIa Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer; NCT02632448; Recruiting

**Website:**
https://standuptocancer.org/research/research-portfolio/research-teams/exploiting-dna-repair/
Pancreatic Cancer Collective Research Team—New Therapies Challenge RT6155

Clinical Trials (Cont’d):

Phase II Proof-of-Concept Trial Testing the PARP Inhibitor Niraparib in Patients With Pancreatic Cancer Harboring Deficiencies in Homologous Recombination DNA Repair; NCT03601923; Recruiting

Phase I Trial of Gemcitabine Combined With the BAY 1895344 ATR Inhibitor With Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer; NCT04616534; Suspended
Pancreatic Cancer Collective Research Team–New Therapies Challenge RT6154

Adoptive Transfer of TGF-β-Resistant TIL to Defeat Immunosuppressive PDAC

**GRANT TERM:** November 2018 – September 2020, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

- **Team Leader:** Patrick Hwu, MD, The University of Texas MD Anderson Cancer Center
- **Team Co-leader:** Chantale Bernatchez, PhD, The University of Texas MD Anderson Cancer Center
- **Team Co-leader:** Cliona M. Rooney, PhD, Baylor College of Medicine

**Project Manager:**

- Karen Millerchip, The University of Texas MD Anderson Cancer Center

**Specific Aims:**

- **AIM 1.** Optimize PDACTIL retroviral transduction method.
- **AIM 2.** Test the impact of the expression of TGF-βDNRII on PDAC TIL function.
- **AIM 3.** Investigate in vivo efficacy of tumor-specific TGF-βDNRII-transduced T cells in patient-derived preclinical models of pancreatic cancer.

**Website:**

https://standuptocancer.org/research/research-portfolio/research-teams/adoptive-transfer/

---

**RESEARCH TEAMS**

**PANCREATIC CANCER COLLECTIVE**

ADOPTIVE TRANSFER OF TGF-β RESISTANT IMMUNOSUPPRESSIVE PDAC
Combined Targeting of MEK1/2 and Autophagy for Pancreatic Cancer Therapy

**GRANT TERM:** November 2018 – December 2020, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Martin McMahon, PhD, University of Utah

**Team Co-leader:**
Eric A. Collisson, MD, University of California, San Francisco

**Principal:**
- Conan G. Kinsey, MD, PhD, University of Utah

**Project Manager:**
- Karrie Lasater, University of Utah

**Advocates:**
- Phyllis D. Coley, University of Utah
- Thomas Kursar, University of Utah

**Specific Aims:**

**AIM 1.** Test if there is a PDA cell genotype–T/HCQ drug response phenotype in PDA cell lines and PDX models with an initial emphasis on TP53 mutation status.

**AIM 2.** Explore novel targets and agents to inhibit trametinib-induced autophagy in PDA cells.

**AIM 3.** Initiate clinical trials of the combination of trametinib plus HCQ(T/HCQ) in PDA patients.

**Clinical Trial:**

THREAD: Phase I Trial of Trametinib and Hydroxychloroquine in Patients With Advanced Pancreatic Cancer; NCT03825289; Recruiting

**Website:**
https://standuptocancer.org/research/research-portfolio/research-teams/combined-targeting-and-autophagy-for-pancreatic-cancer/
Targeting Stem Cell Signals in Pancreatic Cancer

**Team Leader:**
Tannishtha Reya, PhD, University of California, San Diego

**Team Co-leader:**
Andrew M. Lowy, MD, University of California, San Diego

**Team Co-leader:**
Margaret A. Tempero, MD, University of California, San Francisco

**Project Manager:**
Marcie Kritzik, PhD, University of California, San Diego

**Grant Term:**
November 2018–October 2020, administered by the American Association for Cancer Research

**Key Personnel:**

Website: [https://standuptocancer.org/research/research-portfolio/research-teams/targeting-stem-cell-signals/](https://standuptocancer.org/research/research-portfolio/research-teams/targeting-stem-cell-signals/)

**Specific Aims:**

**AIM 1.** Test inhibition of ROR-γ in combination with chemotherapy in preclinical models.

**AIM 2.** Identify biomarkers predictive of response and define a molecular signature reflective of response to ROR-γ inhibition.
Molecularly Targeted Radionuclide Therapy via the Integrin avß6

**Grant Term:** November 2018 – June 2023, administered by the American Association for Cancer Research

**Key Personnel:**

- **Principal:** Cameron C. Foster, MD, University of California, Davis
- **Project Manager:** Sonal J. Desai, PhD, University of California, Davis, sjdesai@ucdavis.edu
- **Advocate:** Lora Kelly, RN

**Specific Aims:**

**AIM 1A.** Establish that 68Ga-avb6-BP can detect lesions in patients with locally advanced or metastatic pancreas cancer. The ability of 68Ga-avb6-BP to detect lesions will be assessed by increased standard uptake values (SUVmax >2-fold above normal lung or liver) of 68Ga-avb6-BP in at least one lesion assessed by 68Ga-avb6-BP PET/CT.

**AIM 1B.** Establish the safety and tolerability of the theranostic pair 68Ga-avb6-BP/177Lu-avb6BP. Safety and tolerability of 68Ga-avb6-BP and/or 177Lu-avb6-BP will be assessed by number of patients with treatment-related adverse events using CTCAE v5.0.

**AIM 1C.** Evaluate the maximum tolerated dose (MTD), and determine the recommended phase II dose (RP2D) of 177Lu-avb6-BP. Dose-limiting toxicities (DLT) of 177Lu-avb6-BP with activity levels starting from 25 mCi and increasing up to the “standard” PRRT level of 200 mCi will be assessed using SPECT/CT.

**AIM 2.** Establish an optimal dosing regimen in pre-clinical models. Fractionated dosing with the 177Lu-avb6-BP as well as combination with standard-of-care chemotherapy and novel avb6-BP drug conjugates will be explored in xenograft, orthotopic and metastatic mouse models.

**Clinical Trial:**

First-in-human Study of the Theranostic Pair (68Ga)Ga DOTA-5G and (177Lu) Lu DOTA-ABM-5G in Pancreatic Cancer; NCT04665947; Recruiting

**Website:** [https://standuptocancer.org/research/research-portfolio/research-teams/molecularly-targeted-radionuclide-therapy/](https://standuptocancer.org/research/research-portfolio/research-teams/molecularly-targeted-radionuclide-therapy/)
Immunotherapy Targeting Mutant KRAS

**KEY PERSONNEL:**

**Team Leader:**
Robert H. Vonderheide, MD, DPhil, University of Pennsylvania

**Team Co-leader:**
Elizabeth M. Jaffee, MD, Johns Hopkins University

**Team Co-leader:**
Beatriz M. Carreno, PhD, University of Pennsylvania

**Principal:**
• Neeha Zaidi, MD, Johns Hopkins University

**Early-Career Investigator:**
• Adham Bear, MD, PhD, University of Pennsylvania

**Project Manager:**
• TBD

**Specific Aims:**

**AIM 1.** Identify and validate mKRAS-specific TCRs in healthy individuals and cancer patients.

**AIM 2.** Identify KRAS-specific TCRs from PDA patients enrolled in two clinical vaccine trials, exploiting the platform in Aim 1.

**Clinical Trials:**

Pilot Study of Mature Dendritic Cell Vaccination Against Mutated KRAS in Patients With Resectable Pancreatic Cancer; NCT03592888; Recruiting

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer; NCT04117087; Recruiting

**Website:**
https://standuptocancer.org/research/research-portfolio/research-teams/immunotherapy-targeting-mutant-kras/
SU2C–Lustgarten Foundation Pancreatic Cancer Interception Research Team RT6059

Developing Novel Approaches to Detect and Treat Early Pancreatic Cancer

**GRANT TERM:** January 2018 – December 2022, administered by the American Association for Cancer Re-

**KEY PERSONNEL:**

**Team Leader:**
David P. Ryan, MD, Massachusetts General Hospital

**Team Co-leader:**
Alec C. Kimmelman, MD, PhD, New York University

**Principals:**
- Richard A. Burkhart, MD, Johns Hopkins University
- Daniel Laheru, MD, Johns Hopkins University
- Wells A. Messersmith, MD, University of Colorado, Denver
- Cullen M. Taniguchi, MD, PhD, The University of Texas MD Anderson Cancer Center

**Project Manager:**
Leilana Ly, Massachusetts General Hospital, LLY2@mgh.harvard.edu

**Advocates:**
- Regina Pyle, Massachusetts General Hospital
- Carole Seigel, Massachusetts General Hospital

**Specific Aims:**

**AIM 1.** Evaluate novel neoadjuvant approaches in PDAC patients.

**AIM 1A:** Conduct neoadjuvant clinical trial to increase curability.

**AIM 1B:** Determine whether therapeutic screening of patient-derived organoids can identify an optimal clinical treatment.

**AIM 1C:** Conduct primary tumor molecular analysis.

**AIM 1D:** Determine the ctDNA, CTC, and exosomes at presentation, during treatment, and after surgery.

**AIM 1E:** Determine the changes in the tumor microenvironment (TME) between arms.

**Clinical Trial:**

Randomized Phase II Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer; NCT03563248; Recruiting

**Website:**
https://standuptocancer.org/research/research-portfolio/research-teams/pancreatic-cancer-interception-research-team/
Blood-Based Early Interception of Lung Cancer

**GRANT TERM:** December 2017 – February 2019, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Lecia V. Sequist, MD, Massachusetts General Hospital

**Team Co-leader:**
Maximilian Diehn, MD, PhD, Stanford University

**Project Manager:**
- Elaina PuiYee Chan, PhD, Massachusetts General Hospital

**Advocate:**
- Chris M. Draft, Chris Draft Family Foundation

**Specific Aim:**

**Website:**
https://standuptocancer.org/research/research-portfolio/research-teams/lung-cancer-interception-research-team/
**Chimeric Antigen Receptor T-cell (CAR T) Therapy for Pancreatic Cancer**

**GRANT TERM:** April 2017 – November 2022

**KEY PERSONNEL:**

**Team Leader:** Carl H. June, MD, University of Pennsylvania

**Team Co-leader:** Shelley L. Berger, PhD, University of Pennsylvania

**Team Co-leader:** E. John Wherry, PhD, University of Pennsylvania

**Principals:**
- M. Angela Aznar, PhD, University of Pennsylvania
- Charly R. Good, PhD, University of Pennsylvania
- Mark H. O’Hara, MD, University of Pennsylvania
- Janos L. Tanyi, MD, PhD, University of Pennsylvania

**Project Manager:**
- Regina M. Young, PhD, University of Pennsylvania, ryoung@upenn.edu

**Advocate:**
- James E. Prevor, Phoenix Media Network

**Specific Aims:**

**AIM 1.** Carry out clinical trials in cancer immunotherapy for metastatic pancreatic cancer and transcriptionally and epigenetically interrogate samples prior to and following therapy to compare CAR T cell signatures from responsive and resistant patients, with the objective of improving therapeutic response.

**AIM 2.** Define the epigenetic landscape and sensitivities of pancreatic cancer cells and therapeutic immune cells, with the goal of identifying baseline molecular differences in pancreatic patients that may impede optimal CAR T cell function.

**Clinical Trials:**

Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin-Expressing Cancers; NCT03054298; Recruiting

Phase I Study of Human Chimeric Antigen Receptor Modified T Cells (CAR T Cells) in Patients With Pancreatic Cancer; NCT03323944; Active, not recruiting

**Website:**
https://standuptocancer.org/research/research-portfolio/research-teams/car-t-therapy-for-pancreatic-cancer-research-team/
Laura Ziskin Translational Award Research Team RT0123

**Phosphatidylinositol 3-kinase δ Inhibition to Treat Patients With Relapsed or Refractory Follicular Lymphoma**

**GRANT TERM:** March 2016 – May 2020

**KEY PERSONNEL:**

**Team Leader:**
Siddhartha Mukherjee, MD, Columbia University

**Co-Investigators:**
- Changchun Deng, MD, PhD, Columbia University
- Owen A. O’Connor, MD, PhD, Columbia University

**Fellow:**
- Lorenzo Falchi, MD, Columbia University

**Project Manager:**
- Alice Lustig, Stand Up To Cancer

**Specific Aims:**

**AIM 1.** Assess markers of responsiveness versus resistance to PI3K δ inhibition in a population of patients with relapsed or refractory FL using genomic, epigenomic, and metabolomics profiling.

**AIM 2.** Use cell lines to determine how PI3K δ inhibition affects growth and survival of lymphoma cells and their sensitivity to other drugs active in lymphoma.

**AIM 3.** Develop mouse models of FL and use these models to study the response of lymphoma to duvelisib in vivo.

**Clinical Trial:**

Study of the Phosphoinositide-3-Kinase-Delta Inhibitor TGR-1202 in Patients With Relapsed or Refractory Follicular Lymphoma; NCT03178201; Terminated
Therapeutic CD8 Vaccines Against Conserved E7 HPV Epitopes Identified by MS

**Grant Term:** July 2014 – February 2020, administered by the American Association for Cancer Research

**Key Personnel:**

**Team Leader:**
Ellis L. Reinherz, MD,
Dana-Farber Cancer Institute

**Team Co-leader:**
Robert I. Haddad, MD,
Dana-Farber Cancer Institute

**Project Managers:**
- Joanie Lindstrom,
  Dana-Farber Cancer Institute
- Farzana Masood, PhD,
  Dana-Farber Cancer Institute

**Advocate:**
Mary-Jo Murphy

**Specific Aims:**

**AIM 1.** Perform a phase IB/II trial of adjuvant E711-19 nanomer vaccine DPX-E7 in 40 HLA-A*0201-positive patients with HPV16+ squamous cancers of the cervix, anus, or oropharynx.

**AIM 2.** Define additional immunogenic HLA-bound tumor antigens on HPV-driven cancers of the cervix, anus, and head and neck.

**AIM 3.** Investigate clonal heterogeneity and molecular functional avidity of TCRs elicited by vaccination to engender those supporting the most sensitive tumor antigen recognition/tumor cell killing as well as future adoptive cell therapy.

**Clinical Trial:**
Phase Ib/II Trial to Test the Safety and Efficacy of Vaccination With HPV16-E711-19 Nanomer for the Treatment of Incurable HPV16-Related Oropharyngeal, Cervical, and Anal Cancer in HLA-A*02-Positive Patients; NCT02865135: Active, not recruiting

**Website:**
https://standuptocancer.org/research/research-portfolio/research-teams/hpv-research-team/
Prospective Use of DNA-Guided Personalized Cancer Treatment

**GRANT TERM:** January 2013 – December 2017, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:** Emile E. Voest, MD, PhD, Netherlands Cancer Institute

**Team Co-leader:** René Bernards, PhD, Netherlands Cancer Institute

**Principals:**
- Trey Ideker, PhD, University of California, San Diego
- Stefan Sleijfer, MD, PhD, Erasmus MC Rotterdam
- Laura J. van’t Veer, PhD, University of California, San Francisco

**Project Manager:** Alice Tondeur, Netherlands Cancer Institute

**Specific Aims:**

**AIM 1.** Identify DNA-based biomarkers of response to neoadjuvant chemotherapy+/- neratinib in breast cancer through analyses of biopsies from the trial.

**AIM 2.** Generate genomic selection criteria for patients with KRAS wild-type colorectal tumors to improve the outcome of anti-EGFR antibody treatment using genomic analyses of metastases for a cancer mini-genome of genes.

**AIM 3.** Deliver systems biology tools to analyze alterations in our cancer mini-genome to refine patient selection criteria for individualized treatment.

**AIM 4.** Identify DNA- and RNA-based biomarkers of response to chemotherapy + atezolizumab in metastatic lobular breast cancer.

**Clinical Trials:**

I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2); NCT01042379; Recruiting

Assessing Efficacy of Carboplatin and Atezolizumab in Metastatic Lobular Breast Cancer GELATO Trial; NCT03147040; Recruiting

Development of a Platform for Next-Generation DNA Sequencing-Based Personalized Treatment for Cancer Patients: Protocol to Obtain Biopsies From Patients With Locally Advanced or Metastatic Cancer (CPCT-02 Biopsy Protocol); NCT01855477; Recruiting

Phase Ib/II Multicenter, Open-Label, Dose-Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer; NCT01719380; Completed

**Website:** [https://standuptocancer.org/research/research-portfolio/research-teams/dna-guided-care-research-team/](https://standuptocancer.org/research/research-portfolio/research-teams/dna-guided-care-research-team/)
SU2C
CONVERGENCE
RESEARCH
TEAMS
Molecular and Biophysical Definition of Tumor-Host Interactions and Impact on Tumorigenesis and Therapeutic Response

**Grant Term:** January 2021 – December 2023

**Key Personnel:**

**Team Leader:**
Ileana Cristea, PhD, Princeton University

**Team Members:**
- Shawn Davidson, PhD, Princeton University
- Scott Manalis, PhD, Massachusetts Institute of Technology
- Benjamin Neel, MD, PhD, New York University

**Project Manager:**
Alice Lustig, Stand Up To Cancer, alustig@su2c.org

**Specific Aims:**

**Cristea Lab/Princeton University**

**AIM 1.** Uncover molecular drivers of tumor-host interactions by developing methods for defining surface proteomes in 3D cell models in conjunction with secretome and intracellular proteome assays.

**AIM 2.** Define global protein complex dynamics underlying signaling and immune responses in organoids.

**AIM 3.** Determine how organelle contact sites link lipid metabolism and immune signaling in organoids.

**Manalis Lab/Massachusetts Institute of Technology**

**AIM 1.** Develop chemostat for organoid culture.

**AIM 2.** Study mechanisms by which microbiota affect tumor responses to anti-PD-1 therapy.

**AIM 3.** Understand how microbial peptides alter biophysical properties of mammalian cells.

**AIM 4.** Use genotype-defined syngeneic organoid models to study tumor/TME interactions and therapy.

**AIM 5.** Determine if single-cell biophysical measurements can optimize strategies to enhance immunotherapy.

**Website:**
SU2C Convergence 3.1416 Research Team CV6204

Specific Aims (Cont'd):

Davidson Lab/Princeton University

AIM 1. Define the metabolic tumor microenvironment by integrating spatial-omics in mouse and organoid models of cancer.

AIM 1A. Define the metabolic and immunologic microenvironment of high-grade serous tubo-ovarian cancer (HGSC).

AIM 1B. Determine the functional metabolic interaction of commensal gut microbiota, T cells, and lung cancer.

AIM 2. Conduct high-throughput metabolic characterization of organoids based on biophysical separation.

AIM 2A. Perform metabolic screening of organoids from primary dissociated tumors separated by biophysical methods.

AIM 3. Develop methods for MALDI (3D imaging and improved spatial resolution) and nanoflow-LCMS.

AIM 3A. Develop 3D MALDI for labeled metabolite distribution in tumors, organs, and organoids.

AIM 3B. Improve MALDI spatial resolution and metabolic pathway coverage.

AIM 3C. Investigate nanoflow metabolomics toward obtaining separation-based single-cell metabolism measurements.

Neel Lab/New York University

AIM 1. Use genotype-defined organoids to delineate cell autonomous/non-autonomous effects on HGSC evolution.

AIM 2. Further characterize tumor/TME interactions and optimize therapy for Ccne1OE and Nf-/- HGSC.

AIM 3. Develop more refined, TME-retaining human and mouse organoid models of HGSC.
SU2C Convergence 3.1416 Research Team CV6205

Integrating Gnotobiotic, Organoid, and Metabolomic Pipelines to Probe the Cancer–Microbiome Connection

**Grant Term:** January 2021 – December 2023

**Key Personnel:**

**Team Leader:**
Kenya Honda, MD, PhD,
Keio University, Japan

**Team Members:**
- Hans Clevers, MD, PhD,
  Hubrecht Institute, Netherlands
- Josh Rabinowitz, MD, PhD,
  Princeton University
- Toshiro Sato, MD, PhD,
  Keio University, Japan

**Project Manager:**
Alice Lustig,
Stand Up To Cancer,
alustig@su2c.org

**Specific Aims:**

**Honda Lab/Keio University**

**AIM 1.** Establish an in vivo model appropriate for screening of CRC-promoting bacteria.

**AIM 2.** Search for bacterial strains that promote CRC development.

**AIM 3.** Model bacteria-induced colon carcinogenesis using an in vitro organoid co-culture system.

**AIM 4.** Search for bacterial strains that can prevent CRC development.

**AIM 5.** Elucidate diet-microbiome-immune connection.

**Clevers Lab/Hubrecht Institute**

**AIM 1.** Build on top of our identification of the first bacterially induced mutational signature by screening further bacterial toxins, strains, and species of potentially genotoxic bacteria.

**AIM 2.** Focus on the impact of colorectal cancer–associated bacteria on cellular behavior beyond mutation accumulation. This will be performed both on individual cancer-associated species and on microbial communities derived from healthy donors and colorectal cancer patients.

**AIM 3.** Study the role in tumorigenesis of bacteria from the Clostridium genus associated with CRC tumorigenesis by metagenomics studies.

**Website:**
SU2C Convergence 3.1416 Research Team CV6205

Specific Aims (Cont’d):

Clevers Lab (Cont’d)

AIM 4. Obtain microbial communities derived from healthy donors and colorectal cancer patients, and expose healthy human colon and colorectal cancer organoids to microbial communities and the metabolites produced by these, to identify community-level effects on colorectal cancer cell behavior.

Rabinowitz Lab/Princeton University

AIM 1. Investigate diet–microbiome connection.

Sato Lab/Keio University

AIM 1. Study carcinogenic potential of gut microbes on colonic epithelium in vivo.
AIM 2. Develop new in vivo human CRC model.
AIM 4. Understand the molecular determinants of invasiveness and metastatic capacity during colon carcinogenesis.
Integrating Microbiome and Organoid Analyses of Patient Cohorts for Immuno-oncology Therapeutic Development

**Grant Term:** January 2021 – December 2023

**Key Personnel:**

**Team Leader:**
Calvin Kuo, MD, PhD,
Stanford University

**Team Members:**
- Ami Bhatt, MD, PhD,
  Stanford University
- Michael Fischbach, PhD,
  Stanford University
- Jennifer Wargo, MD, MMSc,
  The University of Texas MD Anderson Cancer Center

**Project Manager:**
- Alice Lustig,
  Stand Up To Cancer,
  alustig@su2c.org

**Specific Aims:**

**Kuo Lab/Stanford University**

**Aim 1.** Investigate ALI tumor organoid-based anoxic culture for obligate anaerobes.

**Aim 1A.** Flow-based anaerobic/aerobic transwell platform for organoid culture.

**Aim 1B.** Organoid and anaerobic bacterial interaction and growth.

**Aim 2.** Integrate microbiota into ALI tumor organoids from neoadjuvant anti-PD-1 patient cohorts.

**Aim 2A.** Combination with candidate microbiota.

**Aim 2B.** Addition of microbiota-derived small molecules and peptides.

**Aim 2C.** Effects on anti-PD-1 responses.

**Aim 3.** Incorporate peripheral immune components with ALI tumor organoids.

**Aim 3A.** Human ALI tumor organoid co-culture with autologous lymph node organoids.

**Aim 3B.** Murine ALI tumor organoid co-culture with autologous lymph node organoids.

**Website:**
SU2C Convergence 3.1416 Research Team CV6206

Specific Aims (Cont’d):

Bhatt Lab/Stanford University

AIM 1. Leverage culture-free approaches to strain tracking in human microbiome studies.
AIM 1A. Culture-free genome assembly from microbiomes.
AIM 1B. Measuring genomic plasticity.
AIM 1C. Dissecting the role of translated microbial genes in immunotherapy response.
AIM 2. Identify bioactive microbial small peptides that may modulate cancer biology and therapy efficacy.
AIM 2A. Decoding microbial communication.
AIM 2B. Microbial microproteins and their impact on cellular biophysics.
AIM 2C. Mining microbial microprotein communication signals to transform drug discovery.

Fishbach Lab/Stanford University

AIM 1. Study the role of bacterially derived molecules in dictating the fate of an elicited T cell.
AIM 2. Determine whether tumor-specific T cells can be induced by expressing host antigens in bacterial colonists.
AIM 3. Investigate whether we can study the contribution of each strain in a complex community to immune modulation.

Wargo Lab/MD Anderson Cancer Center

AIM 1. Determine characteristics of the gut microbiome associated with optimal response to immunotherapy in a prospective cohort of immunotherapy-treated patients.
AIM 2. Identify optimal strategies to enhance response to immunotherapy via gut microbiota modulation by deep profiling and integrated analysis of data from existing cohorts.
AIM 3. Optimize strategies to enhance immunotherapy response via gut microbiota/functional interventions with testing in preclinical models.
Multi-omic Analysis of Immune System and Microbiota Influence on Temporal and Spatial Evolution of Tumor Microenvironments

GRANT TERM: January 2021 – December 2023

KEY PERSONNEL:

Team Leader:
Dan Littman, MD, PhD,
New York University Grossman School of Medicine

Team Members:
• Karuna Ganesh, MD, PhD,
  Memorial Sloan Kettering Cancer Center
• Tyler Jacks, PhD,
  Massachusetts Institute of Technology
• Raul Rabada, PhD,
  Columbia University

Specific Aims:

Littman Lab/New York University

AIM 1. Investigate mechanisms by which microbiota influence tumor responses to anti-PD-1 therapy.
  AIM 1A: Examination of how gut microbiota exert functions at distal sites.
  AIM 1B: Characterization of candidate microbiota/diet-derived metabolites in regulation of antitumor responses.

AIM 2. Study effects of microbiota on intratumoral T cells in mice and organoids.
  AIM 2B: Screening of bacterial peptide libraries for effects on the tumor microenvironment and T-cell differentiation.

AIM 3. Analyze role of SAAs and effector T cells in tumor growth and checkpoint therapy.
  AIM 3A: Role of SAAs in tumor growth, evolution, and metastasis.
  AIM 3B: Elucidation of the SAA signaling pathway in Th17 cell differentiation.

Website:
SU2C Convergence 3.1416 Research Team CV6207

Specific Aims (Cont’d):

Ganesh Lab/Memorial Sloan Kettering Cancer Center

AIM 1. Develop a prospective functional longitudinal biospecimen platform to dissect tumor, immune, and microbial determinants of metastasis.

AIM 2. Develop a novel fluidic platform for in vitro modeling of epithelial-immune-microbial interactions.

AIM 3. Define molecular determinants of regenerative plasticity and innate immune activation during infection and cancer.

Jacks Lab/Massachusetts Institute of Technology

AIM 1. Investigate the tumor-immune contexture in immunogenic and immune refractory pancreas and colon cancers by single-cell mRNA sequencing (sc-mRNAseq) and spatial analysis of gene expression, protein expression, and metabolites.

AIM 2. Conduct ex vivo and in vivo organoid-based functional studies.

Rabadan Lab/Columbia University

AIM 1. Quantify host expression and microbial abundances for bulk and single-cell data analysis.

AIM 2. Quantify allele-specific HLA class I expression.

AIM 3. Random matrix theory (RMT) for single-cell denoising.

AIM 4. Topological data analysis (TDA) for dissecting dynamical single-cell data.

AIM 5. Gaussian random fields (GRF) approach for studying cell-cell interactions with special protein and transcriptomic data.
SU2C Convergence 3.1416 Research Team

Intra-team Collaboration: The Multi-organ Organoid Chemostat Group

**GRANT TERM:** January 2021 – December 2023

**KEY PERSONNEL:**

**Team Leader:**
Calvin Kuo, MD, PhD, Stanford University

**Team Members:**
- Michael Fischbach, PhD, Stanford University
- Karuna Ganesh, MD, PhD, Memorial Sloan Kettering Cancer Center
- Scott Manalis, PhD, Massachusetts Institute of Technology

**Collaborator:**
- Man-Wah Tan, PhD, Genentech

**Project Manager:**
- Alice Lustig, Stand Up To Cancer, alustig@su2c.org

**Specific Aims:**

**AIM 1.** Build and populate a new device to culture gut organoids with stem cells, lymphoid tissue, and a microbiome.

**AIM 2.** Apply molecular, biochemical, and biophysical technologies to address additional fundamental questions in tumor-host interactions: tumor evolution, the effects of the immune system and the microbiome, and determinants of regenerative plasticity.

**AIM 3.** Use the chemostat platform to be developed to study various organoid types and explore their interactions with immune cells.

**AIM 4.** Use the blood exchange method to uncover soluble and cellular mediators of immune response.

**Website:**
https://standuptocancer.org/research/research-portfolio/research-teams/the-multi-organ-organoid-chemostat-group/

Team Leader:
Calvin Kuo, MD, PhD, Stanford University

**CONVERGENCE TEAMS**
Correlating Immunological Health to Cancer Susceptibility

**Team Leader:**
Mark M. Davis, PhD, Stanford University

**Team Members:**
- David Furman, PhD, Buck Institute
- Thomas Montine, MD, PhD, Stanford University
- Kari Nadeau, MD, PhD, Stanford University
- Stephen Quake, PhD, Stanford University

**Project Manager:**
- Alice Lustig, Stand Up To Cancer, alustig@su2c.org

**Specific Aims:**

**AIM 1.** Correlates of cancer susceptibility in the Stanford-Ellison cohort.

**AIM 2.** Complementary cohorts.

**AIM 3.** Validation cohorts.

**Website:**
https://standuptocancer.org/research/research-portfolio/convergence-teams/cancer-susceptibility-convergence-research-team/
Single-Cell Functional Multi-omics to Characterize and Monitor CAR T Therapy

**Grant Term:** January 2018 – November 2022

**Key Personnel:**

**Team Leader:**
Rong Fan, PhD, Yale University

**Team Members:**
- Pablo Gonzalez Camara, PhD, University of Pennsylvania Perelman School of Medicine
- Stephanie Halene, MD, PhD, Yale University
- Carl H. June, MD, University of Pennsylvania Perelman School of Medicine
- J. Joseph Melenhorst, PhD, University of Pennsylvania Perelman School of Medicine

**Project Manager:**
Alice Lustig, Stand Up To Cancer, alustig@su2c.org

**Specific Aims:**

**AIM 1.** Measure the full spectrum of cytokine functions in pre-infusion CAR T cells upon antigen-specific stimulation, correlating to objective response and adverse effect.

**AIM 2.** Measure circulating and/or tumor-infiltrating CAR T cells ex vivo to monitor patient outcome and investigate the mechanism of efficacy versus immune-toxicity.

**AIM 3.** Develop computational models combining topological analysis and machine learning to unveil the molecular characteristics that underlie therapeutic efficacy and toxicity of CAR T therapy, and identify candidate biomarkers.

**Website:**
https://standuptocancer.org/research/research-portfolio/convergence-teams/single-cell-multi-omics-convergence-research-team/
Machine Learning for Cancer Immunotherapy

**Grant Term:** January 2018 – November 2022

**Key Personnel:**

**Team Co-leader:**
Ernest Fraenkel, PhD,
Massachusetts Institute of Technology

**Team Co-leader:**
Regina Barzilay, PhD,
Massachusetts Institute of Technology

**Project Manager:**
- Alice Lustig, Stand Up To Cancer,
alustig@su2c.org

**Specific Aims:**

**AIM 1.** Conduct integrative modeling of immune health and tumor biology.

**AIM 2.** Identify pathways conferring resistance to natural killer cells.

**Website:**
https://standuptocancer.org/research/research-portfolio/convergence-teams/machine-learning-convergence-research-team/

SU2C Convergence Research Team CV6123

**JUNE 2022**
Computational Deconstruction of Neoantigen-TCR Degeneracy for Cancer Immunotherapy

**GRANT TERM:** January 2018 – November 2022

**KEY PERSONNEL:**

**Team Co-leader:** Benjamin Greenbaum, PhD, Memorial Sloan Kettering Cancer Center

**Team Co-leader:** Vinod Balachandran, MD, Memorial Sloan Kettering Cancer Center

**Team Members:**

- Marta Luksza, PhD, Icahn School of Medicine at Mount Sinai
- Eileen M. O’Reilly, MD, Memorial Sloan Kettering Cancer Center
- Jedd Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center

**Project Manager:** Alice Lustig, Stand Up To Cancer, alustig@su2c.org

**Specific Aims:**

**AIM 1.** Define the rules of recognition of cancer neoantigens by human T cells.

**AIM 2.** Identify the role of the host microbiome in modulating neoantigen recognition.

**AIM 3.** Evaluate a neoantigen cancer vaccine as an adjuvant pancreatic cancer therapy.

**Clinical Trial:**

Phase I Clinical Trial of Personalized Neoantigen Tumor Vaccines and Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Surgically Resected Pancreatic Cancer; NCT04161755; Recruiting

**Website:**

https://standuptocancer.org/research/research-portfolio/convergence-teams/neoantigen-tcr-degeneracy-convergence-research-team/
Integrating Experimental and Computational Pipelines to Develop Biomarkers of Tumor Cell Resistance to NK Cells

**Grant Term:** January 2018 – November 2022

**Key Personnel:**

**Team Leader:**
Constantine S. Mitsiades, MD, PhD, Dana-Farber Cancer Institute

**Team Members:**
- Aedin Culhane, PhD, Dana-Farber Cancer Institute
- Todd Golub, MD, Broad Institute of MIT and Harvard
- Ricardo de Matos Simoes, PhD, Dana-Farber Cancer Institute
- Jennifer Roth, MSc, MBA, Broad Institute of MIT and Harvard
- Michal Sheffer, PhD, Dana-Farber Cancer Institute
- Aviad Tshemiak, MSc, Broad Institute of MIT and Harvard

**Project Manager:**
- Alice Lustig, Stand Up To Cancer, alustig@su2c.org

**Specific Aims:**

**AIM 1.** Apply and develop next-level computational resources to optimize identification of biomarkers of tumor cell sensitivity versus resistance to NK cells.

**AIM 2.** Expand the spectrum of phenotypic data on NK cell responses.

**AIM 3.** Validate candidate markers in our in vitro and in vivo experimental platforms.

**Website:**
https://standuptocancer.org/research/research-portfolio/convergence-teams/natural-killer-cells-convergence-research-team/
Responders and Non-responders to Endometrial Cancers With Mismatch Repair

**GRANT TERM:** January 2018 – December 2021

**KEY PERSONNEL:**

**Team Leader:**
Alessandro D. Santin, MD, Yale University

**Team Members:**
- Ludmil Alexandrov, PhD, University of California, San Diego
- Stephania Bellone, PhD, Yale University
- Akiko Iwasaki, PhD, Yale University

**Project Manager:**
Alice Lustig, Stand Up To Cancer, alustig@su2c.org

**Specific Aims:**

**AIM 1.** How can we predict responders from non-responders to checkpoint inhibitors?

**AIM 2.** Can we predict which patients will develop side effects to these therapies? How can we relate the peptide sequence of antigens to the nucleic acid sequence of T-cell receptor variable regions?

**AIM 3.** Can we predict peptide antigens from T-cell receptor sequences? Can we determine with some confidence the neoantigens that are expressed by tumors that are recognized by the immune system in an HLA-dependent fashion?

**Clinical Trial:**

Phase II Evaluation of Pembrolizumab, a Humanized Antibody Against PD-1, in the Treatment of Persistent or Recurrent Hypermutated/Ultramutated Endometrial Cancer Identified by Next-Generation Sequencing (NGS) and Comprehensive Genomic Profiling (CGP); NCT02899793; Active, not recruiting

**Website:**
https://standuptocancer.org/research/research-portfolio/convergence-teams/endometrial-cancers-convergence-research-team/
SU2C Convergence Research Team CV6127

Connecting Immune Health and Tumor Biology in Gynecologic Cancers

GRANT TERM: January 2018 – November 2022

KEY PERSONNEL:

**Team Leader:**
E. John Wherry, PhD, University of Pennsylvania

**Team Co-leader:**
Claire Friedman, MD, Memorial Sloan Kettering Cancer Center

**Team Members:**
- Shelley Berger, PhD, University of Pennsylvania
- Robert Burger, MD, FACOG, FACS, Hospital of the University of Pennsylvania
- Erica Carpenter, MBA, PhD, University of Pennsylvania
- Travis Hollman, MD, Memorial Sloan Kettering Cancer Center
- Dana Pe’er, PhD, Memorial Sloan Kettering Cancer Center
- Daniel Powell, PhD, University of Pennsylvania
- Dmitriy Zamarin, MD, PhD, Memorial Sloan Kettering Cancer Center

**Project Manager:**
Alice Lustig, Stand Up To Cancer, alustig@su2c.org

**Website:**
https://standuptocancer.org/research/research-portfolio/convergence-teams/gynecologic-cancers-convergence-research-team/

**Specific Aims:**

**AIM 1.** Test how tumor-intrinsic factors predispose to response or resistance to checkpoint blockade.

**AIM 2.** Test how baseline immune function and quality affects response to checkpoint blockade.

**AIM 3.** Define how on-treatment blood markers may reflect the tumor-immune interaction.

**Clinical Trials:**

Pilot Study of Nivolumab in Combination With Front-Line Neoadjuvant Dose-Dense Paclitaxel and Carboplatin Chemotherapy and Postsurgical Dose-Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; NCT03245892; Recruiting

Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer; NCT03241745; Recruiting
SU2C–Breast Cancer Research Foundation Convergence Research Team CV6004

Ecology of the Tumor Microenvironment in Breast Cancer

**GRANT TERM:** June 2015 – December 2019

**KEY PERSONNEL:**

**Team Leader:**
Peter P. Lee, MD, City of Hope

**Team Members:**
- Gurinder S. "Mickey" Singh Atwal, PhD, Cold Spring Harbor Laboratory
- Darrell J. Irvine, PhD, Massachusetts Institute of Technology
- Herbert Levine, PhD, Rice University
- Clare C. Yu, PhD, University of California, Irvine

**Project Manager:**
Alice Lustig, Stand Up To Cancer, alustig@su2c.org

**Specific Aims:**

**AIM 1.** Study the breast cancer TME via deconstruction into key components and 3-D reconstruction.

**AIM 2.** Study the intact breast cancer TME and TDLN via quantitative, spatial tissue analysis.

**AIM 3.** Investigate combination therapy targeting multiple components of the TE.

**Website:**
https://standuptocancer.org/research/research-portfolio/convergence-teams/breast-cancer-tumor-microenvironment/
Rational Design of Anticancer Drug Combinations with Dynamic Multi-Dimensional Input

**GRANT TERM:** September 2015 – August 2019

**KEY PERSONNEL:**

**Team Leader:**
Anthony G. Letai, MD, PhD, Dana-Farber Cancer Institute

**Team Members:**
- Reka Z. Albert, PhD, Pennsylvania State University
- Raul Rabadan, PhD, Columbia University
- Maurizio Scatriti, PhD, Memorial Sloan Kettering Cancer Center
- Nikhil Wagle, MD, Dana-Farber Cancer Institute/ Harvard Cancer Center

**Project Manager:**
- Alice Lustig, Stand Up To Cancer, alustig@su2c.org

**Specific Aims:**

**AIM 1.** Construct dynamic models for signal transduction in PIK3CA-mutant, ER+ breast cancer cells.

**AIM 2.** Perform systematic gain-of-function screens to refine and iterate the dynamic models.

**AIM 3.** Dissect the evolutionary trajectories of acquired cancer drug resistance.

**Clinical Trials:**

Phase I Trial of BYL719 Plus Letrozole or Exemestane for Patients With Hormone Receptor-Positive, Locally Advanced, Unresectable or Metastatic Breast Cancer; NCT01870505; Active, not recruiting

Phase II, Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women With ER-Positive/HER2-Negative, Early-Stage Breast Cancer; NCT02273973; Completed

Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerance, and Pharmacokinetics of GDC-0077 as a Single Agent in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination With Endocrine and Targeted Therapies in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Hormone Receptor-Positive Breast Cancer; NCT03006172; Recruiting

**Website:**
https://standuptocancer.org/research/research-portfolio/convergence-teams/rational-design-of-anticancer-drug-combinations-convergence-research-team/
Genetic, Epigenetic, and Immunological Underpinnings of Cancer Evolution Through Treatment

**GRANT TERM:** September 2015 – December 2019

**KEY PERSONNEL:**

**Team Leader:**
Ross Levine, MD, Memorial Sloan Kettering Cancer Center

**Team Members:**
- Steven J. Altschuler, PhD, University of California, San Francisco
- Chang S. Chan, PhD, Rutgers Cancer Institute of New Jersey
- Daniel S. Fisher, PhD, Stanford University
- Aaron Hata, MD, PhD, Massachusetts General Hospital
- Harlan Robins, PhD, Fred Hutchinson Cancer Research Center
- Lecia VanDam Sequist, MD, MPH, Massachusetts General Hospital

**Project Manager:**
- Alice Lustig, Stand Up To Cancer, alustig@su2c.org

**Specific Aims:**

**AIM 1.** Investigate genetic, epigenetic, and phenotypic diversity in response to cancer therapies.

**AIM 2.** Examine immune system dynamics in response to cancer therapies.

**AIM 3.** Conduct functional interrogation of drug response/resistance.

**Clinical Trial:**
Phase II Study of EGF816 and Gefitinib in TKI-Naive EGFR-Mutant Non-small Cell Lung Cancer; NCT03292133; Recruiting

**Website:**
https://standuptocancer.org/research/research-portfolio/convergence-teams/cancer-evolution-convergence-team/
Liberating T-Cell Mediated Immunity to Pancreatic Cancer

**Grant Term:** September 2015 – January 2020

**Key Personnel:**

- **Team Co-leader:** Peter O’Dwyer, MD, University of Pennsylvania
- **Team Co-leader:** Jeffrey Drebin, MD, Memorial Sloan Kettering Cancer Center
- **Team Co-leader:** Jedd Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center
- **Team Members:**
  - Curtis G. Callan, PhD, Princeton University
  - Benjamin D. Greenbaum, PhD, Icahn Medical School at Mount Sinai
  - Harlan Robins, PhD, Fred Hutchinson Cancer Research Center
  - David T. Ting, MD, Massachusetts General Hospital/Harvard Medical School
- **Project Manager:** Alice Lustig, Stand Up To Cancer, alustig@su2c.org

**Specific Aims:**

- **AIM 1.** Characterize neoadjuvant vitamin D effects on the T-cell repertoire and immunologic milieu in human pancreatic cancer.
  - **AIM 1.1.** Understand the interplay of TCR diversity and neoepitopes in PDAC.
  - **AIM 1.2.** Characterize pancreatic cancer transcriptional response to immunomodulatory signals.
- **AIM 2.** Conduct exploratory study of neoadjuvant chemoimmunotherapy in pancreatic cancer.
  - **AIM 2.1.** Phase I trial of neoadjuvant gemcitabine/nab-paclitaxel/paricalcitol/nivolumab. (Work on this Aim is continuing as an SU2C subproject)
  - **AIM 2.2.** Perform T-cell repertoire analysis and in vitro characterization of neoantigen reactivity.

**Clinical Trial:**

Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer; NCT03300921; Active, not recruiting

**Website:**

SU2C CATALYST® TEAMS
The LiFFT Study (Lurbinectedin in FET-Fusion Tumors)

**Grant Term:** TBD

**Key Personnel:**

**Team Leader:**
Patrick Grohar, MD, PhD,  
Children’s Hospital of Philadelphia

**Team Co-leader:**
Robert Maki, MD, PhD,  
University of Pennsylvania

**Principal:**
Brian D. Compton, MD,  
Dana-Farber Cancer Institute

**Advocates:**
Carol R. Basso  
Laurie E. Karl, Sean Karl Foundation

**Project Managers:**
Jennifer Baldi,  
Children’s Hospital of Philadelphia, baldij@chop.edu  
Cecilia Carlowicz, CCRC,  
Children’s Hospital of Philadelphia, CARLOWICZC@chop.edu

**Specific Aims:**

**AIM 1.** Determine the safety, tolerability, and pharmacokinetic profile of lurbinectedin in patients with FET-fusion tumors.

**AIM 2.** Determine if lurbinectedin inhibits EWS-FLI1 and/or shows antitumor activity in Ewing’s sarcoma.

**Website:** TBD
Identification of Combination Therapeutics Using JZP-815 for the Treatment of NSCLC

**Grant Term:** TBD

**Key Personnel:**

**Team Leader:**
Fred R. Hirsch, MD, PhD,
Icahn School of Medicine at Mount Sinai

**Team Co-leader:**
Kwok-Kin Wong, MD, PhD,
New York University, Grossman School of Medicine

**Project Manager:**
- Benjamin Hopkins, PhD,
  Icahn School of Medicine at Mount Sinai,
  benjamin.hopkins@mssm.edu

**Specific Aims:**

**AIM 1.** Take functional genomics approach to identify JZP-815-based combinations for the treatment of KRAS mutant NSCLC.

**AIM 2.** Evaluate therapeutic potential of JZP-815-based combination in GEMM models of KRAS mutant NSCLC.

**Website:**
TBD
Technology-Enabled Immunotherapy Monitoring in NYC Minority NSCLC Patients

**Grant Term:** TBD

**Key Personnel:**

**Team Leader:** Vamsidhar Velcheti, MD, New York University Grossman School of Medicine

**Team Co-leader:** Rajwanth Veluswamy, MD, Icahn School of Medicine at Mount Sinai

**Principals:**
- Balazs Halmos, MD, MS, Albert Einstein College of Medicine
- Brian Henick, MD, Columbia University

**Advocates:**
- Sulaiha Mastan
- Catherine Paykin, New York University Grossman School of Medicine

**Project Manager:**
- Kristen Labbe, MPH, New York University Grossman School of Medicine, Kristen.Labbe@nyulangone.org

**Specific Aims:**

**AIM 1.** Evaluate the barriers to adoption and optimal utilization of technology-enabled remote monitoring and adverse event management of underserved minority patients with non-small cell lung cancer (NSCLC) on immunotherapy.

**AIM 2.** Determine the impact of patient-reported outcome measures collected using ApricityRx™ and CARE service on the management of NSCLC patients receiving immunotherapy in a highly diverse New York City community.

**AIM 3.** Utilize technology-enabled monitoring to enhance the overall quality of care and translational research in underserved minority patients with NSCLC.

**Website:** TBD
Targeting Adaptive and Acquired Resistance to Direct KRAS Inhibition

**GRANT TERM:** February 2022 – January 2025

**KEY PERSONNEL:**

**Team Leader:**
Ryan B. Corcoran, MD, PhD, Massachusetts General Hospital

**Team Co-leader:**
Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center

**Principals:**
- Rebecca Heist, MD, Massachusetts General Hospital
- David Hong, MD, The University of Texas MD Anderson Cancer Center
- Pasi A. Jänne, MD, PhD, Harvard Medical School and Dana-Farber Cancer Institute

**Project Manager:**
Stephanie McQueen, Massachusetts General Hospital, smcqueen1@partners.org

**Advocates:**
- Bonnie Addario, GO2 Foundation for Lung Cancer
- Anjee Davis, Fight CRC
- Manju George, Colontown

**Specific Aims:**

**AIM 1.** Elucidate mechanisms of adaptive resistance to direct KRAS inhibition and understand the drug-tolerant persister state.

**AIM 2.** Identify mechanisms of acquired resistance to KRASG12C inhibition and perform clinical trials to overcome resistance.

**AIM 3.** Define interactions between direct KRAS inhibition and the tumor immune response and perform preclinical prioritization of novel therapeutic strategies.

**Website:**
TBD
Atezolizumab, Abiraterone, and SBRT in Hormone Sensitive Prostate Cancer

**GRANT TERM:** September 2019 – February 2023, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Sean M. McBride, MD, Memorial Sloan Kettering Cancer Center

**Clinical Lead:**
Dana E. Rathkopf, MD, Memorial Sloan Kettering Cancer Center

**Principals:**
- Yingbei Chen, MD, PhD, Memorial Sloan Kettering Cancer Center
- Jessica E. Hawley, MD, Columbia University Medical Center
- Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center
- Lawrence H. Schwartz, MD, Columbia University Medical Center

**Project Manager:**
Kevin DeRudder, Memorial Sloan Kettering Cancer Center, deruddek@mskcc.org

**Advocates:**
- Jan Manarite, Prostate Cancer International
- Joel Nowark, Cancer ABCs

**Specific Aims:**

**AIM 1.** Determine if the addition of SBRT and atezolizumab to abiraterone + leuprolide improves failure-free survival (FFS) at two years relative to the FFS in the STAMPEDE trial.

**AIM 2.** Evaluate potential immunologic biomarkers of response.

**AIM 3.** Evaluate whether noninvasive blood-based and imaging-based biomarkers can be used to monitor and/or predict treatment response.

**Clinical Trial:**
SAABR: Single-Arm Phase II Study of Abiraterone + Atezolizumab + GnRH Analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men With Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer; NCT04262154; Recruiting

**Website:**
[https://progress.standuptocancer.org/catalyst?team=prostate-cancer](https://progress.standuptocancer.org/catalyst?team=prostate-cancer)
Combination Sacituzumab and Atezolizumab to Prevent Recurrence in Triple Negative Breast Cancer (TNBC)

**GRANT TERM:** July 2019 – December 2022, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

- **Team Leader:** Elizabeth A. Mittendorf, MD, PhD, Dana-Farber Cancer Institute
- **Clinical Lead:** Angela M. DeMichele, MD, University of Pennsylvania
- **Project Manager:** Michelle DeMeo, Dana-Farber Cancer Institute, Michelle_DeMeo@dfci.harvard.edu
- **Advocates:**
  - Caroline Abi-Khattar, JD, University of Pennsylvania
  - Elizabeth S. Frank, Dana-Farber Cancer Institute

**Principals:**

- Vandana Abramson, MD, Vanderbilt University Medical Center
- Heather L. McArthur, MD, Cedars-Sinai Medical Center
- Rita Nanda, MD, University of Chicago
- Ben Ho Park, MD, PhD, Vanderbilt University Medical Center
- Hope S. Rugo, MD, University of California, San Francisco
- Sara M. Tolaney, MD, Dana-Farber Cancer Institute

**Specific Aims:**

**AIM 1.** Conduct a single-arm, phase II trial of sacituzumab govitecan in combination with atezolizumab, enrolling TNBC patients with residual disease and cfDNA following NACT.

**AIM 2.** Perform correlative studies to determine whether PD-L1 expression on CTCs has utility as a pharmacodynamic biomarker, and whether there is an association between molecular and immunobiological features in residual disease after NACT and response to sacituzumab govitecan plus atezolizumab.

**Clinical Trial:**

Single-Arm Phase II Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple-Negative Breast Cancer (ASPRIA); NCT04434040; Recruiting

**Website:**
https://progress.standuptocancer.org/catalyst?team=triple-negative-breast-cancer
Clinical Translation of Novel Immune-Based Combination Therapies for Pediatric Hypermutant Cancers

**GRANT TERM:** June 2019- November 2023

**KEY PERSONNEL:**

**Team Leader and Clinical Lead:**
Uri Tabori, MD,
The Hospital for Sick Children

**Team Co-leader:**
Daniel Morgenstern, MD,
The Hospital for Sick Children

**Principals:**

- Crystal Mackall, MD, Stanford University
- John Maris, MD, Children’s Hospital of Philadelphia

**Project Manager:**

- Vanessa Bianchi, PhD, The Hospital for Sick Children, vanessa.bianchi@sickkids.ca

**Advocates:**

- Denise Bebenek, Meagan’s Hug
- Karen Haas, The Hospital for Sick Children
- Jenell Holstead, PhD, University of Wisconsin
- Parvathy Krishnan, The Hospital for Sick Children

**Specific Aims:**

**AIM 1.** Perform a phase Ib clinical trial of combinational immune checkpoint inhibitor (ICI) therapies in childhood hypermutant cancers.

**AIM 2.** Determine the biological aspects and preclinical benefits of combined BMS lead compounds with ICI on replication repair deficiency (RRD) hypermutant immunocompetent mouse models.

**AIM 3.** Define immediately translatable tumor intrinsic molecular vulnerabilities in RRD hypermutant cancers.

**Clinical Trial:**

3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent, and Young Adult (CAYA) Patients With Relapsed/Refractory Hypermutant Cancers; NCT04500548; Recruiting

**Website:**
https://progress.standuptocancer.org/pediatric-catalyst/?team=hypermutant-cancers-ll
Immunomodulation to Treat Poor-Prognosis Pediatric Brain Tumors

**GRANT TERM:** February 2019 – August 2021

**KEY PERSONNEL:**

**Team Leader:** Maryam Fouladi, MD, Nationwide Children’s Hospital

**Team Co-leader:** James Olson, MD, PhD, Fred Hutchinson Cancer Research Center

**Principals:**
- Rachid Drissi, PhD, Nationwide Children’s Hospital
- Annie Huang, MD, PhD, The Hospital for Sick Children
- Nada Jabado, MD, PhD, McGill University Health Centre

**Project Manager:**
- Sara Lawellin, Cincinnati Children’s Hospital Medical Center, Sara.Lawellin@cchmc.org

**Advocate:**
- Keith Desserich, Cure Starts Now

**Specific Aims:**

**AIM 1.** Determine the extent to which 5-aza, ribo, or other non-cytotoxic FDA-approved drugs enhance T-cell mediated PBT cell death in vitro.

**AIM 1B.** Assess the efficacy of 5-aza, ribo, or a superior candidate in vivo.

**AIM 2.** Establish a biomarker-based responder hypothesis.

**Website:**
https://progress.standuptocancer.org/pediatric-catalyst?team=epigenetics
Targeting Epigenetic Dysregulation in Pediatric Cancer

**GRANT TERM:** January 2019 – June 2023

**KEY PERSONNEL:**

**Team Leader:**
Kimberly Stegmaier, MD, PhD,
Dana-Farber Cancer Institute

**Team Co-leader and Clinical Lead:**
Steven DuBois, MD,
Dana-Farber Cancer Institute

**Principals:**
- Peter Dirks, MD, PhD, The Hospital for Sick Children
- David Kirsch, MD, PhD, Duke University
- Elizabeth Lawlor, MD, PhD, Seattle Children’s Research Institute

**Project Manager:**
- Jennifer Perry, PhD, Dana-Farber Cancer Institute,
  Jennifer_perry@dfci.harvard.edu

**Advocate:**
- Kathleen Malcolmson

**Specific Aims:**

**AIM 1.** Conduct a phase I clinical trial testing the BMS BETi BMS-986158 in children with cancer.

**AIM 2.** Test rational drug combinations with BMS-986158 in preclinical models of pediatric cancer.

**AIM 3.** Identify novel drug combinations with BMS-986158 through genome-scale CRISPR-Cas9 synergy screens.

**Clinical Trial:**

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer; NCT03936465; Recruiting

**Website:**
https://progress.standuptocancer.org/pediatric-catalyst?team=epigenetics
Neoadjuvant Therapy for Patients With High-Risk Stage III Melanoma

**GRANT TERM:** June 2018 – November 2024, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Matthew S. Block, MD, PhD, Mayo Clinic

**Clinical Lead:**
Tina J. Hieken, MD, Mayo Clinic

**Principals:**
- Jun Chen, PhD, Mayo Clinic
- Evidio Domingo-Musibay, MD, University of Minnesota
- Roxana S. Dronca, MD, Mayo Clinic
- Thomas J. Flotte, MD, Mayo Clinic
- Rachel L. Maus, PhD, Mayo Clinic
- Vera J. Suman, PhD, Mayo Clinic

**Project Manager:**
Jill Schimke, Mayo Clinic, schimke.jill@mayo.edu

**Advocates:**
- Cynthia Chauhan
- Heidi Turner, Mayo Clinic
- Simone Veum, University of Minnesota

**Specific Aims:**

**AIM 1.** Test the safety and efficacy of the neoadjuvant combination of vemurafenib/cobimetinib/atezolizumab followed by surgery followed by adjuvant atezolizumab in patients with BRAFm high-risk stage III melanoma.

**AIM 2.** Test the safety and efficacy of neoadjuvant combination of cobimetinib/atezolizumab followed by surgery followed by adjuvant atezolizumab in patients with BRAFwt high-risk stage III melanoma.

**AIM 3.** Test the safety and efficacy of the neoadjuvant combination of tiragolumab/atezolizumab followed by surgery and adjuvant atezolizumab in patients with high-risk stage III melanoma.

**Clinical Trial:**
Neoadjuvant Therapy for Patients With High-Risk Stage III Melanoma: A Pilot Clinical Trial; NCT03554083, Recruiting

**Website:**
https://progress.standuptocancer.org/catalyst?team=neoadjuvant-melanoma
Immunotherapy Combination Strategies in ER-Positive Metastatic Breast Cancer

**Grant Term:** May 2018 – December 2019, administered by the American Association for Cancer Research

**Key Personnel:**

**Team Leader:** Ingrid A. Mayer, MD, Vanderbilt University

**Team Co-leader:** Justin M. Balko, PharmD, PhD, Vanderbilt University

**Principals:**
- Rita Nanda, MD, University of Chicago
- Hope S. Rugo, MD, University of California, San Francisco
- Melinda E. Sanders, MD, Vanderbilt University
- Yu Shyr, PhD, Vanderbilt University

**Project Manager:** Catherine Weir, Vanderbilt University

**Advocates:**
- Lynn Cargen
- Linda J. Horton

**Specific Aims:**

**Aim 1.** Perform preclinical assays to determine the functional effect of MDM2 inhibition on T cells.

**Aim 2.** Perform preclinical studies to model the molecular and therapeutic effects of MDM2 inhibition with anti-PD-L1 therapy in breast cancer.

**Aim 3.** Perform a multicenter, open-label, two-arm phase Ib/II clinical trial that will evaluate the antitumor effect of atezolizumab (ATEZ, an anti-PD-L1 mAb) in combination with cobimetinib (COBI, a MEK inhibitor) in patients with TP53-mutated ER+ mBC (metastatic breast cancer), or idasanutlin (IDASA, an MDM2 antagonist) in patients with TP53-wt ER+ mBC.

**Aim 4.** Determine whether IDASA or COBI enhances T-cell infiltration and activation in ER+ breast tumors, and whether this effect is associated with patient-specific clinical response to ATEZ. In addition, molecular correlates both intra-tumoral and in the peripheral blood of patients will be tested as correlative analyses.

**Aim 5.** Perform active monitoring of T-cell populations in PBMCs from IDASA-treated patients. To ensure that treatment for two weeks with IDASA does not eliminate peripheral effector T-cell populations, we will perform CyTOF to identify expanded or eliminated T-cell populations in the peripheral blood in the phase I portion of the IDASA arm.

**Website:**
https://progress.standuptocancer.org/catalyst/?team=metastatic-breast-cancer
SU2C Catalyst® Research Team With Support From Genentech CT6053

Clinical Trial:

BRE 17107: Phase Ib/II Trial of Atezolizumab (an Anti-PD-L1 Monoclonal Antibody) With Cobimetinib (a MEK1/2 Inhibitor) or Idasanutlin (an MDM2 Antagonist) in Metastatic ER+ Breast Cancer; NCT03566485; Terminated
Overcoming Urothelial Cancer Atezolizumab Resistance by Epigenetic Therapy

**GRANT TERM:** November 2017 – April 2021, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Peter A. Jones, PhD, DSc, Van Andel Institute

**Team Co-leader:**
Elizabeth R. Plimack, MD, Fox Chase Cancer Center

**Principals:**
- Stephen B. Baylin, MD, Johns Hopkins University
- Noah M. Hahn, MD, Johns Hopkins University
- Jean-Pierre J. Issa, MD, Coriell Institute for Medical Research
- David I. Quinn, MD, USC Norris Comprehensive Cancer Center

**Project Managers:**
- Penny Berger, Van Andel Institute, Penny.Berger@vai.org
- Ryan Burgos, Van Andel Institute, Ryan.Burgos@vai.org
- Revathi Penumatsa, Van Andel Institute, Revathi.Penumatsa@vai.org

**Advocates:**
- Rick Bangs
- Beth Flory

**Specific Aims:**

**AIM 1.** Dose selection: Identify a safe, biologically active dose of concurrent guadecitabine and atezolizumab for patients with advanced UC in the safety run-in portion of our phase II study.

**AIM 2.** Dose expansion: Determine the efficacy (ORR) of the combination in patients with advanced UC who progressed after immune checkpoint therapy in a single-arm phase II expansion cohort.

**AIM 3.** Correlative science: Use paired pre- and post-treatment biopsies and peripheral blood to explore genomes, genome-wide expression, pathway alterations, and epigenomes in tumor and immune cells.

**Clinical Trial:**

GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer; NCT03179943; Active, not recruiting

**Website:**
https://progress.standuptocancer.org/catalyst/?team=urothelial-bladder-cancer
Tumor Infiltrating Lymphocyte Adoptive T-Cell Therapy for Non-small Cell Lung Cancer (NSCLC)

**GRANT TERM:** June 2017 – May 2020, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Co-leader:**
Eric B. Haura, MD, H. Lee Moffitt Cancer Center & Research Institute

**Team Co-leader:**
Scott J. Antonia, MD, PhD, Duke University

**Clinical Lead:**
Benjamin C. Creelan, MD, H. Lee Moffitt Cancer Center & Research Institute

**Investigators:**
- Frederic J. Kaye, MD, University of Florida
- John M. Koomen, PhD, H. Lee Moffitt Cancer Center & Research Institute

**Project Manager:**
Carol Ulge, H. Lee Moffitt Cancer Center & Research Institute, Carol.Ulge@moffitt.org

**Advocates:**
- Rosalynne I. Miller
- Joan Tashbar

**Specific Aims:**

**AIM 1.** Conduct a trial of TIL ACT and α-PD-1 in advanced-stage NSCLC patients.

**AIM 2.** Characterize tumor and TIL features associated with response using proteogenomics.

**Clinical Trial:**

A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Non-small Cell Lung Cancer; NCT03215810; Recruiting

**Website:**
https://progress.standuptocancer.org/catalyst/?team=lung-immunotherapy
Immunotherapy to Prevent Progression in Multiple Myeloma

**GRANT TERM:** May 2017 – October 2021, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader and Clinical Lead:**
Irene M. Ghobrial, MD,
Dana-Farber Cancer Institute

**Principals:**
- Viktor A. Adalsteinsson, PhD,
  Broad Institute
- Mark W. Bustoros, MD,
  Weill Cornell Medical College
- Marzia Capelletti, PhD,
  Dana-Farber Cancer Institute
- Jihye Park, PhD,
  Dana-Farber Cancer Institute
- Romanos Sklavenitis Pistofidis, MD,
  Dana-Farber Cancer Institute
- Yujia Shen, PhD,
  Dana-Farber Cancer Institute
- Oksana Zavidij, PhD,
  Dana-Farber Cancer Institute

**Project Manager:**
- Alexandra Savell,
  Dana-Farber Cancer Institute,
asavell@partners.org

**Advocate:**
- Jenny Ahlstrom, Myeloma Crowd

**Specific Aims:**

**AIM 1.** Define the immune-oncogenomic landscape of smoldering multiple myeloma (SMM) in response to immunotherapy.

**AIM 2.** Characterize somatic aberrations present in cell-free DNA (cfDNA) and circulating tumor cells (CTCs) as biomarkers of response/resistance in SMM enrolled in the trial.

**AIM 3.** Define markers of the permissive bone marrow microenvironment that characterize risks of progression in SMM patients enrolled in the trial.

**Clinical Trial:**
Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma; NCT02279394; Active, not recruiting

**Website:**
https://progress.standuptocancer.org/catalyst/?team=multiple-myeloma
Pembrolizumab and Radiation Therapy to Improve Outcome in High-Risk Sarcoma

**GRANT TERM:** May 2017 – October 2022, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader and Clinical Lead:**
David G. Kirsch, MD, PhD,
Duke University Medical School

**Principals:**
- Karla V. Ballman, PhD,
  Weill Cornell Medical College
- Brian E. Brigman, MD,
  Duke Cancer Institute
- George D. Demetri, MD,
  Dana-Farber Cancer Institute
- Richard F. Riedel, MD,
  Duke Cancer Institute
- Matt van de Rijn, MD, PhD,
  Stanford University
- Andrew J. Wagner, MD,
  PhD, Dana-Farber Cancer Institute
- Kent J. Weinhold, PhD,
  Duke University Medical Center
- Steven Young, Sarcoma Alliance for Research Through Collaboration

**Early Career Investigators:**
- Everett Moding, MD, PhD,
  Stanford University
- Yvonne Mowery, MD, PhD,
  Duke Cancer Institute

**Project Managers:**
- Erin Kozlowski,
  Sarcoma Alliance for Research Through Collaboration,
  ekozlowski@sarctrials.org
- Lindsay Overman,
  Sarcoma Alliance for Research Through Collaboration,
  leoverman@sarctrials.org

**Advocate:**
- Corrie A. Painter, PhD,
  Broad Institute

**Specific Aims:**

**AIM 1.** Test the safety and efficacy of pembrolizumab combined with preoperative radiotherapy to reduce the development of metastatic disease in sarcoma patients.

**AIM 2.** Characterize immune response to radiotherapy with or without pembrolizumab and identify predictors of pembrolizumab response in patients with soft-tissue sarcoma.

**Clinical Trial:**

SU2C-SARC032: Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft-Tissue Sarcoma of the Extremity; NCT03092323; Recruiting

**Website:**
[https://progress.standuptocancer.org/catalyst/?team=sarcoma](https://progress.standuptocancer.org/catalyst/?team=sarcoma)
Reversing Primary Anti-PD-1 Resistance with Ipilimumab and Nivolumab

**GRANT TERM:** May 2017 – October 2022, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Antoni Ribas, MD, PhD, University of California, Los Angeles

**Clinical Lead:**
Ari M. Vanderwalde, MD, West Cancer Center and Research Institute

**Principals:**
- Kenneth F. Grossmann, MD, PhD, Huntsman Cancer Institute, University of Utah
- Siwen Hu-Lieskovan, MD, PhD, Huntsman Cancer Institute, University of Utah
- Jeffrey A. Sosman, MD, Northwestern University

**Project Manager:**
Jia M. Chen, PhD, University of California, Los Angeles, JiaChen@mednet.ucla.edu

**Advocate:**
Samantha Guild, AIM at Melanoma Foundation

**Specific Aims:**

**AIM 1.** Conduct a phase II study of ipilimumab and nivolumab in patients with metastatic melanoma progressing on prior anti-PD-1 therapy.

**AIM 2.** Investigate cellular and genomic changes in biopsies when adding ipilimumab to continued PD-1 inhibition.

**Clinical Trial:**
Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent; NCT03033576; Active, not recruiting

**Website:**
https://progress.standuptocancer.org/catalyst/?team=reversing-resistance-melanoma
Targeting VDR to Make Pancreatic Cancer Competent for Immunotherapy

**GRANT TERM:** May 2017 – June 2020, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader and Clinical Lead:**
Daniel D. Von Hoff, MD, Translational Genomics Research Institute

**Principals:**

- Angela T. Alistar, MD, Atlantic Health System
- Michael T. Barrett, PhD, Mayo Clinic Arizona
- Carlos H. Becerra, MD, Baylor University Medical Center
- Erkut H. Borazanci, MD, Honor Health Research Institute
- Vincent Chung, MD, City of Hope
- Michael R. Downes, PhD, Salk Institute for Biological Studies
- Ronald M. Evans, PhD, Salk Institute for Biological Studies
- Haiyong Han, PhD, Translational Genomics Research Institute
- Anup Kasi, MD, University of Kansas Medical Center
- Ronald L. Korn, MD, PhD, Imaging Endpoints, LLC
- Winnie Liang, PhD, Translational Genomics Research Institute
- Andrew M. Lowy, MD, University of California, San Diego
- Hitendra P. Patel, MBBS, UCSD Moores Cancer Center
- Paul S. Ritch, MD, Medical College of Wisconsin

**Project Manager:**

- Jatan Clark, Translational Genomics Research Institute, jclark@tgen.org

**Advocates:**

- Roger E. Magowitz, Seena Magowitz Foundation
- Howard E. Young, General Wholesale Beer Company

**Specific Aims:**

**AIM 1.** Determine the synergy between the VDR agonist paricalcitol and the PD-1 inhibitor pembrolizumab in effecting an antitumor immune response in clinical trials.

**AIM 2.** Define the impact of paricalcitol and pembrolizumab combination therapy on the mutational landscapes and transcriptional programs of pancreatic tumors.

**AIM 3.** Identify cellular and molecular VDR targets in the immune microenvironment that synergize with PD-1 blockade.

**Website:**
https://progress.standuptocancer.org/catalyst/?team=pancreatic
SU2C Catalyst® Research Team With Support From Merck CT6031

Clinical Trial:

SU2C Catalyst® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response; NCT03331562; Completed
Combined Epigenetic Therapy and Pembrolizumab for Advanced Non-small Cell Lung Cancer (NSCLC)

**GRANT TERM:** April 2017 – June 2022, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Stephen B. Baylin, MD, Johns Hopkins University

**Team Co-leader:**
Kathryn C. Arbour, MD, Memorial Sloan Kettering Cancer Center

**Principals:**
- Hossein Borghaei, DO, Fox Chase Cancer Center
- Peter A. Jones, PhD, DSc, Van Andel Institute
- Kristen A. Marrone, MD, Johns Hopkins University
- Jarushka Naidoo, MBBCh, Johns Hopkins University
- Charles M. Rudin, MD, Memorial Sloan Kettering Cancer Center
- Hui Shen, PhD, Van Andel Institute
- E. John Wherry, PhD, University of Pennsylvania

**Project Managers:**
- Penny Berger, Van Andel Institute, Penny.Berger@vai.org
- Ryan Burgos, Van Andel Institute, Ryan.Burgos@vai.org
- Kerri Muenkel Calderone, Memorial Sloan Kettering Cancer Center, muenkelk@mskcc.org
- Revathi Penumatsa, Van Andel Institute, Revathi.Penumatsa@vai.org

**Advocate:**
Beth Flory, Van Andel Institute

**Specific Aims:**

**AIM 1.** Dose selection: Identify a safe, biologically active dose of concurrent combination pembrolizumab, guadecitabine, and mocetinostat for patients with advanced NSCLC in a Phase I study.

**AIM 2.** Dose expansion: Determine the efficacy of this triplet combination in patients with advanced NSCLC as part of a Phase Ib dose expansion, in the context of tumor PD-L1 expression.

**AIM 3.** Use paired pre-and post-treatment biopsies and serial peripheral blood to explore (in collaboration with Merck) the attraction of immune cells to the tumor microenvironment and genome-wide changes in expression, pathway alterations, and epigenome in tumor and host immune cells.

**Website:**
https://progress.standuptocancer.org/catalyst/?team=lung-immuno-epigenetics
SU2C Catalyst® Research Team With Support From Merck CT6030

Clinical Trial:

Phase I/II Study of Combined Pembrolizumab Plus Guadecitabine and Mocetinostat for Patients With Advanced NSCLC (dose selection); NCT03220477; Active, not recruiting
Combined Approaches by Immune Checkpoint Inhibition for Hypermutant Cancers

**GRANT TERM:** April 2017 – March 2020, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
- Uri Y. Tabori, MD, The Hospital for Sick Children
- Michael J. Fisher, MD, Children’s Hospital of Philadelphia

**Principals:**
- Eric Bouffet, MD, The Hospital for Sick Children
- Michael J. Fisher, MD, Children’s Hospital of Philadelphia

**Project Manager:**
- Melissa Edwards, PhD, The Hospital for Sick Children, melissa.edwards@sickkids.ca

**Advocate:**
- Denise Bebenek, Meagan’s Walk: Creating a Circle of Hope

**Specific Aims:**

**AIM 1.** Determine the prevalence and type of hypermutant human cancers.

**AIM 2.** Test three types of combinational ICI therapies using hypermutant cancer mouse models.

**AIM 3.** Perform pilot case studies of ICI combinational therapies on recurrent hypermutant human cancers.

**Clinical Trial:**
Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers; NCT02992964; Active, not recruiting

**Website:**
https://progress.standuptocancer.org/pediatric-catalyst?team=hypermutant-cancers
DNA Repair Therapies for Ovarian Cancer

**GRANT TERM:** July 2016 – December 2020, administered by the American Association for Cancer Research

**KEY PERSONNEL:**

**Team Leader:**
Alan D. D’Andrea, MD, Dana-Farber Cancer Institute

**Team Co-leader:**
Elizabeth M. Swisher, MD, University of Washington

**Principal:**
- Panagiotis (Panos) A. Konstantinopoulos, MD, PhD, Dana-Farber Cancer Institute

**Project Manager:**
- Donald R. Watson, Dana-Farber Cancer Institute, donald_watson@dfci.harvard.edu

**Advocates:**
- Jamie Crase, University of Washington
- Sue Friedman, FORCE: Facing Our Risk of Cancer Empowered
- Kathleen Gavin, Minnesota Ovarian Cancer Alliance
- Deborah Polinsky, FORCE: Facing Our Risk of Cancer Empowered (deceased)

**Specific Aims:**

**AIM 1.** Collect and distribute tumor samples and blood samples from TNBC (triple-negative breast cancer) and HGSOC (high-grade serous ovarian cancer) patients enrolled in this joint Tesaro/Merck/SU2C clinical trial.

**AIM 2.** Complete the indicated biomarker studies, from multiple industry-sponsored and academic laboratories, and analyze the collected data.

**Clinical Trial:**

Phase I/II Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer; NCT02657889; Active, not recruiting

**Websites:**
https://progress.standuptocancer.org/catalyst/?team=ovarian
INNOVATIVE RESEARCH GRANTS
INNOVATIVE RESEARCH GRANTS

CLASS OF 2017

The 2017 class is specifically focused on immuno-oncology, supported by a grant from Bristol Myers Squibb.

Harnessing Dipeptidyl Peptidase Inhibition for Cancer Immunotherapy
Daniel A. Bachovchin, PhD, Memorial Sloan Kettering Cancer Center

Rescuing T-Cell Function for Immunotherapy of Pediatric Malignancies
David M. Barrett, MD, PhD, Children’s Hospital of Philadelphia

Targeting the Pro-Metastatic Niche in the Liver for Cancer Immunotherapy
Gregory L. Beatty, MD, PhD, University of Pennsylvania

T-Cell Immunotherapy for Core Binding Factor Acute Myeloid Leukemia
Marie E. Bleakley, MD, PhD, Fred Hutchinson Cancer Research Center

Imaging CAR T Cells With a Dual-Function PET Reporter Gene
Michael D. Farwell, MD, University of Pennsylvania

Identifying and Targeting Mechanisms of Resistance to Immunotherapy
Rizwan Haq, MD, PhD, Dana-Farber Cancer Institute

Reworking Negative Receptor Signals for Improved Anti-glioma T-Cell Therapy
Meenakshi G. Hegde, MD, Baylor College of Medicine

Potentiating Novel Engineered Cellular Therapies for Solid Tumors
Marcela V. Maus, MD, PhD, Massachusetts General Hospital

Delineating the Role of the Microbiome in Modulating Tumor and Host Immunity
Jennifer A. Wargo, MD, The University of Texas MD Anderson Cancer Center

Reprogramming Tumor Immunogenicity with STING-Activating Nanoparticles
John T. Wilson, PhD, Vanderbilt University
CLASS OF 2016

Targeting Cellular Plasticity in Individual Basal-Type Breast Cancer Cells
John G. Albeck, PhD, University of California, Davis

Uncovering How RAD51 Paralog Mutations Contribute to Cancer Predisposition
Kara A. Bernstein, PhD, University of Pittsburgh

Phospholipid Messengers as Drivers of Dendritic Cell Dysfunction in Cancer
Juan R. Cubillos-Ruiz, PhD, Weill Cornell Medicine

Metabolic Reprogramming Using Oncolytic Viruses to Improve Immunotherapy
Greg M. Delgoffe, PhD, University of Pittsburgh

"Weak Links" in Cancer Proteostasis Networks as New Therapeutic Targets
Martin Kampmann, PhD, University of California, San Francisco

Algorithmically Driven Quantitative Combination Cancer Therapy Engineering
Dan A. Landau, MD, PhD, Weill Cornell Medicine

Deubiquitinating Enzymes as Novel Anticancer Targets
Li Ma, PhD, The University of Texas MD Anderson Cancer Center

Imaging Cell-Level Heterogeneity in Solid Tumors for Personalized Treatment
Melissa C. Skala, PhD, Morgridge Institute for Research

Defining the Metabolic Dependencies of Tumors
Matthew Vander Heiden, MD, PhD, Massachusetts Institute of Technology

Defining the Mechanistic Connections Between Injury, Regeneration, and Cancer
Hao Zhu, MD, The University of Texas Southwestern Medical Center
CLASS OF 2011

Targeting MLL in Acute Myeloid Leukemia
Yali Dou, PhD, University of Michigan

Targeting Genetic and Metabolic Networks in T-ALL
Adolfo A. Ferrando, MD, PhD, Columbia University

Targeting Protein Quality Control for Cancer Therapy
Estela Jacinto, PhD, Rutgers University

Targeting PP2A and the Glutamine-Sensing Pathway as Cancer Treatment
Mei Kong, PhD, Beckman Research Institute, City of Hope

Chimeric RNAs Generated by Trans-splicing and Their Implications in Cancer
Hui Li, PhD, University of Virginia

Allan H. (Bud) and Sue Selig Stand Up To Cancer Melanoma Innovative Research Grant: Exome Sequencing of Melanomas With Acquired Resistance to BRAF Inhibitors
Roger S. Lo, MD, PhD, University of California, Los Angeles

Identification and Targeting of Novel Rearrangements in High-Risk ALL
Charles G. Mullighan, MD, St. Jude Children’s Research Hospital

A Systems Approach to Understanding Tumor-Specific Drug Response
Dana Pe’er, PhD, Columbia University

Targeting Sleeping Cancer Cells
Sridhar Ramaswamy, MD, Massachusetts General Hospital

Inhibiting Innate Resistance to Chemotherapy in Lung Cancer Stem Cells
Eric Alejandro Sweet-Cordero, MD, Stanford University

Developing New Therapeutic Strategies for Soft-Tissue Sarcoma
Amy J. Wagers, PhD, Joslin Diabetes Center

Framing Therapeutic Opportunities in Tumor-Activated Gametogenic Programs
Angelique W. Whitehurst, PhD, UT Southwestern Simmons Comprehensive Cancer Center

Coupled Genetic and Functional Dissection of Chronic Lymphocytic Leukemia
Catherine J. Wu, MD, Dana-Farber Cancer Institute
CLASS OF 2009

An Emerging Tumor Suppressor Pathway in Human Cancer
Fernando D. Camargo, PhD, Boston Children’s Hospital

Modeling Ewing Tumor Initiation in Human Neural Crest Stem Cells
Elizabeth R. Lawlor, MD, PhD, University of Michigan

Cancer Cell-Specific, Self-Delivering Prodrugs
Matthew Levy, PhD, Albert Einstein College of Medicine of Yeshiva University

Targeted Inhibition of BCL6 for Leukemia Stem Cell Eradication
Markus Müschen, MD, PhD, Children’s Hospital Los Angeles

Identifying Solid Tumor Kinase Fusions via Exon Capture and 454 Sequencing
William Pao, MD, PhD, Vanderbilt University

Therapeutically Targeting the Epigenome in Aggressive Pediatric Cancers
Charles M. Roberts, MD, PhD, Dana-Farber Cancer Institute

Endogenous Small Molecules That Regulate Signaling Pathways in Cancer Cells
Rajat Rohatgi, MD, PhD, Stanford University

Genetic Approaches for Next Generation of Breast Cancer Tailored Therapies
Jose M. Silva, PhD, Columbia University

Modulating Transcription Factor Abnormalities in Pediatric Cancer
Kimberly Stegmaier, MD, Dana-Farber Cancer Institute

Noninvasive Molecular Profiling of Cancer via Tumor-Derived Microparticles
Muneesh Tewari, MD, PhD, Fred Hutchinson Cancer Research Center

A Transformative Technology to Capture and Drug New Cancer Targets
Loren D. Walensky, MD, PhD, Dana-Farber Cancer Institute

Functional Oncogene Identification
David M. Weinstock, MD, Dana-Farber Cancer Institute

Probing EBV-LMP-1’s Transmembrane Activation Domain With Synthetic Peptide
Hang Hubert Yin, PhD, University of Colorado
THE PHILLIP A. SHARP INNOVATION IN COLLABORATION AWARDS
CLASS OF 2020

Genomic and Therapeutic Implications of Selective Bacterial and Fungal Colonization of Gastrointestinal Malignancies
Luis A. Diaz Jr., MD, and Florencia McAllister, MD

Utilizing Tumor Organoids to Facilitate the Development of Effective Strategies to Target Pancreatic Cancer with Engineered T Cells
Philip D. Greenberg, MD, Tyler E. Jacks, PhD, and William A. Freed-Pastor, MD, PhD

Harnessing NK Cells to Treat Pediatric Cancers
David G. Kirsch, MD, PhD, and Michal Sheffer, PhD

Can scRNAseq-Derived Gene Programs Predict Anti-PD-1 Response in High TMB CRC and NSCLC Patients?
Karin Pelka, PhD, and Matthew D. Hellmann, MD

Enhancing Ferroptosis to Block Ewing Sarcoma Metastatic Capacity
Poul H. B. Sorenson, MD, PhD, and Elizabeth Lawlor, MD, PhD

CLASS OF 2019

Resistance to PARP Inhibitor Plus Anti-PD1 Therapy Driven by ER Stress and Bioactive Lipids in Ovarian Cancer
Juan R. Cubillos-Ruiz, PhD, and Alan D. D’Andrea, MD

Uncovering Mutant TP53 Dependencies in Spontaneously Arising Triple-Negative Breast Cancer
Denada Dibra, PhD, and Peter P. Lee, MD

Noninvasive Monitoring of Tumor Phenotype by Interrogation of Plasma Cell Free RNA
Maximilian Diehn, MD, PhD, and Aaron N. Hata, MD, PhD

Precision Combinatorial Immunotherapeutic Targeting of Thymic Stromal Lymphopoietin Receptor (TSLPR) Signaling in Pediatric and Young Adult CRLF2-Rearranged ALL
Sarah K. Tasian, MD, and Kimberly Stegmaier, MD

Antigenicity of Mutant KRAS and Impact on Cancer Evolution
Robert H. Vonderheide, D Phil, MD, and Vinod P. Balachandran, MD

CLASS OF 2018

Defining Effective T-Cell Response in Viral and Nonviral Gynecologic Cancers
Claire F. Friedman, MD, and Marta J. Luksza, PhD

Cupid-Seq-High Throughput Transcriptomic Spatial Mapping of Immune-Tumor Interactions in the Microenvironment
Dan Landau, MD, PhD, and Raul Rabadan, PhD

Characterizing Immune Variability in Children Following Standard-of-Care Treatment to Enable Precision
Trevor J. Pugh, PhD, and David M. Barrett, MD, PhD

Studies of Colorectal Cancer Patient-Derived Organoids to Validate Candidate Biomarkers of Resistance to Natural Killer Cells
Michal Sheffer, PhD, and Hugo J. Snippert, PhD

Interrogating Impact of Epigenetic Modifiers on Durable Reprogramming of Exhausted CD8 T Cells in Patients With NSCLC Treated With PD-1 Blockade
E. John Wherry, PhD, and Matthew D. Hellmann, MD
CLASS OF 2017

Interrogation of Resistance Mechanisms to Checkpoint Inhibitors Using Functional Genomics
Siwen Hu-Lieskovan, MD, PhD, and René Bernards, PhD

Dissecting the Epigenetic Mechanisms of Repeat RNA Regulation in Cancer
David T. Ting, MD, and Shelley L. Berger, PhD

Probing the Metabolic Interactions Between Tumor and Stroma in Pancreatic Cancer
Matthew G. Vander Heiden, MD, PhD, and Melissa C. Skala, PhD

Aptamer-Based Detection and Binding of Peptide-MHC Complexes
Cassian Yee, MD, and Bruce A. Sullenger, PhD

CLASS OF 2016

Defining the Role of Epigenetics in Chimeric Antigen Receptor T-cell Therapy for CLL
Shelley L. Berger, PhD, Carl H. June, MD, and Junwei Shi, PhD

Towards Predictive Models of Immunotherapy Response
Benjamin D. Greenbaum, PhD and Jedd D. Wolchok, MD, PhD

Checkpoint Inhibition in Children With Ultra-Mutated Cancer Due to Biallelic Mismatch Repair Deficiency (bMMRD)
Crystal L. Mackall, MD, and Patrick M. Forde, MD

Fingerprinting the Systemic Microbiome in Plasma to Predict Immunotherapy Outcomes in Melanoma
Muhammed Murtaza, MBBS, PhD, and Antoni Ribas, MD, PhD

Functional Verification of DNA Repair Mutations in Prostate and Ovary Tumors
Eliezer M. Van Allen, MD, and Maria Jasin, PhD

CLASS OF 2015

Development of a High-Throughput Method to Screen Drugs With Organoids
Hans Clevers, MD, PhD, and David A. Tuveson, MD, PhD

Cross-talk Between Histone H3K4 Mono-Methylolation and Cancer Metabolism to Explore New Therapeutic Strategies
Yali Dou, PhD and Mei Kong, PhD

Targeting Epigenetic Plasticity and Drug Resistance in Pediatric Cancer
Adolfo Ferrando, MD, PhD, and Kimberly Stegmaier, MD

Identification and Analysis of Prostate Reactive TCRs for T-cell Mediated Adoptive Cellular Immunotherapy of Metastatic Prostate Cancer
Owen N. Witte, MD, and Padmanee Sharma, MD, PhD

CLASS OF 2014

The Intersection of Epigenetic and Immune Checkpoint Therapy
Stephen B. Baylin, MD, and James P. Allison, PhD

Determinants of Sensitivity and Resistance to MEK-Based Targeted Therapies in NRAS Mutant Melanomas
Roger S. Lo, MD, PhD, and Jeffrey A. Sosman, MD

Analysis of High-Dimension Single-Cell Data From Cancer Immunotherapy Clinical Trials
Dana Pe’er, PhD, and Padmanee Sharma, MD, PhD

Clinical Development of CFI-400945, a PLK4 Inhibitor, in Breast Cancer
Dennis J. Slamon, MD, PhD, and Tak W. Mak, PhD

cBioPortal for Stand Up To Cancer
David B. Solit, MD, and Nikolaus Schultz, PhD
ADDITIONAL AWARDS AND PRIZES
ADDITIONAL AWARDS AND PRIZES

ZISKIN PRIZE
The Ziskin Prize is named for Laura Ziskin, legendary Hollywood producer, who cofounded SU2C and lived with breast cancer for seven years before she died in 2011.

• The prize provides a one-year, $250,000 grant.
• The grant is shared by two scientists at different institutions.
• Funds are used to collaborate on high-risk, high reward breast cancer research.

Recipients:
2012 – Stephen B. Baylin, MD, and Feyruz V. Rassool, PhD
2014 – Taru E. Muranen, PhD, and Gordon B. Mills, MD, PhD
2015 – Matthew J. Ellis, PhD, and Charles Swanton, PhD
2018 – Jos Jonkers, PhD, and Helen Piwnica-Worms, PhD
2019 – Silvia C. Formenti, MD, and Heather L. McArthur, MD, MOH
2020 – Leisha A. Emens, MD, PhD, and Xiang Zhang, PhD
2022 – Jane E. Visvader, PhD, and Geoffrey J. Lindeman, MBBS (Hon.), PhD

THE JIM TOTH SR. BREAKTHROUGH LUNG CANCER RESEARCH AWARD
This award is named in honor of Jim Toth Sr., who passed away from lung cancer. It provides funding for highly innovative, clinically focused lung cancer research.

Two awards, covering the period 2014 – 2017
Leaders: Stephen B. Baylin, MD, and Peter A. Jones, PhD

PEGGY PRESCOTT EARLY CAREER SCIENTIST AWARD
The SU2C-Peggy Prescott Early Career Scientist Award in Colorectal Cancer Research supports a novel cancer research project with significant potential for advancing key questions in colorectal cancer research.

Recipient: 2019 – Karin Pelka, PhD
ADDITIONAL AWARDS AND PRIZES

GOLDEN ARROW EARLY CAREER SCIENTIST AWARD

The SU2C Golden Arrow Early Career Scientist Award supports a novel cancer research project that, through collaboration with a current SU2C project, has significant potential for advancing key questions in cancer research.

Recipient: 2019 – William Freed-Pastor, MD, PhD

SU2C SHARP TANK EARLY CAREER SCIENTIST AWARD

The SU2C Sharp Tank Early Career Scientist Award supports an early-career investigator with a novel cancer research proposal incorporating cutting-edge, high-risk ideas and offering the greatest potential impact for cancer patients.

Recipient: 2020 – Catherine Marinac, PhD

PHILLIP A. SHARP CHALLENGE AWARD

The Pancreatic Cancer Collective Phillip A. Sharp Challenge Award supports a novel cancer research project that explores synergistic and innovative collaborations exploring pancreatic cancer interception.

Recipients: 2021 – Alec Kimmelman, MD, PhD, and Benjamin Greenbaum, PhD

SU2C MAVERICK AWARD

The SU2C Maverick Award supports an early-career investigator with a novel cancer research proposal incorporating cutting-edge, high-risk ideas and offering the greatest potential impact for cancer patients.

Recipient: 2022 – Anirban Das, MD
EMPEROR SCIENCE AWARDS

From 2016 to 2018 the Emperor Science Award program encouraged high school students to explore careers in cancer research through a unique mentoring opportunity. This education initiative was inspired by the Ken Burns documentary Cancer: The Emperor of All Maladies and supported with grants from Genentech, Bristol-Myers Squibb, and Novartis. Three hundred students were selected in national competitions and received a $1,500 stipend, a laptop computer, and the opportunity to work alongside an esteemed scientist on a multi-week cancer research project.
REVIEWERS
SU2C’s groundbreaking research programs are made possible because of the dedicated efforts of dozens of scientific reviewers. We thank them for their commitment and hard work.

James L. Abbruzzese, MD  
Duke University

Julian Adams, PhD  
Gamida Cell

Christine Alewine, MD, PhD  
National Cancer Institute

Stephen M. Ansell, MD, PhD  
Mayo Clinic

Scott A. Armstrong, MD, PhD  
Dana-Farber Cancer Institute

Carlos L. Arteaga, MD  
UT Southwestern Medical Center

Gurinder Singh (Mickey) Atwal, PhD  
Cold Spring Harbor Laboratory

Dafna Bar-Sagi, PhD  
NYU Langone Health

Charles Baum, MD, PhD  
Mirati Therapeutics, Inc.

Stephen B. Baylin, MD  
Johns Hopkins University

David G. Beer, PhD  
University of Michigan

Stacey L. Berg, MD  
Texas Children’s Cancer Center

Shelley L. Berger, PhD  
University of Pennsylvania School of Medicine

Jordan D. Berlin, MD  
Vanderbilt-Ingram Cancer Center

Nina Bhardwaj, MD, PhD  
Icahn School of Medicine at Mount Sinai

Elizabeth H. Blackburn, PhD  
University of California, San Francisco

Krstan B. Blagoev, PhD  
National Science Foundation

Jeffrey A. Boyd, PhD  
Florida International University

Cynthia Brogdon, RN, PhD  
Bristol Myers Squibb

Howard S. Brown  
Patient Advocate

Steven J. Burakoff, MD  
Tisch Cancer Institute

Lauren A. Byers, MD, MS  
The University of Texas MD Anderson Cancer Center

Curtis Callan, Jr., PhD  
Princeton University

Lewis C. Cantley, PhD  
Weill Cornell Medicine

Lisa A. Carey, MD  
UNC Lineberger Comprehensive Cancer Center

John D. Carpten, PhD  
Keck School of Medicine of USC

Debasish Chakrabarti, MD, PhD  
Jazz Pharmaceuticals

Andrew Chan, MD, MPH  
Massachusetts General Hospital

Chang S. Chan, PhD  
Rutgers Cancer Institute of New Jersey

Suresh T. Chari, MD  
Mayo Clinic College of Medicine

James Christensen, PhD  
Mirati Therapeutics, Inc.

Christine H. Chung, MD  
Moffitt Cancer Center

Susan L. Cohn, MD  
University of Chicago

Neal Copeland, PhD  
The University of Texas MD Anderson Cancer Center

Sara A. Courtneidge, PhD  
Oregon Health and Science University

Marcia Cruz-Correa, MD, PhD  
University of Puerto Rico Comprehensive Cancer Center

Suzanne Dahlberg, PhD  
Boston Children’s Hospital

Nancy E. Davidson, MD  
Fred Hutchinson Cancer Research Center

Yves DeClerck, MD  
USC Norris Comprehensive Cancer Center

Maximilian Diehn, MD, PhD  
Stanford University

Jessica Donington, MD  
University of Chicago
SU2C’s groundbreaking research programs are made possible because of the dedicated efforts of dozens of scientific reviewers. We thank them for their commitment and hard work.

Bettina Drake, PhD, MPH  
Washington University  
School of Medicine in St. Louis

Steven M. Dubinett, MD  
University of California, Los Angeles

Raymond N. DuBois, MD, PhD  
Medical University of South Carolina

Gail Eckhardt, MD  
University of Texas at Austin

Matthew J. Ellis, MD, PhD  
Baylor College of Medicine

Tariq Enver, PhD  
University College  
London Cancer Institute

Meira Epplein, PhD  
Duke University Medical Center

Awny Farajallah, MD  
Bristol Myers Squibb

David Feltquate, MD, PhD  
Bristol Myers Squibb

Leslie G. Ford, MD,  
National Cancer Institute

Margaret Foti, PhD, MC (hc)  
American Association for Cancer Research

Justin F. Gainor, MD  
Massachusetts General Hospital

Shridar Ganesan, MD, PhD  
Rutgers Cancer Institute of New Jersey

Judy E. Garber, MD  
Dana-Farber Cancer Institute

Chris Garcia, PhD  
Stanford University

Levi Garraway, MD, PhD  
Genentech, Inc.

Richard B. Gaynor, MD  
BioNTech US

Elodie Ghedin, PhD  
National Institute of Allergy and Infectious Diseases

John Glaspy, MD, MPH  
University of California, Los Angeles

Nancy F. Goodman, JD  
Kids v Cancer

Jennifer Grandis, MD  
University of California, San Francisco

Benjamin D. Greenbaum, PhD  
Memorial Sloan Kettering Cancer Center

Philip D. Greenberg, MD  
Fred Hutchinson Cancer Research Center

James L. Gulley, MD, PhD  
National Cancer Institute

William C. Hahn, MD, PhD  
Dana-Farber Cancer Institute

William N. Hait, MD, PhD  
Johnson & Johnson

Raj Hanesvakul, MD, PhD  
Jazz Pharmaceuticals

Eric Haura, MD  
Moffitt Cancer Center

Ernest T. Hawk, MD  
The University of Texas  
MD Anderson Cancer Center

Adrian Hayday, PhD  
Francis Crick Institute

James R. Heath, PhD  
Institute for Systems Biology

Elizabeth M. Hecht, MD  
Weill Cornell Medicine

Matthew Hellman, MD  
AstraZeneca

Lee J. Helman, MD  
Keck School of Medicine, USC

Kathy J. Helzlsouer, MD, MPH  
National Cancer Institute

Candace Henley  
Blue Hat Foundation

Helen E. Heslop, MD  
Baylor College of Medicine

Eric C. Holland, MD, PhD  
Fred Hutchinson Cancer Research Center

Michael A. Hollingsworth, PhD  
University of Nebraska  
Medical Center

Nancy Hopkins, PhD  
Massachusetts Institute of Technology

A. McGarry Houghton, MD  
Fred Hutchinson Cancer Research Center
SU2C’s groundbreaking research programs are made possible because of the dedicated efforts of dozens of scientific reviewers. We thank them for their commitment and hard work.

Shawna Hudson, PhD
Rutgers Robert Wood Johnson Medical School

Patrick Hwu, MD
Moffitt Cancer Center

Elizabeth M. Jaffee, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Nancy Jenkins, PhD
The University of Texas MD Anderson Cancer Center

Michael B. Kastan, MD, PhD
Duke Cancer Institute

Kimberly A. Kelly, PhD
University of Virginia

Mark Kieran, MD, PhD
Day One Biopharmaceuticals

Edward Kim, MD, MBA
City of Hope

Ann S. LaCasce, MD
Dana-Farber Cancer Institute

Suzanne Lentzsch, MD, PhD
Columbia University

Caryn Lerman, PhD
USC Norris Comprehensive Cancer Center

Caleb Levell, MA
American Cancer Society

Arnold J. Levine, PhD
Institute for Advanced Study

Scott M. Lippman, MD
University of San Diego Moores Cancer Center

Jeffrey M. Lipton, MD, PhD
LI School of Medicine at Hofstra North Shore

Andrew M. Lowy, MD
University of California, San Diego

Guillermina Lozano, PhD
The University of Texas MD Anderson Cancer Center

Rishi Manchanda, MD, MPH
HealthBeings

Richard M. Marais, PhD
Cancer Research UK Manchester Institute

Ingrid A. Mayer, MD, MSCI
AstraZeneca

Ira Mellman, PhD
Genentech, Inc.

Ari M. Melnick, MD
Weill Cornell Medicine

Gordon B. Mills, MD, PhD
Oregon Health & Science University

Cherie-Ann Nathan, MD
Ochsner LSU Health Shreveport

William G. Nelson, MD, PhD
Johns Hopkins University

Andre Nussenzweig, PhD
National Cancer Institute

Olufunmilayo Olopade, MD
University of Chicago

Eileen M. O’Reilly, MD
Memorial Sloan Kettering Cancer Center

William Pao, MD, PhD
Roche

Premal Patel, MD, PhD
eFFECTOR Therapeutics

Dana Pe’er, PhD
Memorial Sloan Kettering Cancer Center

Edith A. Perez, MD
Mayo Clinic Cancer Center Jacksonville

Cecil Pickett, PhD
Boston Children’s Hospital

Mark Powers, PhD
Thermo Fisher Scientific

Carol L. Prives, PhD
Columbia University

Scott K. Pruitt, MD
Merck & Company, Inc.

Ellen Puré, PhD
University of Pennsylvania

Raul Rabada, PhD
Columbia University

Timothy Rebbeck, PhD
Dana-Farber Cancer Institute

Karen Reckamp, MD
City of Hope
SU2C’s groundbreaking research programs are made possible because of the dedicated efforts of dozens of scientific reviewers. We thank them for their commitment and hard work.

James W. Rocco, MD, PhD
Ohio State University
Comprehensive Cancer Center

David P. Ryan, MD
Massachusetts General Hospital

Lynn M. Schuchter, MD
University of Pennsylvania

Padmanee Sharma, MD, PhD
The University of Texas
MD Anderson Cancer Center

Arlene H. Sharpe, MD, PhD
Harvard Medical School

Reuben Shaw, PhD
Salk Institute for Biological Studies

Dennis Slamon, MD, PhD
University of California, Los Angeles

Jodi Smith, PhD
Mirati Therapeutics, Inc.

Poul Sorensen, MD, PhD
BC Cancer Research Institute

Kimberly Stegmaier, MD
Dana-Farber Cancer Institute

Margaret A. Tempero, MD
University of California, San Francisco

Kim Thiboldeaux
Cancer Support Community

Jeffrey M. Trent, PhD
Translational Genomics Research Institute

David A. Tuveson, MD, PhD
Cold Spring Harbor Laboratory
Cancer Center

Kees Verhoef, PhD
Erasmus Medical Center

Selwyn M. Vickers, MD
University of Alabama
Birmingham

Marc Vooijs, PhD
Maastricht University

H. Josef Vormoor, MD
Princess Máxima Center

Tony Wagner, PhD
Jazz Pharmaceuticals

Scott A. Waldman, MD, PhD
Thomas Jefferson University

Ru-Amir Walker, MD
Genentech, Inc.

Katherine E. Warren, MD
Dana-Farber Cancer Institute

Lesley Watson, PhD
NORC at the University of Chicago

Jelle Wesseling, MD, PhD
Netherlands Cancer Institute

Raymond M. Williams, JD
DLA Piper

Karen Winkfield, MD, PhD
Meharry-Vanderbilt Alliance

Jordan M. Winter, MD
University Hospitals
Cleveland Medical Center

Jedd Wolchok, MD, PhD
Memorial Sloan Kettering Cancer Center

Brian M. Wolpin, MD, MPH
Dana-Farber Cancer Institute

Susan Yang, PharmD
Mirati Therapeutics, Inc.

Nancy Yao, MD
Genentech, Inc.

Jen Jen Yeh, MD
UNC Lineberger Comprehensive Cancer Center

Benjamin A. Youngblood, PhD
St. Jude Children’s Research Hospital

Kenneth H. Yu, MD
Memorial Sloan Kettering Cancer Center

Jianda Yuan, MD, PhD
Merck & Company, Inc.
INDEX BY TYPES OF CANCER
INDEX BY TYPES OF CANCER

Anal Cancer 89
Brain Tumors 31, 38, 50, 71, 73, 120, 137
Cervical Cancer 89
Colorectal Cancer 20, 29, 32, 33, 43, 44, 45, 47, 48, 61, 77, 84, 90, 94, 95, 21
Endometrial Cancer 65, 106
Gastric Cancer 74
Gynecologic Cancer 42, 65, 107, 142
Head and Neck Cancer 70, 89
Hypermutant Cancers 119, 134
Leukemia 31, 44, 45, 49, 50, 51, 62, 137, 139, 140, 142, 143
Liver Cancer 22, 45, 137
Lung Cancer 27, 28, 33, 39, 40, 44, 45, 53, 55, 61, 62, 63, 69, 77, 86, 93, 96, 110, 126, 132, 133, 139, 142
Lymphoma 25, 31, 50, 51, 88
Melanoma 33, 53, 59, 122, 129, 139, 143
Myeloma 26, 127
Ovarian Cancer 41, 42, 47, 65, 79, 93, 107, 135, 142, 143
Pancreatic Cancer 23, 29, 33, 36, 37, 45, 46, 47, 48, 60, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 104, 111, 130, 131, 142, 143
Pediatric Cancer 30, 31, 38, 49, 50, 51, 71, 72, 73, 119, 120, 121, 134, 137, 140, 142, 143
Prostate Cancer 22, 53, 54, 55, 56, 57, 58, 63, 117, 143
Sarcoma 31, 49, 72, 128, 139, 140, 142
Urothelial Cancer 53, 125
INDEX BY PERSON
INDEX BY PERSON

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abi-Khattar, C.</td>
<td>118</td>
</tr>
<tr>
<td>Abramson, V.</td>
<td>118</td>
</tr>
<tr>
<td>Acevedo, R. V.</td>
<td>69, 127</td>
</tr>
<tr>
<td>Adalsteinsson, V. A.</td>
<td>127</td>
</tr>
<tr>
<td>Adams, James</td>
<td>73</td>
</tr>
<tr>
<td>Adams, Julian</td>
<td>13</td>
</tr>
<tr>
<td>Addario, B.</td>
<td>116</td>
</tr>
<tr>
<td>Aguirre, A.</td>
<td>78</td>
</tr>
<tr>
<td>Ahlstrom, J. M.</td>
<td>26, 127</td>
</tr>
<tr>
<td>Ahmed, N. M.</td>
<td>30</td>
</tr>
<tr>
<td>Albeck, J. G.</td>
<td>135, 143</td>
</tr>
<tr>
<td>Albert, R. Z.</td>
<td>109</td>
</tr>
<tr>
<td>Alexandrov, L.</td>
<td>106</td>
</tr>
<tr>
<td>Algül, H.</td>
<td>77</td>
</tr>
<tr>
<td>Allister, A. T.</td>
<td>130</td>
</tr>
<tr>
<td>Allison, J. P.</td>
<td>52, 143</td>
</tr>
<tr>
<td>Altschuler, S. J.</td>
<td>110</td>
</tr>
<tr>
<td>Anderson, J.</td>
<td>71</td>
</tr>
<tr>
<td>Andrews, E.</td>
<td>76</td>
</tr>
<tr>
<td>Antonia, S. J.</td>
<td>126</td>
</tr>
<tr>
<td>Anyim, M.</td>
<td>71</td>
</tr>
<tr>
<td>Aparici, C. M.</td>
<td>27</td>
</tr>
<tr>
<td>Aparicio, S.</td>
<td>34</td>
</tr>
<tr>
<td>Aquirre, A.</td>
<td>23</td>
</tr>
<tr>
<td>Arrowsmith, C. H.</td>
<td>38</td>
</tr>
<tr>
<td>Arteaga, C. L.</td>
<td>14, 64</td>
</tr>
<tr>
<td>Ashworth, A.</td>
<td>66</td>
</tr>
<tr>
<td>Atwal, G. S.</td>
<td>108</td>
</tr>
<tr>
<td>Aune, G.</td>
<td>72</td>
</tr>
<tr>
<td>Ayala, G.</td>
<td>25</td>
</tr>
<tr>
<td>Azad, N. S.</td>
<td>32</td>
</tr>
<tr>
<td>Aznar, M. A.</td>
<td>87</td>
</tr>
<tr>
<td>Baber, B. A.</td>
<td>49</td>
</tr>
<tr>
<td>Bachovchin, D. A.</td>
<td>137</td>
</tr>
<tr>
<td>Bader, G. D.</td>
<td>38</td>
</tr>
<tr>
<td>Baker, M.</td>
<td>20</td>
</tr>
<tr>
<td>Balachandran, V.</td>
<td>104</td>
</tr>
<tr>
<td>Balachandran, V. P.</td>
<td>142</td>
</tr>
<tr>
<td>Baldi, J.</td>
<td>113</td>
</tr>
<tr>
<td>Baldi, J. L.</td>
<td>30, 49</td>
</tr>
<tr>
<td>Baliko, J. M.</td>
<td>123</td>
</tr>
<tr>
<td>Ballman, K. V.</td>
<td>128</td>
</tr>
<tr>
<td>Barne, T. L.</td>
<td>59</td>
</tr>
<tr>
<td>Bangs, R.</td>
<td>125</td>
</tr>
<tr>
<td>Barazzuol, L.</td>
<td>73</td>
</tr>
<tr>
<td>Barlow, J.</td>
<td>66</td>
</tr>
<tr>
<td>Barrett, D. M.</td>
<td>137, 142</td>
</tr>
<tr>
<td>Barrett, M. T.</td>
<td>130</td>
</tr>
<tr>
<td>Barzilay, R.</td>
<td>76, 103</td>
</tr>
<tr>
<td>Baselga, J.</td>
<td>64</td>
</tr>
<tr>
<td>Basso, C. R.</td>
<td>113</td>
</tr>
<tr>
<td>Baylin, S. B.</td>
<td>44, 61, 125, 132, 143, 145</td>
</tr>
<tr>
<td>Bear, A.</td>
<td>84</td>
</tr>
<tr>
<td>Beatty, G. L.</td>
<td>137</td>
</tr>
<tr>
<td>Bebenek, D.</td>
<td>119, 134</td>
</tr>
<tr>
<td>Becerra, C. H.</td>
<td>130</td>
</tr>
<tr>
<td>Beer, T. M.</td>
<td>54</td>
</tr>
<tr>
<td>Behrens, R. E.</td>
<td>52</td>
</tr>
<tr>
<td>Belinsky, S. A.</td>
<td>61</td>
</tr>
<tr>
<td>Bellone, S.</td>
<td>106</td>
</tr>
<tr>
<td>Berenger, S.</td>
<td>36</td>
</tr>
<tr>
<td>Berger, P.</td>
<td>44, 125, 132</td>
</tr>
<tr>
<td>Berger, S. L.</td>
<td>87, 107, 143</td>
</tr>
<tr>
<td>Berger, T.</td>
<td>34</td>
</tr>
<tr>
<td>Bernards, R.</td>
<td>77, 90, 143</td>
</tr>
<tr>
<td>Bernatchez, C.</td>
<td>80</td>
</tr>
<tr>
<td>Bernstein, A.</td>
<td>13, 14</td>
</tr>
<tr>
<td>Bernstein, K. A.</td>
<td>138</td>
</tr>
<tr>
<td>Bhatia, S. N.</td>
<td>63</td>
</tr>
<tr>
<td>Bhatt, A.</td>
<td>96</td>
</tr>
<tr>
<td>Bianchi, V.</td>
<td>119</td>
</tr>
<tr>
<td>Bickell, N. A.</td>
<td>22</td>
</tr>
<tr>
<td>Bilchik, A.</td>
<td>20</td>
</tr>
<tr>
<td>Bishop, A.</td>
<td>72</td>
</tr>
<tr>
<td>Blackburn, E. H.</td>
<td>13</td>
</tr>
<tr>
<td>Black, D.</td>
<td>52</td>
</tr>
<tr>
<td>Bleakley, M. E.</td>
<td>137</td>
</tr>
<tr>
<td>Block, M. S.</td>
<td>122</td>
</tr>
<tr>
<td>Bold, R. J.</td>
<td>83</td>
</tr>
<tr>
<td>Booher, B.</td>
<td>46</td>
</tr>
<tr>
<td>Borazanci, E. H.</td>
<td>130</td>
</tr>
<tr>
<td>Borghaei, H.</td>
<td>132</td>
</tr>
<tr>
<td>Borrello, L. M.</td>
<td>26</td>
</tr>
<tr>
<td>Bos, J. L.</td>
<td>48</td>
</tr>
<tr>
<td>Bouffet, E.</td>
<td>134</td>
</tr>
<tr>
<td>Bove, N.</td>
<td>22</td>
</tr>
<tr>
<td>Boyce, C. A.</td>
<td>16, 26</td>
</tr>
<tr>
<td>Brahmcr, J. R.</td>
<td>27</td>
</tr>
<tr>
<td>Breininger, A.</td>
<td>70</td>
</tr>
<tr>
<td>Brigna, B. E.</td>
<td>128</td>
</tr>
<tr>
<td>Brodney, S.</td>
<td>20</td>
</tr>
<tr>
<td>Brown, E.</td>
<td>32</td>
</tr>
<tr>
<td>Brown, W.</td>
<td>57</td>
</tr>
<tr>
<td>Brugge, J. S.</td>
<td>66</td>
</tr>
<tr>
<td>Brunak, S.</td>
<td>76</td>
</tr>
<tr>
<td>Buit, T. S.</td>
<td>125</td>
</tr>
<tr>
<td>Bulbeck, H.</td>
<td>73</td>
</tr>
<tr>
<td>Burger, R.</td>
<td>107</td>
</tr>
<tr>
<td>Burgos, R.</td>
<td>44, 125, 132</td>
</tr>
<tr>
<td>Burke, K.</td>
<td>22</td>
</tr>
<tr>
<td>Burkhardt, R. A.</td>
<td>85</td>
</tr>
<tr>
<td>Burtness, B.</td>
<td>70</td>
</tr>
<tr>
<td>Bustoros, M. W.</td>
<td>127</td>
</tr>
</tbody>
</table>

INDEX BY PERSON

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cabardo, R.</td>
<td>20</td>
</tr>
<tr>
<td>Calderone, K. M.</td>
<td>132</td>
</tr>
<tr>
<td>Callan, C. G.</td>
<td>111</td>
</tr>
<tr>
<td>Camara, P. G.</td>
<td>102</td>
</tr>
<tr>
<td>Camargo, F. D.</td>
<td>140</td>
</tr>
<tr>
<td>Cantarella, P.</td>
<td>64</td>
</tr>
<tr>
<td>Cantley, L. C.</td>
<td>32, 64</td>
</tr>
<tr>
<td>Capelletti, M.</td>
<td>127</td>
</tr>
<tr>
<td>Cargen, L.</td>
<td>123</td>
</tr>
<tr>
<td>Carlowicz, C.</td>
<td>113</td>
</tr>
<tr>
<td>Carpenter, E.</td>
<td>107</td>
</tr>
<tr>
<td>Carpten, J. D.</td>
<td>13, 16</td>
</tr>
<tr>
<td>Carreno, B. M.</td>
<td>84</td>
</tr>
<tr>
<td>Chan, A. T.</td>
<td>16, 74</td>
</tr>
<tr>
<td>Chan, C. S.</td>
<td>110</td>
</tr>
<tr>
<td>Chan, E. P.</td>
<td>86</td>
</tr>
<tr>
<td>Chang, J. C.</td>
<td>14</td>
</tr>
<tr>
<td>Chauhan, C.</td>
<td>122</td>
</tr>
<tr>
<td>Chen, J.</td>
<td>122</td>
</tr>
<tr>
<td>Chen, J. M.</td>
<td>129</td>
</tr>
<tr>
<td>Chen, Y.</td>
<td>117</td>
</tr>
<tr>
<td>Cherisol, M.</td>
<td>26</td>
</tr>
<tr>
<td>Chesler, L.</td>
<td>71</td>
</tr>
<tr>
<td>Chingos, D. T.</td>
<td>61</td>
</tr>
<tr>
<td>Chinnaian, A. M.</td>
<td>57, 66</td>
</tr>
<tr>
<td>Chung, V.</td>
<td>130</td>
</tr>
<tr>
<td>Clark, J.</td>
<td>36, 130</td>
</tr>
<tr>
<td>Cleary, J. M.</td>
<td>78</td>
</tr>
<tr>
<td>Clevers, H.</td>
<td>48, 94, 143</td>
</tr>
<tr>
<td>Colchie, J.</td>
<td>26</td>
</tr>
<tr>
<td>Coley, P. D.</td>
<td>81</td>
</tr>
<tr>
<td>Collisson, E. A.</td>
<td>81</td>
</tr>
<tr>
<td>Compton, B. D.</td>
<td>113</td>
</tr>
<tr>
<td>Cook, C.</td>
<td>24</td>
</tr>
<tr>
<td>Cope, A.</td>
<td>71</td>
</tr>
<tr>
<td>Corcoran, R. B.</td>
<td>32, 116</td>
</tr>
<tr>
<td>Costello, Rev. Z.</td>
<td>22</td>
</tr>
<tr>
<td>Cotter, K.</td>
<td>30, 49</td>
</tr>
<tr>
<td>Coupé, V.</td>
<td>43</td>
</tr>
<tr>
<td>Coutinho, F. J.</td>
<td>38</td>
</tr>
<tr>
<td>Crase, J.</td>
<td>41, 135</td>
</tr>
<tr>
<td>Creelan, B. C.</td>
<td>126</td>
</tr>
<tr>
<td>Cristea, I.</td>
<td>92</td>
</tr>
<tr>
<td>Cubillos-Ruiz, J. R.</td>
<td>138, 142</td>
</tr>
<tr>
<td>Carlone, A. D.</td>
<td>15, 41, 78, 135, 142</td>
</tr>
<tr>
<td>Dang, C.</td>
<td>60</td>
</tr>
<tr>
<td>Das, A.</td>
<td>146</td>
</tr>
<tr>
<td>Davidson, N. E.</td>
<td>61</td>
</tr>
<tr>
<td>Davidson, S.</td>
<td>92</td>
</tr>
</tbody>
</table>
INDEX BY PERSON

D (Cont’d)
Davis, A.  116
Davis, A. Q.  32
Davis, M. M.  101
de Bono, J. S.  57
Dekker, E.  43
Delgoffe, G. M.  138
DeMeo, M.  118
Demetri, G. D.  128
DeMichele, A. M.  118
den Brok, W.  34
Deng, C.  88
DeRudder, K.  117
Desai, S. J.  83
DeSantes, K. B.  30
Desserich, K.  120
de Wit, M.  43
Diaz, J.  74
Diaz Jr., L. A.  32, 142
Dibra, D.  142
Diehn, M.  86, 142
Diller, L. R.  15
Dimitrov, D.  30
Dirks, P. B.  38, 121
Dodd, A.  23
Domingo-Musibay, E.  122
Donovan, L.  71
Doorn, A.  77
Dotti, Gianpietro  25
Douglass, R.  63
Doumani, R.  52, 54
Dou, Y.  139, 143
Downes, M. R.  130
Draft, C. M.  86
Dranoff, G. E.  52
Drebin, J. A.  60, 111
drissi, R.  120
Dronca, R. S.  122
Dubinett, S. M.  27
Dubois, R. N.  13
DuBois, S.  121
Duran, T.  20
Durigon, W. M.  38

E
Edwards, M.  134
Elgart, K. S.  22
El-Khoueiry, A. B.  44
Ellis, M. J.  145
Emens, L. A.  145
Eth, R. A.  85
Evans, G. I.  36
Evans, C. P.  54
Evans, R. M.  36, 130
Evers, P.  48

F
Falchi, L.  88
Fan, R.  102
Farrington, T. A.  57
Farwell, M. D.  137
Fax, R.  64
Feinstein, A.  41
Ferrando, A.  139, 143
Ferris, A. E.  39
Fischbach, M.  96, 100
Fisher, D. S.  110
Fisher, M. J.  134
Fleming, G. F.  41
Fleshman, J. M.  60
Flory, B.  44, 125, 132
Follie, T. J.  122
Forde, P. M.  143
Ford, M. E.  69
Forebough, K.  30
Formenti, S. C.  145
Foster, C. C.  83
Fouladi, M.  120
Fraenkel, E.  103
Frank, E. S.  64, 118
Freed-Pastor, W.  142, 146
Friedman, C.  107, 142
Friedman, S.  41, 135
Fry, T. J.  30
Fuchs, J. R.  32
Furman, D.  101

G
Gainor, J. F.  39
Gallinger, S.  23
Gandara, D. R.  39
Geness, K.  98, 100
Garber, J. E.  13
Garraway, L. A.  57
Gavin, K. A.  41, 135
Gaynor, R. B.  13
Gelman, K. A.  34
Gentile, L.  24
Geoghegan, C.  66
George, M.  32, 116
Getz, G. A.  26, 39
Ghobrial, I. M.  26, 127
Giles, K.  57
Gleave, M. E.  54
Glimcher, L. H.  13
Goddard, J.  73
Goggins, M. G.  29
Golub, T.  105
Good, C. R.  87
Goodman, N. F.  13
Gore, L.  30
Gorman, M.  59
Gray, J. W.  66
Greenbaum, B.  104, 111, 143, 146
Greenberg, P. D.  46, 52, 142
Gregory, W. G.  57
Grilley, B. J.  25, 30
Grohar, P.  113
Grompe, M.  70
Grønbæk, K.  44
Grossmann, K. F.  129
Grupp, S.  30
Guild, S.  129
Guild, V.  52
Gulley, J. L.  13
Gutkind, J. S.  70

H
Haas, J.  20
Haas, K.  119
Haber, D. A.  63
Haddad, R. I.  89
Hahn, N. M.  125
Hall, W. N.  13
Halene, S.  102
Hall, D. M.  59
Halmos, B.  115
Han, H.  130
Hannon, G. J.  66
Haq, R.  137
Hargrave, D.  71
Hargraves, T.  69
Hata, A.  110, 142
Hauru, E. B.  126
Haussler, D.  66
Hawley, J. E.  117
Haynes, R. M.  69
Heath, J. R.  52
Hegde, M. G.  137
Heist, R.  116
Hellmann, M. D.  142
Helman, L. J.  13, 15
Henderson, L.  69
Henick, B.  115
Herbst, R. S.  39
Herman, J. G.  43
Herrera, R.  25
Heslop, H. E.  25
Heymach, J. V.  39, 63
Hieken, T. J.  122
Him, K.  72
Hirsch, F.  114
Hirschfield-Bartek, J.  64
Hodi, F. S.  52
<table>
<thead>
<tr>
<th>INDEX BY PERSON</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>H (Cont’d)</strong></td>
</tr>
<tr>
<td>Hollman, T. 107</td>
</tr>
<tr>
<td>Holstead, J. 119</td>
</tr>
<tr>
<td>Honda, K. 94</td>
</tr>
<tr>
<td>Hong, D. 116</td>
</tr>
<tr>
<td>Hong, W. K. 13</td>
</tr>
<tr>
<td>Hopkins, B. 114</td>
</tr>
<tr>
<td>Horn, M. 27, 43</td>
</tr>
<tr>
<td>Horton, L. J. 123</td>
</tr>
<tr>
<td>Huang, A. 120</td>
</tr>
<tr>
<td>Hubbard, K. 22</td>
</tr>
<tr>
<td>Hudson, S. 16</td>
</tr>
<tr>
<td>Hughes-Halbert, C. 16</td>
</tr>
<tr>
<td>Hu-Lieskovan, S. 129, 143</td>
</tr>
<tr>
<td>Hwu, P. 80</td>
</tr>
<tr>
<td><strong>I</strong></td>
</tr>
<tr>
<td>Ideker, T. 90</td>
</tr>
<tr>
<td>Irvine, D. J. 108</td>
</tr>
<tr>
<td>Issa, J. P. J. 44, 61, 125</td>
</tr>
<tr>
<td>Iwasaki, A. 106</td>
</tr>
<tr>
<td><strong>J</strong></td>
</tr>
<tr>
<td>Jabado, N. 38, 120</td>
</tr>
<tr>
<td>Jacinto, E. 139</td>
</tr>
<tr>
<td>Jacks, T. 29, 98, 142</td>
</tr>
<tr>
<td>Jaffee, E. M. 23, 46, 84</td>
</tr>
<tr>
<td>Jänne, P. A. 39, 116</td>
</tr>
<tr>
<td>Jänzen, J. 48</td>
</tr>
<tr>
<td>Jasin, M. 41, 143</td>
</tr>
<tr>
<td>Jeffries, C. 20</td>
</tr>
<tr>
<td>Jensen, M. C. 49</td>
</tr>
<tr>
<td>Johnson, B. E. 63</td>
</tr>
<tr>
<td>Johnson, J. A. 26</td>
</tr>
<tr>
<td>Jones, P. A. 44, 61, 125, 132, 145</td>
</tr>
<tr>
<td>Jonker, M. 48</td>
</tr>
<tr>
<td>Jonkers, J. 145</td>
</tr>
<tr>
<td>Jordan, C. V. 66</td>
</tr>
<tr>
<td>June, C. H. 87, 102, 143</td>
</tr>
<tr>
<td><strong>K</strong></td>
</tr>
<tr>
<td>Kaelin, W. G. 14</td>
</tr>
<tr>
<td>Kaittan, E. 70</td>
</tr>
<tr>
<td>Kamen, B. A. 60</td>
</tr>
<tr>
<td>Kampmann, M. 138</td>
</tr>
<tr>
<td>Kantoff, P. W. 57</td>
</tr>
<tr>
<td>Kaplan, K. 60</td>
</tr>
<tr>
<td>Kaplan, R. N. 30</td>
</tr>
<tr>
<td>Kapoor, P. 26</td>
</tr>
<tr>
<td>Karl, L. E. 113</td>
</tr>
<tr>
<td>Kasi, A. 130</td>
</tr>
<tr>
<td>Kastan, M. B. 14</td>
</tr>
<tr>
<td>Katz, R. M. 60</td>
</tr>
<tr>
<td>Kaufmann, S. H. 41</td>
</tr>
<tr>
<td>Kaye, F. J. 126</td>
</tr>
<tr>
<td>Kelly, L. 83</td>
</tr>
<tr>
<td>Kenner, B. J. 29</td>
</tr>
<tr>
<td>Kern, A. H. 54</td>
</tr>
<tr>
<td>Keffert, J. 57</td>
</tr>
<tr>
<td>Kimmelman, A. 85, 146</td>
</tr>
<tr>
<td>King, D. 23</td>
</tr>
<tr>
<td>Kinsey, C. G. 81</td>
</tr>
<tr>
<td>Kirsch, D. G. 121, 128, 142</td>
</tr>
<tr>
<td>Kitzenberg, E. 26</td>
</tr>
<tr>
<td>Klein, S. 57</td>
</tr>
<tr>
<td>Knox, J. 23</td>
</tr>
<tr>
<td>Kong, M. 139, 143</td>
</tr>
<tr>
<td>Konstantinopoulos, P. A. 135</td>
</tr>
<tr>
<td>Koome, J. M. 126</td>
</tr>
<tr>
<td>Koopman, M. 43</td>
</tr>
<tr>
<td>Kopetz, S. 116</td>
</tr>
<tr>
<td>Koren, T. 75</td>
</tr>
<tr>
<td>Korn, R. L. 130</td>
</tr>
<tr>
<td>Kozlowski, E. 128</td>
</tr>
<tr>
<td>Kraft, P. 76</td>
</tr>
<tr>
<td>Krause, P. 70</td>
</tr>
<tr>
<td>Krishnan, P. 119</td>
</tr>
<tr>
<td>Kris, M. G. 63</td>
</tr>
<tr>
<td>Kritzik, M. 82</td>
</tr>
<tr>
<td>Kroes, J. 43</td>
</tr>
<tr>
<td>Kuipers, E. J. 43</td>
</tr>
<tr>
<td>Kuo, C. 96, 100</td>
</tr>
<tr>
<td>Kursar, T. 81</td>
</tr>
<tr>
<td>LaBaer, J. 59</td>
</tr>
<tr>
<td>Labbe, K. 115</td>
</tr>
<tr>
<td>Lacey, S. F. 87</td>
</tr>
<tr>
<td>Laheru, D. 23, 85</td>
</tr>
<tr>
<td>Lamendola-Essel, M. F. 32</td>
</tr>
<tr>
<td>Landau, D. 138, 142</td>
</tr>
<tr>
<td>Lasater, K. 81</td>
</tr>
<tr>
<td>Lawellin, S. 120</td>
</tr>
<tr>
<td>Lawlor, E. 121, 140, 142</td>
</tr>
<tr>
<td>Lee, J. 74</td>
</tr>
<tr>
<td>Lee, P. 64</td>
</tr>
<tr>
<td>Lee, P. P. 108, 142</td>
</tr>
<tr>
<td>Lentai, A. G. 109</td>
</tr>
<tr>
<td>Levine, A. J. 13, 15</td>
</tr>
<tr>
<td>Levine, H. 108</td>
</tr>
<tr>
<td>Levine, R. 110</td>
</tr>
<tr>
<td>Levy, M. 140</td>
</tr>
<tr>
<td>Liang, W. 130</td>
</tr>
<tr>
<td>Li, H. 139</td>
</tr>
<tr>
<td>Lindberg, G. 30</td>
</tr>
<tr>
<td>Lindstrom, J. 89</td>
</tr>
<tr>
<td>Lippman, S. M. 29</td>
</tr>
<tr>
<td>Liston, I. S. 57</td>
</tr>
<tr>
<td>Listwin, D. 64</td>
</tr>
<tr>
<td>Littman, D. 98</td>
</tr>
<tr>
<td>Lo, R. S. 139, 143</td>
</tr>
<tr>
<td>LoRusso, P. M. 59</td>
</tr>
<tr>
<td>Lowy, A. M. 82, 130</td>
</tr>
<tr>
<td>Lozano, G. 14, 16</td>
</tr>
<tr>
<td>Lucas, C. L. 59</td>
</tr>
<tr>
<td>Lu, K. H. 41</td>
</tr>
<tr>
<td>Lukszza, M. 104, 142</td>
</tr>
<tr>
<td>Lupien, M. 38</td>
</tr>
<tr>
<td>Lutz, O. 77</td>
</tr>
<tr>
<td>Ly, L. 85</td>
</tr>
<tr>
<td><strong>M</strong></td>
</tr>
<tr>
<td>Mackall, C. 30, 49, 119, 143</td>
</tr>
<tr>
<td>Magicheva-Gupta, M. 74</td>
</tr>
<tr>
<td>Magowitz, R. E. 130</td>
</tr>
<tr>
<td>Maitra, A. 29</td>
</tr>
<tr>
<td>Maki, R. 113</td>
</tr>
<tr>
<td>Mak, T. W. 14, 34, 143</td>
</tr>
<tr>
<td>Ma, L. 138</td>
</tr>
<tr>
<td>Malats, N. 75</td>
</tr>
<tr>
<td>Malcolmson, K. 121</td>
</tr>
<tr>
<td>Manalis, S. 92, 100</td>
</tr>
<tr>
<td>Manarite, J. 117</td>
</tr>
<tr>
<td>Mancuso, J. J. 52</td>
</tr>
<tr>
<td>Manji, G. 75</td>
</tr>
<tr>
<td>Marinac, C. 146</td>
</tr>
<tr>
<td>Maris, J. M. 30, 49, 119, 134</td>
</tr>
<tr>
<td>Markovic, S. N. 59</td>
</tr>
<tr>
<td>Marra, M. A. 38</td>
</tr>
<tr>
<td>Marrone, K. A. 132</td>
</tr>
<tr>
<td>Masood, F. 89</td>
</tr>
<tr>
<td>Mastan, S. 115</td>
</tr>
<tr>
<td>Maus, M. V. 137</td>
</tr>
<tr>
<td>Maus, R. L. 122</td>
</tr>
<tr>
<td>Mayer, I. A. 123</td>
</tr>
<tr>
<td>May, F. 20</td>
</tr>
<tr>
<td>Mazilli, S. 27</td>
</tr>
<tr>
<td>McAllister, F. 142</td>
</tr>
<tr>
<td>McArthur, H. L. 118, 145</td>
</tr>
<tr>
<td>McBride, S. M. 117</td>
</tr>
<tr>
<td>McCabe, M. G. 73</td>
</tr>
<tr>
<td>McCormick, F. 39</td>
</tr>
<tr>
<td>McGillicuddy III, C. A. 59</td>
</tr>
<tr>
<td>McMahon, M. 81</td>
</tr>
<tr>
<td>McNeill, K. 54</td>
</tr>
<tr>
<td>McQueen, S. 116</td>
</tr>
<tr>
<td>Meijer, G. A. 43</td>
</tr>
<tr>
<td>Melenhorst, J. J. 102</td>
</tr>
<tr>
<td>Mellon, R. 34</td>
</tr>
<tr>
<td>Merchant, T. E. 73</td>
</tr>
<tr>
<td>Messersmith, W. A. 85</td>
</tr>
</tbody>
</table>
## INDEX BY PERSON

### M (Cont’d)

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meyerson, M. L.</td>
<td>27</td>
</tr>
<tr>
<td>Millerchip, K.</td>
<td>80</td>
</tr>
<tr>
<td>Miller, R. I.</td>
<td>126</td>
</tr>
<tr>
<td>Mills, G. B.</td>
<td>64, 145</td>
</tr>
<tr>
<td>Mitsiades, C. S.</td>
<td>105</td>
</tr>
<tr>
<td>Mittendorf, E. A.</td>
<td>118</td>
</tr>
<tr>
<td>Moding, E.</td>
<td>128</td>
</tr>
<tr>
<td>Moll, M. F.</td>
<td>30</td>
</tr>
<tr>
<td>Monje, M.</td>
<td>101</td>
</tr>
<tr>
<td>Morgenstern, D.</td>
<td>30, 119</td>
</tr>
<tr>
<td>Morris, M. J.</td>
<td>117</td>
</tr>
<tr>
<td>Moss, P.</td>
<td>71</td>
</tr>
<tr>
<td>Mowery, Y.</td>
<td>128</td>
</tr>
<tr>
<td>Mukherjee, S.</td>
<td>88</td>
</tr>
<tr>
<td>Mullighan, C. G.</td>
<td>139</td>
</tr>
<tr>
<td>Muranen, T. E.</td>
<td>145</td>
</tr>
<tr>
<td>Morgenstern, D.</td>
<td>30, 119</td>
</tr>
<tr>
<td>Morris, M. J.</td>
<td>117</td>
</tr>
<tr>
<td>Moss, P.</td>
<td>71</td>
</tr>
<tr>
<td>Mowery, Y.</td>
<td>128</td>
</tr>
<tr>
<td>Mukherjee, S.</td>
<td>88</td>
</tr>
<tr>
<td>Mullighan, C. G.</td>
<td>139</td>
</tr>
<tr>
<td>Muranen, T. E.</td>
<td>145</td>
</tr>
<tr>
<td>Morgenstern, D.</td>
<td>30, 119</td>
</tr>
<tr>
<td>Morris, M. J.</td>
<td>117</td>
</tr>
<tr>
<td>Moss, P.</td>
<td>71</td>
</tr>
<tr>
<td>Mowery, Y.</td>
<td>128</td>
</tr>
<tr>
<td>Mukherjee, S.</td>
<td>88</td>
</tr>
<tr>
<td>Mullighan, C. G.</td>
<td>139</td>
</tr>
<tr>
<td>Muranen, T. E.</td>
<td>145</td>
</tr>
<tr>
<td>Morgenstern, D.</td>
<td>30, 119</td>
</tr>
<tr>
<td>Morris, M. J.</td>
<td>117</td>
</tr>
<tr>
<td>Moss, P.</td>
<td>71</td>
</tr>
</tbody>
</table>

### N

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nadeau, K.</td>
<td>101</td>
</tr>
<tr>
<td>Naidoo, J.</td>
<td>132</td>
</tr>
<tr>
<td>Nanda, R.</td>
<td>118, 123</td>
</tr>
<tr>
<td>Neel, B.</td>
<td>92</td>
</tr>
<tr>
<td>Nelson, P. S.</td>
<td>57</td>
</tr>
<tr>
<td>Nelson, S.</td>
<td>29</td>
</tr>
<tr>
<td>Nelson, W. G.</td>
<td>13, 15</td>
</tr>
<tr>
<td>Nephew, K. P.</td>
<td>44</td>
</tr>
<tr>
<td>Nickoloff, B. J.</td>
<td>59</td>
</tr>
<tr>
<td>Norris, K.</td>
<td>27</td>
</tr>
<tr>
<td>Nowark, J.</td>
<td>117</td>
</tr>
<tr>
<td>Nussenzweig, A.</td>
<td>14</td>
</tr>
<tr>
<td>Nutley, R. A.</td>
<td>26</td>
</tr>
</tbody>
</table>

### O

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>O’Connor, O. A.</td>
<td>88</td>
</tr>
<tr>
<td>O’Dwyer, P.</td>
<td>111</td>
</tr>
<tr>
<td>O’Harra, M. H.</td>
<td>87</td>
</tr>
<tr>
<td>Olive, K.</td>
<td>75</td>
</tr>
<tr>
<td>Olson, J.</td>
<td>120</td>
</tr>
<tr>
<td>O’Reilly, E. M.</td>
<td>23, 104</td>
</tr>
<tr>
<td>Orentas, R.</td>
<td>30</td>
</tr>
<tr>
<td>Osborne, C. K.</td>
<td>66</td>
</tr>
<tr>
<td>Overman, L.</td>
<td>128</td>
</tr>
</tbody>
</table>

### P

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page, I.</td>
<td>32</td>
</tr>
<tr>
<td>Pager, D.</td>
<td>36</td>
</tr>
<tr>
<td>Painter, C. A.</td>
<td>128</td>
</tr>
<tr>
<td>Palmer, A.</td>
<td>30</td>
</tr>
<tr>
<td>Pao, W.</td>
<td>140</td>
</tr>
<tr>
<td>Papadopoulos, P. C.</td>
<td>29</td>
</tr>
<tr>
<td>Pardoll, D. M.</td>
<td>39, 52</td>
</tr>
<tr>
<td>Park, B. H.</td>
<td>118</td>
</tr>
<tr>
<td>Park, J.</td>
<td>127</td>
</tr>
<tr>
<td>Park, J. R.</td>
<td>30</td>
</tr>
<tr>
<td>Park, M.</td>
<td>34</td>
</tr>
<tr>
<td>Parsons, D. W.</td>
<td>30, 49</td>
</tr>
<tr>
<td>Parsons, R. E.</td>
<td>64</td>
</tr>
<tr>
<td>Patel, H. P.</td>
<td>130</td>
</tr>
<tr>
<td>Paulovich, A.</td>
<td>70</td>
</tr>
<tr>
<td>Paykin, C.</td>
<td>115</td>
</tr>
<tr>
<td>Pe’er, D.</td>
<td>107, 139, 143</td>
</tr>
<tr>
<td>Pelka, K.</td>
<td>142, 145</td>
</tr>
<tr>
<td>Penumatsa, R.</td>
<td>44, 125, 132</td>
</tr>
<tr>
<td>Perez, E. A.</td>
<td>13, 16</td>
</tr>
<tr>
<td>Peragament, D.</td>
<td>57</td>
</tr>
<tr>
<td>Perlmutter, J.</td>
<td>59, 64</td>
</tr>
<tr>
<td>Perry, J.</td>
<td>121</td>
</tr>
<tr>
<td>Petersen, G. M.</td>
<td>29</td>
</tr>
<tr>
<td>Petricoin, E. F.</td>
<td>59</td>
</tr>
<tr>
<td>Pettitgrew, R. I.</td>
<td>14</td>
</tr>
<tr>
<td>Pickett, C. B.</td>
<td>14, 15</td>
</tr>
<tr>
<td>Pistofidis, R. S.</td>
<td>127</td>
</tr>
<tr>
<td>Piwnica-Worms, H.</td>
<td>145</td>
</tr>
<tr>
<td>Plimack, E. R.</td>
<td>125</td>
</tr>
<tr>
<td>Polinsky, D.</td>
<td>41, 135</td>
</tr>
<tr>
<td>Polite, B.</td>
<td>74</td>
</tr>
<tr>
<td>Pollik, M. N.</td>
<td>24</td>
</tr>
<tr>
<td>Porter, S.</td>
<td>46</td>
</tr>
<tr>
<td>Postovit, L. M.</td>
<td>24</td>
</tr>
<tr>
<td>Powell, B. L.</td>
<td>25</td>
</tr>
<tr>
<td>Powell, D.</td>
<td>107</td>
</tr>
<tr>
<td>Prabhu, S.</td>
<td>72</td>
</tr>
<tr>
<td>Prevor, J. E.</td>
<td>87</td>
</tr>
<tr>
<td>Pritchard, K. I.</td>
<td>34</td>
</tr>
<tr>
<td>Prives, C. L.</td>
<td>14</td>
</tr>
<tr>
<td>Propper, D. J.</td>
<td>36</td>
</tr>
<tr>
<td>Pugh, T. J.</td>
<td>142</td>
</tr>
<tr>
<td>Pyle, R.</td>
<td>85</td>
</tr>
</tbody>
</table>

### Q

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quake, S.</td>
<td>101</td>
</tr>
<tr>
<td>Quinn, D. I.</td>
<td>125</td>
</tr>
</tbody>
</table>

### R

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rababan, R.</td>
<td>75, 98, 109, 142</td>
</tr>
<tr>
<td>Rabinowitz, J. D.</td>
<td>36, 60, 94</td>
</tr>
<tr>
<td>Ralph-Birkett, P.</td>
<td>75</td>
</tr>
<tr>
<td>Ramanathapuaram, L.</td>
<td>39</td>
</tr>
<tr>
<td>Ramaswamy, S.</td>
<td>139</td>
</tr>
<tr>
<td>Rapkin, B.</td>
<td>22</td>
</tr>
<tr>
<td>Rassool, F. V.</td>
<td>44, 145</td>
</tr>
<tr>
<td>Rathkopf, D. E.</td>
<td>117</td>
</tr>
<tr>
<td>Raymond, M.</td>
<td>32</td>
</tr>
<tr>
<td>Rebbeck, T. R.</td>
<td>26</td>
</tr>
<tr>
<td>Reidy, K.</td>
<td>30</td>
</tr>
<tr>
<td>Reinherz, E. L.</td>
<td>89</td>
</tr>
<tr>
<td>Reya, T.</td>
<td>82</td>
</tr>
<tr>
<td>Rezvani, K.</td>
<td>25</td>
</tr>
<tr>
<td>Ribas, A.</td>
<td>52, 129, 143</td>
</tr>
<tr>
<td>Richards, T.</td>
<td>38</td>
</tr>
<tr>
<td>Rickerson, S.</td>
<td>46</td>
</tr>
<tr>
<td>Riedel, R. F.</td>
<td>128</td>
</tr>
<tr>
<td>Ritch, P. S.</td>
<td>130</td>
</tr>
<tr>
<td>Roach, N.</td>
<td>32</td>
</tr>
<tr>
<td>Roberts, C. M.</td>
<td>140</td>
</tr>
<tr>
<td>Roberts, T. M.</td>
<td>64</td>
</tr>
<tr>
<td>Robins, H.</td>
<td>110, 111</td>
</tr>
<tr>
<td>Rohatgi, R.</td>
<td>140</td>
</tr>
<tr>
<td>Roland-Jaremba, D.</td>
<td>69</td>
</tr>
<tr>
<td>Rooney, C. M.</td>
<td>80</td>
</tr>
<tr>
<td>Rosen, N.</td>
<td>59</td>
</tr>
<tr>
<td>Rosenthal, M.</td>
<td>76</td>
</tr>
<tr>
<td>Roth, J.</td>
<td>105</td>
</tr>
<tr>
<td>Rubin, M. A.</td>
<td>57</td>
</tr>
<tr>
<td>Rudin, C. M.</td>
<td>39, 44, 132</td>
</tr>
<tr>
<td>Rugo, H. S.</td>
<td>118</td>
</tr>
<tr>
<td>Rutfledge, L. J.</td>
<td>72</td>
</tr>
<tr>
<td>Ryan, D. P.</td>
<td>85</td>
</tr>
<tr>
<td>Ryem, S. W.</td>
<td>74</td>
</tr>
<tr>
<td>Sadelain, M.</td>
<td>52</td>
</tr>
<tr>
<td>Saltse, M. W.</td>
<td>38</td>
</tr>
<tr>
<td>Sampayo, I.</td>
<td>22</td>
</tr>
<tr>
<td>Sander, C.</td>
<td>76</td>
</tr>
<tr>
<td>Sanders, M. E.</td>
<td>123</td>
</tr>
<tr>
<td>Sandi, C.</td>
<td>30</td>
</tr>
<tr>
<td>Santin, A. D.</td>
<td>106</td>
</tr>
<tr>
<td>Sato, T.</td>
<td>94</td>
</tr>
<tr>
<td>Savell, A.</td>
<td>127</td>
</tr>
<tr>
<td>Sawyer, C. L.</td>
<td>57, 64</td>
</tr>
<tr>
<td>Scaltriti, M.</td>
<td>109</td>
</tr>
<tr>
<td>Schimke, J.</td>
<td>122</td>
</tr>
<tr>
<td>Schipper, H.</td>
<td>43</td>
</tr>
<tr>
<td>Schoolcraft, K.</td>
<td>20</td>
</tr>
<tr>
<td>Schork, N. J.</td>
<td>59</td>
</tr>
<tr>
<td>Schreiber, R. D.</td>
<td>46</td>
</tr>
<tr>
<td>Schultz, K. R.</td>
<td>30</td>
</tr>
<tr>
<td>Schultz, L.</td>
<td>30, 71</td>
</tr>
<tr>
<td>Schultz, N.</td>
<td>143</td>
</tr>
<tr>
<td>Schumacher, T. N.</td>
<td>52</td>
</tr>
<tr>
<td>Schwartz, L. H.</td>
<td>117</td>
</tr>
<tr>
<td>Schwarze, S.</td>
<td>32</td>
</tr>
<tr>
<td>Scott, J.</td>
<td>49</td>
</tr>
<tr>
<td>Scott, L.</td>
<td>49</td>
</tr>
<tr>
<td>Scrivens, Z.</td>
<td>34</td>
</tr>
<tr>
<td>Seigal, C.</td>
<td>85</td>
</tr>
<tr>
<td>Sekulic, A. D.</td>
<td>59</td>
</tr>
</tbody>
</table>
INDEX BY PERSON

S (Cont’d)
Sequist, L. V. 86, 110
Shah, N. N. 30
Shapiro, G. I. 78
Sharma, P. 143
Sharpe, A. H. 14
Sharp, P. A. 13, 14, 15
Shaw, K. 69
Shawver, L. K. 14
Sheffer, M. 105, 142
Shen, H. 132
Shen, Y. 127
Shi, J. 143
Shockney, L. D. 61
Shyr, Y. 123
Silva, J. M. 140
Simons, J. W. 52
Skala, M. C. 138, 143
Slamon, D. J. 66, 143
Sleijfer, S. 90
Small, E. J. 54
Smith, A. A. 74
Smith, H. W. 24
Smith, K. 26
Smith, S. 36
Smith, Y. 26
Smogorzewska, A. 70
Snippert, H. 142
Solit, D. B. 64, 143
Sondel, P. M. 143
Sondergeld, B. A. 143
Sorger, P. K. 66
Sosman, J. A. 59, 129, 143
Spears, P. 25
Speed, T. P. 66
Spira, A. E. 27
Spychala, L. 22
Stegmaier, K. 121, 140, 142, 143
Stoval, E. L. 66
Stratton, Sir M. R. 48
Stuart, J. M. 54
Sullenger, B. A. 143
Sullivan, J. P. 14, 30, 38, 49
Suman, V. J. 122
Sutcliffe, J. L. 83
Swanton, C. 27, 145
Sweet-Cordero, E. A. 139
Swisher, E. M. 41, 135
Syngal, S. 20, 29
T
Tabori, U. Y. 119, 134
Taniguch, C. M. 85
Tan, M. 100
Tanyi, J. L. 87
Tao, A. 22
Tashbar, J. 126
Tasian, S. K. 142
Taylor, M. D. 30, 38, 49
Tempero, M. A. 82
Terry, M. B. 22
Tewari, M. 140
Ting, D. T. 111, 143
Tolaney, S. M. 118
Tondre, A. 90
Toner, M. 63
Tran, C. A. 39
Transfer, C. 48
Trent, J. M. 59
Tsimelak, A. 105
Turner, H. 122
Tuveson, D. A. 23, 143
Tyers, M. 38
U
Ulge, C. 126
Ungerleider, J. 63
V
Van Allen, E. M. 143
Vander Heiden, M. 138, 143
van de Rijn, M. 128
Vanderwalde, A. M. 129
van Engeland, M. 43
van Es, J. H. 48
van Luenen, H. 77
van’t Veer, L. J. 90
Vaughan, K. 73
Velchetti, V. 115
Velculescu, V. E. 43
Veluswamy, R. 115
Veum, S. 122
Visco, F. M. 66
Visvader, J. E. 145
Voest, E. E. 77, 90
Vonderheide, R. H. 46, 84, 142
Von Hoff, D. D. 36, 60, 130
Vuori, K. 59
W
Wagers, A. J. 139
Wagle, N. 109
Wagner, A. J. 128
Wahl, G. M. 60
Walensky, L. D. 140
Walker, D. 22
Wang, Z. J. 32
Wargo, J. 96, 137
Watson, D. R. 41, 64, 78, 135
Wei-Chen, C. 72
Weinhold, K. J. 128
Weinstock, D. M. 140
Weir, C. 123
Weiss, Samuel 38
Weiss, Sara 64
Wendt, S. J. 20
Werb, Z. 66
Wessels, L. 48
Wherry, E. J. 87, 107, 132, 142
Whitehurst, A. W. 139
Whyte, J. 16
Wicha, M. S. 66
Wigtels, L. J. 39
Williams, H. L. 20
Williams, M. E. 52
Williams, R. M. 16
Wilson, D. R. 16
Wilson, J. T. 137
Winkfield, K. M. 16
Winn, R. A. 16, 69
Witte, O. N. 54, 143
Wolchok, J. D. 39, 52, 104, 111, 143
Wolpin, B. M. 76, 78
Wong, K. 114
Woo, Y. 74
Wright, B. 20
Wu, C. J. 139
Y
Yagnik, R. M. 22
Yee, C. 52, 143
Yin, H. H. 140
Yoon, S. S. 74
Youngblood, B. A. 44
Young, H. E. 36, 60, 130
Young, R. M. 87
Young, S. 128
Yu, C. C. 108
Yu, K. 23
Z
Zaidi, N. 84
Zamarin, D. 107
Zavidij, O. 127
Zhang, X. 145
Zhu, H. 138
THANK YOU
Stand Up To Cancer thanks the generous collaborators, donors and organizations that have helped fund our groundbreaking programs, including:

- David Alden & Dina Al-Sabah
- Amgen
- American Airlines
- American Cancer Society
- American Head & Neck Society
- American Lung Association
- Mark & Debbie Attanasio
- Breast Cancer Research Foundation
- Bristol Myers Squibb
- C4C Fund
- Canadian Cancer Society
- Canadian Institutes of Health Research
- Cancer Research UK
- Cancer Stem Cell Consortium
- Cless Family Foundation
- Count Me In
- Dutch Cancer Society
- Draft Kings
- Exact Sciences
- Fanconi Anemia Research Fund
- Farrah Fawcett Foundation
- Fisher Family
- Forever 21
- Genentech, a Member of the Roche Group
- Genome Canada
- GlaxoSmithKline
- Head and Neck Cancer Alliance
- William Randolph Hearst Foundation
- Janssen Pharmaceutical Companies of Johnson & Johnson
- Jazz Pharmaceuticals
- Jeopardy! With Katie Couric
- Jewelers Mutual
- Bob Judelson
- Sidney Kimmel Foundation
- LUNGevity Foundation
- Lustgarten Foundation
- Major League Baseball
- The Marcus Corporation Foundation
- Mastercard
- The Kate McGarrigle Fund
- Merck & Co., Inc.
- Mirati Therapeutics
- Arte & Carole Moreno, Angels Baseball Foundation
- National Ovarian Cancer Coalition
- Night Nation Run/I Run 4 Movement
- Ontario Institute for Cancer Research
- Optum
- Ovarian Cancer Research Alliance
- Pancreatic Cancer Canada
- Providence (Providence Saint John's Health Center)
Stand Up To Cancer thanks the generous collaborators, donors and organizations that have helped fund our groundbreaking programs, including:

Jerry & Martyl Reinsdorf
Sara Schottenstein Foundation
Peter & Sheel Seidler
Bud & Sue Selig
SHEIN
Society for Immunotherapy of Cancer
St. Baldrick’s Foundation
ThermoFisher
Torrey Coast Foundation
Trebek Family Foundation
The V Foundation
Van Andel Institute
VisualEyes
Emily Whitehead Foundation
Kari Wolff
Lewis & Jean Wolff
Zentalis
The Laura Ziskin Family Trust